CLIFTON, NJ–(Marketwire – August 6, 2010) –  Electronic Control Security, Inc. (OTCBB: EKCS) (ECSI) (www.ecsiinternational.com), a global leader in entry control and perimeter security systems, today announced the appointment of Robert Oliver as Vice President, Operations. 

Arthur Barchenko, President of ECSI, stated that “Robert will fill an important position in the Company to meet the growing demand for its products and services now and in the future. The position of Vice President, Operations will address product design and engineering, R&D, production scheduling, purchasing and inventory control in accordance with ISO 9001:2008.”

About Mr. Oliver
Robert Oliver brings decades of experience and innovation in engineering design and management to this position. He has successfully performed and managed the design, test, manufacturing, installation and maintenance of products and systems in avionics, nuclear power plant, power instruments, medical device, medical instruments, research instruments, surveillance and life safety for military, law enforcement, hospital, surgical, industrial, commercial and consumer markets domestically and internationally. He has functioned at all levels, including CEO. He has enjoyed successful deployment of security systems of his own design while working through AE firms such as Syska & Hennessey and Flack & Kurtz, among others, and for clients that include major banks and brokerage houses. He holds multiple patents in the US and elsewhere for industrial and security products and systems.”

About ECSI
ECSI is a global leader in perimeter security and a quality provider to the Department of Defense, Department of Energy, nuclear power stations, and other large commercial-industrial complexes. The Company designs, manufactures and markets physical electronic security systems for high profile, high threat environments utilizing risk assessment and analysis to determine and address the security needs of its customers. Teaming agreements with major system integrators enable ECSI to support the installation and aftermarket of its products in the U.S. and overseas. ECSI is located at 790 Bloomfield Avenue, Bldg. C-1, Clifton, NJ 07012. Tel: 973-574-8555; Fax: 973-574-8562. For more information on ECSI and its customers, please visit http://www.ecsiinternational.com.

ECSI INTERNATIONAL, INC. SAFE HARBOR STATEMENT: This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, acceptance of our proposals, sufficiency of working capital, receipt and timing of collections from purchase orders, the availability of working capital, changes in economic conditions generally and in our industry specifically, changes in security technology, legislative or regulatory changes that affect us, changes in costs and the availability of goods and services, the introduction of competing products, changes in our operating strategy or development plans, sufficiency of cash reserves and the risks and uncertainties discussed under the heading “RISK FACTORS” in Item 1 of our Annual Report on Form 10-K for the fiscal year ended June 30, 2009 and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

LOS ANGELES, CA–(Marketwire – August 6, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF)

Dear Stockholder:

In the entertainment industry, 2012 was the name of a major motion picture. In China, 2012 will be the Year of the Dragon. At MMRGlobal, 2012 will be the Year of the Personal Health Record (PHR). That’s when health care professionals will be required to provide Personal Health Records to patients as part of compliance with Meaningful Use.

At MMRGlobal, we’re ready for the future of health care today.

The MyMedicalRecords.com PHR already offers patented Emergency Login features, patient selected privacy controls, the ability to securely receive and send a medical record from and to any health care professional (or anyone) anywhere in the world. And it does not matter how a record is created, with paper and pen or from the most sophisticated of EMRs. Further, the MMR Stimulus Program pays physicians for simply doing what they will have to do; specifically, electronically provide patients with timely access to their personal health information. Also, because we believe in the quality, safety and security of our product, MMR carries cyber liability insurance to protect our consumer and professional users from actual loss or damage caused by an error in the Company’s PHR system.

Last week in Chicago and yesterday in Los Angeles, we met with senior executives of two hospital systems representing more than 2,000 staff physicians. Working with these hospital systems, MMR is in the process of developing programs designed to enable hospitals and larger group practices to underwrite the installation of an MMRPro system through the MMR Stimulus Program.

Also last week in meetings at Kodak headquarters in Rochester, N.Y., we began planning on numerous expanded distribution strategies and joint sales and marketing opportunities. Additionally, this month we will begin testing the next generation of an MMRPro system with new Kodak hardware, improved software and a more seamless interface that will make it faster and more efficient for doctors’ offices to digitize patient records and offer MMRPatientView.com upgrades. We anticipate distributing the new MMRPro branded system later this year at which time we will upgrade any systems in the field at no cost to our customers.

Kodak will also promote the new MMRPro system in Kodak merchandising and marketing materials designed to make it easier for resellers and distributors to sell directly. We also will participate with Kodak in an expanded tradeshow schedule, with coverage in the Kodak newsletter and inclusion on Kodak’s Partner Web site. This quarter, National Payment Providers will also begin presenting MMRPro to its database of more than 160,000 physician billing clients with delivery and installation support from Kodak starting later this year. 

I also spent last week with Chartis International executives in New York regarding sales of MyEsafeDepositBox and MyMedicalRecords domestically. Rich Teich, MMRGlobal’s Executive Vice President, also attended preliminary implementation meetings in New York this week. We anticipate announcements on these and other similar programs in the first quarter of 2011 while we continue to push forward on the international front.

Later this month, expect the launch of the new redesigned MyEsafeDepositBox, which will be the structural backbone for Chartis Esafe and numerous banking programs, including one that has been in development for more than two years.

In China, we are deploying MMRGlobal developers in Zhengzhou City to work side-by-side with the local development teams at Unis-TongHe. They will begin design plans on the two projects for presentation to China’s hospital system. These proposal efforts represent the groundwork for two health information exchange systems that can provide services to over 100 million people. 

In October, I plan on visiting our technology partner Nihilent in India as part of a strategy to present MMR to government officials, private hospital networks and local health care professionals.

In addition to our ongoing efforts to identify a strategic partner to develop the Company’s anti-CD20 monoclonal antibody assets, we continue to look at our many other biotech assets arising out of the pre-merger Favrille Specifid vaccine and, as such, we are seeking opportunities with biotech and institutional investment partners to exploit those assets.

It is an extremely busy time at MMRGlobal. I have touched on a few of the many initiatives that this company is pursuing around the world. When the recently filed S1/A goes effective, the Company will have access to up to $10 million in capital which can help accelerate our ability to execute on these business opportunities and more. It will provide resources for development, marketing and sales of our products to our consumer, health care professional, corporate and affinity clients worldwide. As the largest beneficial holder of this company, I am excited about the fact that we will have these additional resources and look forward to being in a better position to execute on our plans and grow with the global health care market.

I rarely talk about the people on the MMRGlobal team and how they are the recipe for success. It’s two o’clock AM and I am working with Bobbie after 10 years and a full day of meetings with Rich (who I have worked with for 33 years), AJ (15 years), Ingrid (20 years) and Ralph (15 years), all of whom work around the clock seven days a week. 

Then there’s our Board of Directors. They also get to be on call 24-hours a day and utilize their entire network of contacts in support of the Company. For example, Hector Barreto has supported the Company for nearly three years after leaving as the longest running Administrator of the U.S. Small Business Administration. He presided over 9/11 and Katrina and brings with him a wealth of knowledge and experience.

George Rebensdorf has worked with me on finance and regulatory affairs for more than 15 years. Bernie Stolar, who I have worked with for nearly 30 years, brings the experience of launching Sony PlayStation®, running Sega and being the Gaming Industry Evangelist for Google. Also in the 30-year category is Jack Zwissig, who is an expert in executive leadership and corporate team building. Doug Helm, who was appointed to the board of pre-merger Favrille, is a world-class expert on insurance, benefits and banking and helps lead the Company’s insurance and banking efforts. Dave Boyden, another Favrille appointee, is the biotech answer man on the scientific assets in the Company’s portfolio.

There are not many people who can write about a team that’s been together for more than 175 years.

Sincerely,

Robert H. Lorsch
Chairman, President & Chief Executive Officer

About MMRGlobal, Inc.

MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheater.com.

Forward-Looking Statements
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue.” MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

TAMPA, FL–(Marketwire – August 6, 2010) – Zimek Technologies (www.zimek.com), the industry leader in infection control and biohazard remediation technology, today announced The Honorable Emil Jones Jr. has joined the company’s prestigious Advisory Board. From 2003-2009, Jones served as President of the Illinois State Senate, a position that culminated more than three decades of service in the Illinois legislature. Jones has been a mentor and friend to many politicians over the years including former Illinois State Senator Barack Obama with whom Jones served. Jones is currently a Senior Counselor at Mercury Public Affairs, leading the firm’s operations based in Chicago, Ill.

“Recognized as one of the most effective political leaders in Illinois state history, Emil Jones left an unparalleled legacy of achievement, making lasting contributions throughout the state, particularly in the areas of education, health care and criminal justice,” stated Kurt Grosman, CEO and President of Zimek Technologies. “We are extremely delighted he is joining our team. His contributions will be vital as we continue to spread the word that Zimek’s sophisticated three-dimensional touch-less decontamination technology can effectively defeat and prevent the spread of deadly viruses and bacteria.”

“Zimek’s automatic rapid decontamination and disinfection technology is a powerful addition to our arsenal of weapons to fight infectious diseases and biohazard attacks,” Senator Jones said. “Zimek’s technology can meaningfully help hospitals throughout our country improve infection control quality standards and ensure they use best practices to comply with new federal provisions issued by CMS (Centers for Medicare & Medicaid Services) which encourage hospitals to disclose and, proactively, reduce their healthcare acquired infections (HAIs). HAIs will now be tied to hospital Medicare reimbursement incentives.”

Jones joins other Zimek Advisory Board members including Dr. Brad Spellberg, scientist, researcher and infectious disease specialist at the David Geffen School of Medicine at UCLA and Harbor-UCLA Medical Center; Dr. Peder Bo Nielsen, consultant in Microbiology with the United Kingdom’s North West London NHS Trust; and Dr. Lindsey Shaw, Assistant Professor of Molecular Microbiology at the University of South Florida. (see http://www.zimek.com/advisoryboard.asp).

Zimek Technologies, based in Tampa, Florida, has been developing and marketing its patented automatic Micro-Mist™ decontamination technologies for more than five years. Zimek’s industry-leading technologies are used by the U.S. Department of Homeland Security, Fire and EMS departments, healthcare facilities, public health agencies, transit systems, correctional facilities and local law enforcement agencies across America.

ISSAQUAH, WA–(Marketwire – August 6, 2010) –  A new simplified and easily accessible video format where the health care professional can go to obtain the latest in medical equipment and supply information and use has finally arrived: Qtube™.

According to one research study, 50% of online retailers in the US added video in some form last year, and 31% of Fortune 500 companies have public blogs that incorporate video blogging.

“Considering that 177 million Americans watch some sort of video online each month, and they saw 4.3 billion ads in June, it’s not surprising why we would add an educational video site,” said Scott Hanna, CEO at QuickMedical®. “With nearly 150 full feature product videos and educational clinics, QuickMedical® and Qtube™ can offer our customers an easy-to-use educational site where they can learn more about the latest in product development, use and technology.”

The majority of Qtube™ product and clinic video presentations are filmed on site at QuickMedical® in their state of the art display and video production room. A number of videos are also supplied to Qtube™ by the QuickMedical® vendor/manufacturers for review and placement on the Qtube™ site.

“Our video/media team put together a dynamic website that will feature future product promotions and will help the QuickMedical® vendors create and use new video content that will promote their goods and services,” said Tim Lightell, Social Media Coordinator at QuickMedical®. “Over a two day period, this June at our open house, we filmed nearly 150 vendor/product presentations and ten educational clinics, so there is a lot of content on the Qtube™ site.”

About QuickMedical® and Qtube™:

QuickMedical® has the professional medical equipment needed by health care providers. Look for diagnostic equipment, exam tables, weighing and measuring devices, and medical basics such as stethoscopes, thermometers, and sphygmomanometers. Qtube™ Videos are supplied by our manufacturers or produced in house by our Production Team. Most videos are shot in our state of the art showrooms. Current displays include medical, surgical, and a pediatric exam rooms. Look for QuickMedical’s® new television commercial, currently airing in the Seattle market on local ABC affiliate KOMO 4.

Click here to see all recent news from this company

MOUNTAIN VIEW, CA–(Marketwire – August 5, 2010) –  eHealth, Inc. (NASDAQ: EHTH), the nation’s leading online source of health insurance for individuals, families, seniors and small businesses, today announced that its senior management will present at Oppenheimer & Co. Inc.’s Annual Technology, Media & Telecommunications Conference on Wednesday, August 11 at 8:30 a.m. ET. This event will be held at the Four Seasons Hotel in Boston, MA.

Interested investors can access the live audio webcast of each presentation at www.ehealthinsurance.com under Investor Relations. Please visit the website at least 15 minutes early to register, download, and install any necessary software. A replay of each event will be available on the company’s website shortly after the conclusion of the event and will remain available for 14 days.

About eHealth, Inc.

eHealth, Inc. (NASDAQ: EHTH), the parent company of eHealthInsurance and PlanPrescriber, is the nation’s leading online source of health insurance for individuals, families, seniors and small businesses. Through the company’s websites (http://www.eHealthInsurance.com, http://www.PlanPrescriber.com and http://eHealthMedicare.com), consumers can get quotes from leading health insurance carriers, compare plans side by side, and apply for and purchase individual and family, Medicare, small group, short-term and ancillary health insurance products. eHealthInsurance is authorized by more than 180 of the nation’s leading health insurance companies and offers thousands of health plans. eHealthInsurance is licensed to sell health insurance in all 50 states and the District of Columbia, making it an excellent model of a successful, high-functioning health insurance exchange. Through its eCommerce On-Demand solution (eOD), http://www.ehealth.com/eOD/, eHealth is also a leading provider of on-demand e-commerce software services for health plan providers. eHealthInsurance and eHealth are registered trademarks of eHealthInsurance Services, Inc. PlanPrescriber is a registered trademark of PlanPrescriber, Inc.

CHICAGO, IL–(Marketwire – August 5, 2010) –  Titan Commercial today announces the completion of a lease for 9,620 square feet located at 1806 S. Highland Ave. in Lombard, Ill. Ben Rosenfield, principal of Titan Commercial, represented the tenant Health Resource Solutions (HRS) in their relocation and helped facilitate the transaction with landlord StoneCreek Properties, represented by Cawley Chicago Commercial. HRS executed a primary term of 10 years.

“With so much vacant space in the market, we wanted to ensure that we found the best deal, location and landlord to work with. Ben Rosenfield was an excellent resource and negotiated an amazing deal on our behalf that surpassed our expectations,” said Glenn Steigbigel, President of HRS.

Health Resource Solutions is a privately owned hi-tech home health company committed to serving healthcare professionals and patients. Open 365 days a year, HRS provides quality care for patients of all ages including hi-tech geriatric and pediatric nursing, physical therapy, occupational therapy, speech therapy, telemonitoring, and all other necessary coordinated services. They are currently located at 1700 W. Hubbard Street in Chicago. For more information visit the HRS website at www.healthrs.net.

Founded in 2007, Titan Commercial is a commercial real estate brokerage firm whose mission is to improve the lives beyond those involved in the negotiation. While specializing in the acquisition, disposition and leasing of commercial real estate properties, this full service firm has completed over $200 million in transactions and is active in representing landlords, tenants, sellers, purchasers and investors nationwide. Headquartered in Illinois, Titan Commercial also has an office in Arizona. For more information, visit www.titancommercialrealestate.com or call 312.373.7100.

Click here to see all recent news from this company

TORONTO, ONTARIO–(Marketwire – Aug. 5, 2010) – The John Howard Society of Toronto will be releasing ‘Homeless and Jailed: Jailed and Homeless;’ a report on the increasing number of homeless individuals in Toronto area jails who are being released to areas that are unable to provide sufficient resources to aid in reintegration and deter recidivism. John Howard researchers undertook 363 interviews with incarcerated individuals in 2009 and 2010. Among this group, 22.9 percent, or roughly one of every five prisoners, was homeless when incarcerated, that is they were staying in a shelter, living on the street (in places considered unfit for human habitation), in a treatment facility, or staying at the home of a friend, paying no rent. Overall, 32.2 percent, or almost one of every three prisoners had plans upon discharge to go to a shelter, live on the street, or couch-surf at the home of a friend. Another 12 percent of these prisoners are at risk of being homeless since they do not know where they will go.

The report will be released as part of Prisoners Justice Day activities at the Holy Trinity Anglican Church (10 Trinity Square – Bay and Queen – Behind the Eaton Centre) at 12:30pm on August 10^th. Prisoner’s Justice Day is an annual memorial day, dedicated to all those who have lost their lives while in custody.

Researchers Amber Kellen and Sylvia Novac will be among the presenters.

Email a Friend

Printer Friendly Version

Latest News Releases

DALLAS, TX–(Marketwire – August 5, 2010) – Metiscan’s (PINKSHEETS: MTIZ) majority owned subsidiary Schuylkill Open MRI, Inc. (Schuylkill), which is an outpatient diagnostic imaging facility located in Pottsville, Pennsylvania providing Magnetic Resonance Imaging (MRI) services, announced today that it has upgraded its legacy electronic healthcare records (EHR) system to a new Web 2.0 based Health Language Seven (HL7) compliant EHR and practice management system.

The new EHR system enhances practice workflow, improving operational efficiencies which management believes will increase cost savings and aid the center’s staff in providing high quality patient care. The EHR system enables Schuylkill to operate as a virtually paper free and filmless practice and includes features such as patient scheduling, practice management and the electronic archiving and distribution of high-quality MRI images and patient reports. Secure access is available to radiologists and referring physicians from any location having a web-browser and a broadband connection.

Schuylkill historically licensed the use of its former EHR system. Since 2003, Schuylkill has paid a licensing fee on a per-study basis. Going forward Schuylkill has determined to purchase its own EHR system and retain FirstView EHR, Inc. (FirstView), which is also a majority owned subsidiary of Metiscan, to host and administer the system. Purchasing the new EHR system provides Schuylkill with a productivity tool that embraces today’s latest secure web technologies and eliminates the need to pay a third party a license fee on a per-study basis.

About Schuylkill Open MRI, Inc.
Schuykill Open MRI, Inc. (Schuylkill) is an outpatient diagnostic facility located in Pottsville, Pennsylvania providing Magnetic Resonance Imaging (MRI) services. Schuylkill began operations in March 2003 and currently performs MRI exams on a Siemens OPEN MRI platform and a Siemens 1.5T high-field MRI platform. Having both platforms provides Schuylkill flexibility in the studies it can conduct. Schuylkill participates in most major insurance plans and accepts Medicare, Medicaid, Worker’s Compensation claims, Personal Injury Protection (PIP) and Letters of Protection (LOPs). Schuylkill is accredited by the American College of Radiology (ACR) and is a majority owned subsidiary of Metiscan, Inc. 

Safe Harbor Statement: Certain of the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Metiscan’s actual results to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Click here to see all recent news from this company

CENTERVILLE, MA–(Marketwire – August 5, 2010) – UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) is very pleased to announce that it has received an order from specialized indoor air quality distributor Puravair for a shipment to the prestigious Miami Anatomical Research Center (“M.A.R.C.”) located in Miami, Florida (www.marctraining.com).

M.A.R.C. is one of the finest medical technology training facilities in the country, offering world class surgical training for a variety of specialties. It is one of the few places in the country offering as many as forty, state-of-the art bio skill lab stations in a hospital style setting alongside custom designed conference and lecture facilities delivering full videoconferencing in a dedicated facility. The introduction of new technologies and medical devices requires constantly evolving expertise and the centre offers training to a huge and skilled market of medical specialists encompassing North, Central and South America, as well as the Caribbean. 

“This order is significant when you consider the client’s needs and perspective,” stated Jack Lennon, President of UV Flu Technologies. “They are an internationally-respected medical facility that instructs a diverse client list of doctors, surgeons and other talented practitioners of the medical profession from throughout the western hemisphere.”

“We trust that other teaching facilities, at home and abroad, will take note and quickly identify that our product offers a cost effective and easy to implement method to increase the overall safety level of any facility by immediately lessening the risk of airborne bacteria, and one that also limits the spread of noxious odors and Volatile Organic Compounds (‘VOC’),” said Mr. Lennon, as he further comments, “The ViraTech UV-400 is specifically designed to kill dangerous strains of bacteria which may present themselves from time to time, while also reducing the levels of other contaminants and odors from the air we breathe.”

Mr. Lennon concluded by saying, “Here is a sale which clearly demonstrates product penetration into a massive market encompassing all forms of medical teaching facilities, as well as businesses such as funeral homes and working pathology labs worldwide. The potential list of users in this sector is huge.”

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
—————————–
John J. Lennon, President & CEO

Click here to see all recent news from this company

MARINA DEL RAY, CA–(Marketwire – August 5, 2010) –  Marijuana Incorporated (PINKSHEETS: PCIO) (http://www.marijuana-incorporated.com) and Medical Marijuana, Inc. (PINKSHEETS: MJNA) has been galvanized by the New Rasmussen Poll showing 75% of Americans support the use of Medical Marijuana by Adults if prescribed by a physician, up from 63% last October. This number clearly shows that a large majority believes in the efficacy of Cannabis, and is an indication that the 14 States and the District of Columbia, recognizing Medical Marijuana were on the right course in fulfilling the will of their citizens.

“We see these numbers as a ‘Tipping Point,'” stated CEO Bruce Perlowin. “More states that are currently in the process of Legalization efforts will certainly come into the fold and it is also interesting to note that the Poll showed that 95% believe that it is likely that Marijuana will be fully legalized in the next 10 years.

Furthermore, Rasmussen shows that the California Bill to Tax and Regulate Cannabis, Prop 19, has 52% approving while opposed by only 36% indicating strongly that recreational Marijuana will be legal in California in November. Additionally, the City of Detroit is also voting this November to legalize recreational Marijuana.

These facts underscore the decision by PCIO to apply for and receive a name change to “Marijuana, Inc.” and jump into this quickly emerging multi-billion dollar industry. With several divisions being created in Marijuana, Inc., from 420 friendly resorts, to licensing the rights of Medical Marijuana, Inc.’s (PINKSHEETS: MJNA) attractive logo for an entire clothing line, Marijuana, Inc. is positioning itself to be a leader and trend setter in the medical marijuana, cannabis, hemp and related peripheral industries.

About Marijuana, Inc.

Marijuana Inc., a Colorado corporation, is one of the first and most prolific distributors in “The Hemp Network.” The Hemp Network is a division of our sister company, MJNA. Marijuana Inc. invites those that would like to capitalize on this fast growth industry to become a part of The Hemp Network by logging onto http://www.thehempnetwork.com using first name “Marijuana” last name “Inc” and phone # 239-738-0434; 239-738-0434. The company is also the first to develop “420” friendly resorts, through the acquisition of a new division. The company continues to market the world’s most expensive coffee, like the one described in the movie with Morgan Freeman, “The Bucket List,” and this civet coffee will be available in the company’s “420” resorts. Marijuana Inc. has also entered into an agreement to acquire certain marketing rights for a clothing line from Medical Marijuana Inc. and if the agreement is consummated, PCIO will issue shares to MJNA and/or its shareholders.

Forward-Looking Statements

This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law.

SAN FRANCISCO, CA–(Marketwire – August 4, 2010) – Find the AAAnswers, a multi-faceted public education campaign designed to raise awareness of abdominal aortic aneurysms (AAA) and drive at-risk individuals to be screened, today announced the launch of a podcast and video series. Find the AAAnswers developed the series as an alternate avenue to educate consumers about AAA risk factors, and encourage at-risk individuals to be screened for the disease.

Podcast segments will cover a range of topics including:

• AAA survivor stories from patients and family members
• AAA in the news
• Tips for prevention and management of the disease

The first podcast in the series is currently available at http://www.slideshare.net/FindtheAAAnswers/podcast-1 and features a discussion with Find the AAAnswers Coalition partners Dr. Thomas Maldonado and Karen Fitzgerald, NP. Dr. Maldonado, a representative of Peripheral Vascular Surgery Society (PVSS), is also Chief of Vascular Surgery at Bellevue Hospital and Associate Professor of Surgery at NYU School of Medicine. He will provide listeners with an overview of AAA, explain who is potentially at-risk for the disease, and why it is known as a silent killer. Fitzgerald, a member of the Society for Vascular Nursing and Director of Nursing for The Vascular Group, PLLC, discusses the process of an AAA screening, how to discuss AAA with a loved one, and where to turn for more resources.

New podcast segments will be added monthly and available for download on www.FindtheAAAnswers.org and additional audio channels including iTunes and Podcast Alley. 

The first Find the AAAnswers webisode launched today and features impromptu, “man-on-the-street” style interviews with passersby in San Francisco to assess their level of awareness of AAA. Upcoming videos in the series will include behind the scenes looks at local AAA screening events and one-on-one chats with Campaign spokesperson and NFL legend, Joe Theismann. New videos will be added to the series monthly, and available for viewing on the Campaign’s YouTube channel.

Both series will also provide consumers with an opportunity to interact with Find the AAAnswers spokespersons, medical experts and AAA survivors by allowing them to submit their own questions to be posed in upcoming episodes.

About the Find the AAAnswers Campaign
Find the AAAnswers is a multi-faceted public education campaign designed to raise awareness of abdominal aortic aneurysms (AAA) and drive at-risk individuals to be screened. The campaign is supported by the Find the AAAnswers Coalition, an alliance of concerned medical societies, including the American College of Preventive Medicine, Peripheral Vascular Surgical Society, Society for Vascular Nursing, Society for Vascular Surgery and Society for Vascular Ultrasound.

Medtronic, Inc. provides sponsorship for the program due to the lack of awareness and accurate information available to the millions of at-risk Americans. Former professional football quarterback and sportscaster, Joe Theismann serves as the campaign’s spokesperson due to his family history of AAA.

• Follow us on Twitter
• Like us on Facebook
• Visit our YouTube channel
• Get updated AAA information with our widget

id=”nav_links”>

WEST HARTFORD, CT–(Marketwire – August 4, 2010) –  ORLive, the vision of improving health, presents a live broadcast of one of the newest total knee systems on the market presented by Wright Labs. Also explore the capabilities available at Morgan Stanley Children’s Hospital’s Center for Prenatal Care, as its world renowned staff presents its capabilities. In addition to these videos, ORLive invites you to take part in the latest installment of the Virtual Brain Tumor Board, and go back to school this month as your watch and learn from this month’s featured channel of medical education content.

NEW ON ORLIVE

LIVE SURGERY VIDEO – EVOLUTION™ Medial-Pivot Knee System
Live Monday, August 2, 2010, 6:00 PM EDT

Designed to replicate the function of a normal knee, the EVOLUTION™ Medial-Pivot Knee is one of the newest total knee systems on the market. This surgery is performed by Dr. David DeBoer, and he’ll answer questions during the broadcast. Learn the latest on the knee system that was built utilizing state-of-the-art design and manufacturing technologies… don’t miss “EVOLUTION™ Medial-Pivot Knee System.”

This surgery video is available to members of the ORLive community, and members can interact and ask questions via the ORLive website. Learn more about this broadcast at ORLive.com, and be ready to view this exciting procedure by activating your free membership to ORLive today.

NOW ON-DEMAND – Prenatal Pediatrics
Now Available On-Demand

Managing a high risk pregnancy can be difficult. NewYork-Presbyterian Morgan Stanley Children’s Hospital provides the maternal, fetal and pediatric expertise to care for high-risk pregnancies. NewYork-Presbyterian Morgan Stanley Children’s Hospital was one of only eight hospitals in the country ranked in each medical specialty measured by U.S. News & World Report, with distinct leadership in neonatology and pediatric cardiac surgery.

Join Dr. Mary D’Alton, Chair, Department of OB/GYN, Columbia University College of Physicians and Surgeons, and a team that includes Dr. Richard Polin, Director, Neonatology, as they review the capabilities and treatments available at the Center for Pediatrics. 

Viewers of this video are invited to interact with the team via the ORLive website, and to join the community and receive regular updates from the NewYork-Presbyterian Morgan Stanley Children’s Hospital Center for Neonatal Pediatrics.

ORLIVE REFERRALS – Week of August 2, 2010
Each week ORLive highlights on-demand videos for our membership and visitors. 

Medical Education Referral: Access to Surgical Intervention for Metabolic Syndrome and Other Diseases from Synovis Life Technologies

CME Referral: The New Frontiers in Atrial Fibrillation from CMEducation Resources

Viewer’s Referral: Webinar Series: Leading Causes of Life Among Those Who Care for Others from Methodist University Hospital

HIGHLIGHTS

NOW ON-DEMAND – Total Thoracoscopic Maze
Now Available On-Demand

The total thoracoscopic maze is a surgical procedure intended to permanently cure atrial fibrillation. This minimally invasive, beating heart procedure will be performed by Dr. Mubashir Mumtaz, Chief of Cardiothoracic Surgery at PinnacleHealth. 

Viewers are still invited to interact with the surgical team by submitting questions via the ORLive website. To learn more about this broadcast go to ORLive.com.

PREVIEW – DePuy® Rotating Platform Revision Knee Replacement
Live August 12, 2010, 7:00 PM

Dr. Russ Nevins will perform a revision total knee replacement using the Sigma® TC3 RP and M.B.T. Revision Tray system from DePuy Orthopaedics, Inc. The broadcast will be moderated by Dr. William Barrett (Renton, WA). This broadcast will take place from Spring Valley Hospital Medical Center in Las Vegas, NV. 

At 4PM Pacific (7PM EDT), Dr. Nevins will perform the revision total knee replacement surgery featuring the Sigma TC3 RP, a rotating platform knee implant design. This system helps diffuse loosening forces from the increased mechanical constraint typical in revision implant systems and offers surgeons enhanced fixation options through the use of metaphyseal sleeves on the femoral and tibial side. 

Viewers are invited to interact with the surgical team by submitting questions via the ORLive website. To learn more about this broadcast and to sign up for an e-mail reminder go to ORLive.com.

About ORLive
ORLive is the leading provider of video communication channels to the healthcare community. Working collaboratively with hospitals and device manufacturers, ORLive produces and distributes customized, interactive, video programs that demonstrate the latest advances in medicine, surgical techniques and product innovations. The ORLive broadcasting network provides an intimate look at over 650 live and on-demand surgeries to a global audience, streaming over 50,000 hours of programming each month. The ORLive network can be found on-line at www.ORLive.com.

id=”nav_links”>

NEW YORK, NY–(Marketwire – August 4, 2010) –  MedLink (OTCBB: MLKNA), a leading provider of Electronic Health Records and practice management solutions, is pleased to announce the acquisition of Health Informatics, Inc. a provider of cutting edge clinical data digitization technology that simplifies and streamlines the adoption of Electronic Health Records. 

The Health Informatics Digital Pen, in conjunction with MD Form Manager, is the flagship offering of the Company. The Digital Pen looks and feels like a normal ball point pen, however, the Digital Pen contains an integrated infrared digital camera, an advanced image microprocessor and a mobile communications device for wireless connection. The camera records the precise location of ink strokes as it moves over a uniquely constructed grid of microscopic dot patterns. These dots provide the pen with exact co-ordinates of its position, which, through MD Form Manager, are designed to interface directly with the MedLink EHR to collect discrete data elements that electronically populate the patient chart. The solution provides doctors and their staff with the traditional documentation approach of pen and paper, but the advanced ability of digitally documenting and capturing the data required to provide ‘meaningful use’ and other quality data reports.

Ray Vuono, President of MedLink, stated, “We partnered with Health Informatics a little over three months ago to offer the Digital Pen and the immediate reception to the technology in the marketplace was overwhelming. Both parties immediately realized the potential and the overall benefits of a combined solution and we’ve worked diligently over the past few months with Health Informatics to move beyond the inherent limitations of a partnership. The MD Form Manager and Digital Pen provides MedLink with a significant competitive advantage and I’m very excited to welcome Mr. Sayed Alam to the MedLink team, who I’m sure will be one of our most valuable assets. Mr. Alam, the President of Health Informatics, in addition to building a technology platform and enterprise offering, provides MedLink with a wealth of Industry knowledge, foresight and business acumen.”

About Health Informatics

Health Informatics provides cutting edge technology for the automated digitization of patient clinical forms. The solution eliminates the need for a separate digitization process and the associated time and expense involved with traditional paper medical records, by seamlessly integrating digital form with Electronic Health Record (EHR) systems. Please visit www.healthinformatics.us.com, to learn more about the technology and offerings.

About MedLink

MedLink is a healthcare IT company that provides the medical community with products and services designed to help create, manage, and share medical information. The company’s flagship product, MedLink TotalOffice EHR 3.1, a CCHIT Certified® 08 Ambulatory EHR, provides physicians with full EHR and practice management functionality. For more information regarding MedLink’s products and services, please visit www.medlinkus.com.

Safe Harbor Statement

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, outlined in our 2009 Annual Report on Form 10-K available through www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

MOUNTAIN VIEW, CA–(Marketwire – August 4, 2010) – Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible medical robotics and the developer of robotic technology for accurate 3D control of catheter movement, today reported its recent business highlights and financial results for the second quarter ended June 30, 2010.

Recent Business Highlights

• System Sales: The company recognized revenue on seven Sensei® Robotic Catheter Systems and shipped three systems during the second quarter. Second quarter revenue consisted of one system that was shipped in the quarter and six systems from deferred revenue that had been shipped in prior quarters. From commercial launch in 2007 through June 30, 2010, the company has shipped a cumulative total of 91 Sensei systems worldwide and recognized revenue on a total of 77 systems.
• Catheter Sales: The company recognized revenue on 555 Artisan^™ Control Catheters shipped during the second quarter.
• Procedures: Electrophysiology procedures performed with Hansen Sensei systems increased over 50% in the first half of 2010 as compared to such procedures performed in the first half of 2009.
• Vascular Platform: The company announced the successful completion of a pre-clinical in-vivo study evaluating its new vascular robot, which demonstrated improvements in catheter navigation, reduction in vessel trauma during catheter manipulation, and improvements in access time for some vessels, as compared to manual catheter manipulation during endovascular procedures. Results also showed that the company’s vascular robot has the potential to standardize catheter navigation, which may lead to more predictable procedures. The early, but encouraging results were presented June 12, 2010 at the Society of Vascular Surgery’s 2010 Vascular Annual Meeting in Boston.
• Electrophysiology: The company announced a joint development and cooperation agreement with Siemens Healthcare to co-develop integrated products designed to help simplify complex cardiac procedures for the diagnosis and treatment of cardiac arrhythmias, or irregular heartbeats. The agreements will enable the creation of integrated product solutions by combining Siemens’ Artis zee® family of angiography systems and the syngo® DynaCT Cardiac (angiographic computed tomography) with Hansen Medical’s Sensei® X Robotic Catheter System. The integrated products are being designed to enable electrophysiologists to perform complex cardiac procedures with greater confidence and improved efficiency.
• Clinical Trial Update: During the second quarter, enrollment began in the company’s conditional IDE clinical trial evaluating use of the Sensei® Robotic Catheter System and the Artisan^™ Control Catheter in patients with Atrial Fibrillation (AF).
• On June 9, 2010 veteran medical device industry executive Bruce J Barclay joined the company as president and chief executive officer, and a member of the Board of Directors. In addition, Frederic H. Moll, M.D. became executive chairman of the Board and Russell C. Hirsch, M.D., Ph.D., transitioned from his former role as chairman of the Board to lead outside director.

“The company is making important progress on several fronts that include key initiatives in growing our EP business, developing and commercializing our vascular platform and improving our operating efficiency,” said Bruce Barclay, president and chief executive officer of Hansen Medical. “During the second quarter, we commenced a previously announced conditional IDE clinical trial using our Sensei Robotic Catheter System for the treatment of patients with AF and results from a recently completed pre-clinical in-vivo study evaluating our new vascular robot validate the important progress of our vascular platform in addressing significant new markets for the company. Finally, while the company successfully raised $29.8 million of capital early in the second quarter, we are continuing to take a hard look at operating expenses while maintaining our focus on our strategic key initiatives.”

2010 Second Quarter Financial Results

Total revenue for the three months ended June 30, 2010 was $7.0 million compared to revenue of $2.9 million in the same period in 2009. During the second quarter, the company recognized revenue on seven Sensei Robotic Systems as well as on shipments of 555 Artisan control catheters. During the quarter the company shipped a total of three systems; one of which was recognized as revenue and two of which will be recognized as revenue as they are installed and physicians are trained, which the company expects will occur during 2010. In addition, six systems from deferred revenue that had been shipped in prior quarters were recognized as revenue in the second quarter of 2010. As of June 30, 2010 the company had a total deferred revenue balance of $10.3 million. The company has shipped 14 Sensei systems that have not been recognized as revenue.

Cost of goods sold for the three months ended June 30, 2010 was $4.5 million and included non-cash stock compensation expense of $156,000. As a result, gross profit for the quarter was $2.5 million and gross margin was 35.7%. This compares to gross profit of $0.3 million and gross margin of 9.7% for the same period in 2009, which included non-cash stock compensation expense of $214,000. Looking ahead for the remainder of 2010, the company expects that cost of goods sold, both as a percentage of revenue and on a dollar basis, will continue to vary from quarter to quarter as manufacturing levels fluctuate and as revenues fluctuate due to changes in system and catheter sales volumes, the timing of revenue recognition on shipped systems, product mix and average sales prices per system and per catheter.

Research and development expenses for the three months ended June 30, 2010, including non-cash stock compensation expense of $372,000, were $6.1 million, compared to $5.0 million for the same period in 2009, which included non-cash stock compensation expense of $688,000. The increase in research and development expenses was primarily the result of development of the company’s vascular system platform. During the remainder of 2010, the company expects research and development expenses to increase from 2009 levels principally due to the on-going vascular system platform development, the atrial fibrillation clinical trial sponsored by the company and engineering activities to support the fiber optic shape sensing and localization technology under our Luna Innovations development agreement.

Selling, general and administrative expenses for the three months ended June 30, 2010, including non-cash stock compensation expense of $504,000, were $7.2 million, compared to $9.9 million for the same period in 2009, which included non-cash stock compensation expense of $1.0 million. The decrease in selling, general and administrative expenses was primarily due to decreased employee-related expenses, related primarily to lower average headcount and a decrease in non-cash stock compensation expense. During the remainder of 2010, the company expects selling, general and administrative expenses to decline from 2009 levels primarily as a result of a decrease in legal and restatement-related expenses.

Other expense, net, for the three months ended June 30, 2010 was $131,000, compared to other expense, net, of $115,000 for the same period in 2009.

Net loss for the three months ended June 30, 2010, including total non-cash stock compensation expense of $1.0 million, was $10.9 million, or $(0.22) per basic and diluted share, based on average basic and diluted shares outstanding of 50.1 million shares. Net loss for the second quarter of 2009, including non-cash stock compensation expense of $1.9 million, was $14.7 million, or $(0.42) per basic and diluted share, based on average basic and diluted shares outstanding of 35.2 million shares.

Cash, cash equivalents and short-term investments as of June 30, 2010 were $44.2 million, compared to $28.3 million as of December 31, 2009. The higher cash, cash equivalents and short-term investments balance is primarily due to the successful completion of a secondary public offering of common stock in the second quarter of 2010, which included the sale of approximately 16.1 million shares with net proceeds to the company, after expenses, of approximately $29.8 million.

Hansen Medical Conference Call

Company management will hold a conference call to discuss its 2010 second quarter results today, August 4, 2010, at 2:00 p.m. Pacific (5:00 p.m. Eastern). Investors are invited to listen to the call live via the Internet using the link available within the “Investor Relations” section of Hansen Medical’s website at www.hansenmedical.com. A replay of the webcast will be available approximately one hour after the completion of the live call. Additionally, participants can dial into the live conference call by calling 888-549-7750 or 480-629-9867. An audio replay will be available approximately one hour after the completion of the conference call through August 11, 2010, by calling 800-406-7325 or 303-590-3030, and entering access code 4333050.

About Hansen Medical, Inc.

Hansen Medical, Inc., based in Mountain View, California, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The company’s robotic navigation system enables clinicians to place mapping catheters in hard-to-reach anatomical locations within the heart easily, accurately and with stability during complex cardiac arrhythmia procedures. Hansen Medical’s Sensei® system and its Sensei X Robotic Catheter System are compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. The remote navigation platform was cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in Electrophysiology (EP) procedures. The safety and effectiveness of the Sensei and Sensei X systems for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established. In the European Union, the Sensei and the Sensei X systems are cleared for use during EP procedures, such as guiding catheters in the treatment of AF. Additional information can be found at www.hansenmedical.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Hansen’s results to differ materially from those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “plan,” “expects,” “believes,” “goal,” “estimate,” “enable” and similar words. Hansen intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in such statements due to various factors, including but not limited to: the effect of credit, financial and general economic conditions on capital spending by our potential customers; risks and uncertainties inherent in our business, including potential safety and regulatory issues that could delay, slow or suspend our clinical trial or our sale efforts, uncertain timelines, costs and results of clinical trials and of developing new products, our ability to effectively sell, service and support our products, the rate of adoption of our systems and the rate of use of our catheters at customers that have purchased our systems, our ability to plan and manage cost-reduction or operational efficiency initiatives, the scope and validity of intellectual property rights applicable to our products and competition from other companies; additional costs and resources necessary to address existing shareholder litigation regarding the restatement of our financial statements; potential claims and proceedings relating to our restatement, such as additional shareholder litigation and any action by the SEC, U.S. Attorney’s Office or other governmental agency which could result in civil or criminal sanctions against the company and/or current or former officers, directors or employees; our ability to remediate material weaknesses in internal controls over financial reporting; and other risks more fully described in the “Risk Factors” section contained in Hansen’s periodic SEC filings, including its Quarterly Report on Form 10-Q filed with the SEC on May 10, 2010.

“Sensei,” “Artisan,” and “CoHesion” are trademarks of Hansen Medical, Inc., and “Hansen Medical,” “Hansen Medical and Heart Logo,” and “Hansen Medical Heart Logo” are registered trademarks of Hansen Medical, Inc. in the United States and other countries. Artis zee and syngo are registered trademarks of Siemens AG.

Condensed Consolidated Statements of Operations (unaudited)
(in thousands, except per share data)

Condensed Consolidated Balance Sheets (unaudited)
(in thousands)

NEW YORK, NY–(Marketwire – August 4, 2010) –  The need to reduce hospital costs is driving sales of new wound care products, even advanced products with a higher price tag, according to healthcare market research publisher Kalorama Information. Innovations such as biotechnology, biomaterials and tissue engineering will continue to boost revenues, according to its recent report “World Wound Care Markets 2010.” Kalorama estimates the worldwide wound care market reached revenues of $14 billion in 2009 and expects annual growth of over 6% for the next few years.

There have been many research developments in the acceleration of wound healing over the last decade. However, recently these advancements are taking place even more frequently and some of the new products now represent the best new change in the past 30 years. New developments are providing the health care arena of today with some truly sophisticated, highly effective wound care treatments that are poised for growth.

“Many of these new products are proven cost-savers,” said Mary Ann Crandall, analyst for Kalorama Information and author of the report. “There’s always a demand to reduce hospital stays and improve patient outcomes, and a product that can save money in the long run can get a favorable result in reimbursement decisions.”

Wound healing is much like solving a puzzle that involves a series of integrated physiological processes. Various steps must be synchronized and organized in order for everything to fall into place. Without the proper signals at the correct time, a wound cannot heal properly. Having the right tools available, such as appropriate cells, proper nutrition and proper support, is essential. The nature of healing is the same for all wounds with variations depending on the location, severity, and extent of injury. More sophisticated products and a better understanding of the healing processes are increasingly helping to better solve this puzzle.

Beyond new products, Kalorama predicts the market will expand into the future due to demographic factors such as an aging population and an increasing number of sicker patients with more complex coexisting illnesses including diabetes, heart failure, obesity, pulmonary and vascular diseases, immobility issues and chronic wounds. Pressures to cut costs and move patients out of hospitals faster are also leading manufacturers to develop more effective wound care products, according to the report.

The top four wound care companies worldwide include Johnson & Johnson, Kinetic Concepts, Hill Rom and Smith & Nephew. These companies are responsible for about 60% of the revenues of the total market.

“World Wound Care Markets 2010” investigates what the wound care market looks like today; how the market has fared during the recent economic downturn; which segments offer the best market opportunity for companies; and many other key issues and trends. For further information visit: http://www.kaloramainformation.com/redirect.asp?progid=79420&productid=2675467.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

SUNRISE, FL–(Marketwire – August 4, 2010) –  Interim HealthCare® Inc., the nation’s first and finest healthcare and in-home senior care franchise company, is offering Philadelphia residents the opportunity to own their own business with an Interim HealthCare franchise. With a network of more than 300 independently owned franchises across the country, Interim is now seeking franchisee candidates in Philadelphia to be part of an aggressive growth campaign designed to increase its U.S. presence over time. 

Interim’s senior care franchises include non-medical and medical personal care, nursing and healthcare staffing services. The system has a 40 year history within the healthcare industry and many of their franchisees have an average tenure of 24 years.

Executives from Interim will be in town to host a franchise opportunities seminar on August 17 at 7:00 p.m. at the Crowne Plaza – Valley Forge located on 260 Mall Boulevard for all interested candidates. To register for the event and learn more, please log onto www.interimfranchising.com or call 866-767-4730.

“Interim HealthCare has been assisting patients and their families since 1966 and we are excited to expand our footprint in Philadelphia,” said Kathleen Gilmartin, CEO of Interim Healthcare. “We’re looking for interested individuals to join our team who have the sensitivity and compassion needed in our business to help our customers when it matters most.”

Currently with more than15 locations in Pennsylvania, Interim is looking to expand its presence throughout the state by indentifying eight new openings in Philadelphia over four years. Qualified candidates should possess a minimum net worth of $400,000, and a minimum liquidity of $50,000. Franchisees can expect their initial investment to range from approximately $115,500 to $188,500 including the franchise fee.

“Today there are 1 in 8 people 65 or older and by 2030 there will be more than twice that number,” said Gilmartin. “Therefore the growing senior population and home care growth market is a great niche for franchising and with additional Interim HealthCare franchises in the Philadelphia area, we will help the increasing need,” said Gilmartin.

Franchisees utilize comprehensive operations, financial, training, and sales systems to assist in operating their business at maximum efficiency and effectiveness. Additionally, they receive extensive local and national marketing support throughout the year. Interim HealthCare franchise owners share a commitment to improving the lives of their patients and communities, and they continue to realize opportunities for growth in the growing baby boomer segment and home care industry.

About Interim HealthCare:
Founded in 1966, Interim HealthCare® is the nation’s oldest proprietary national health care franchise organization providing health care personnel at all skill levels in all settings. Through a comprehensive network of more than 300 independently owned franchise offices, Interim HealthCare® franchisees are the largest combined provider of community-based home care (skilled and non-medical) and health care staffing. Interim HealthCare is unique in combining the commitment of local ownership with the support of a national organization that develops innovative programs and quality standards that improve the delivery of service through franchisees who employ more than 75,000 health care workers who serve 50,000 people each day. For more information or to locate an Interim HealthCare office, visit www.interimhealthcare.com.

Click here to see all recent news from this company

IRVINE, CA–(Marketwire – August 4, 2010) –  Bivar, a leading specialty provider of LED indication products and solutions, today announced ORCAdapt™ a complete light pipe system. The new system arms design engineers with a host of options that make moving LED light in existing and emerging applications much easier. The new ORCAdapt solution consists of an ORCA adaptor with a built-in ORCA Super Flux LED and a flexible light pipe system available in 1mm or 2mm size options.

The ORCAdapt unites the well-known brightness and durability of the ORCA Super Flux LED with the optimized light transmission and customized routing of Bivar’s flexible light pipe systems. Bivar’s ORCAdapt is ideally suited for a wide variety of applications such as field instrumentation, heavy equipment, medical devices and transportation.

“The new ORCAdapt brings together a solution that features our ORCA Super Flux LEDs and our 1mm and new 2mm flexible light pipe system,” said Michael Finn, Bivar vice president of sales and marketing. “The ORCAdapt is our answer to customer demand for a complete, cost-effective light pipe system that offers a greater level of design freedom with brilliant light output and high performance.”

The new ORCAdapt light pipe system features Bivar’s ORCA series of Super Flux LEDs, which are an expansion of the company’s high power LEDs designed for use on standard printed circuit boards. ORCA Super Flux LEDs offer greater luminous intensity, higher power efficiency and additional lens configurations while maintaining an industry standard 7.6mm square package form factor. In addition, ORCAdapt supports Bivar’s 1mm and 2mm flexible light pipe systems. The 2mm plastic optical fiber light pipe system is Bivar’s newest addition to the light pipe family and is an ideal LED indication alternative to custom rigid light pipes. The optical fiber maximizes light transmission up to 98 percent, has no light leakage, and is covered with a tough, flexible RoHS compliant PVC alloy outer jacket that maximizes light transmission.

Additional features of the ORCAdapt Complete Light Pipe System:

• Available in lengths from 2.5″ to 238′;

• Works with single, bi-color and tri-color ORCA LEDs;

• Input driven color adjustment capabilities;

• Simple press fit lens mounting provides rapid installation while retention is vibration and shock resistant.

The new ORCAdapt is immediately available. For more information please visit www.bivar.com. For application assistance and samples, please contact Bivar Sales at [email protected].

About Bivar
Bivar is a leading specialty provider of LED indication products and solutions with a long-standing history of more than 40 years of innovation in the optoelectronics industry. With a global base of customers in 35 countries, Bivar’s products are designed to meet the increased demand for point-to-point indication and address a growing range of industrial markets and applications. Bivar’s focus is on moving and positioning light. An employee-owned company, Bivar’s corporate headquarters are located in Southern California, with manufacturing in California, China and Taiwan. 

Bivar’s Asia Pacific production and logistics centers offer scalable capacity, execution, control and movement of product around the world. Bivar is widely supported by a highly qualified network of authorized representatives and distributors. For more information, please visit www.bivar.com.

Click here to see all recent news from this company

MIAMI, FL–(Marketwire – August 4, 2010) –  Renato Corporation (FRANKFURT: 4OZ) is pleased to announce the merger with a major pharmaceutical group in California and Texas as well as 8 medical clinics in California and Arizona. Due diligence has just completed and we look forward to the closing of the merger within the next 14 days.

Healthcare in the United States is undergoing a profound change, driven by both legislation and cost. The new healthcare legislation, the excessive cost of American Health Care, and an estimated 35 million more people under the healthcare will drive the growth of medical clinic groups.

The 8 medical clinics have a combined revenue of $10.5 million dollars.

This group operates 20 natural pharmacies in southern California and Texas and has annual revenues in excess of $8 million, targeted primarily at the Hispanic market, the fastest growing segment of the US population, with vitamins, nutraceuticals and wellness products, the fast growing category of consumer consumption.

The merger of the health clinics with the natural pharmacies is an ideal mix that is designed to enhance the bottom line of both operations with a blend of Hispanic and Non Hispanic clientele.

The established revenues of the properties plus the expected growth of the merged entity will ensure the success of Renato Corporation. The company is in serious discussion with a further 8 groups comprising 27 clinics with revenue in 2010 of approximately $65 million and EBITDA of $14.5 million.

The incoming board comprises Bob Pritchard as Chairman as well as Marketing Director with Dwight Staffelback, BA, MS Public Administration, who will take on the position as CEO, and John Falting is taking up position as Company Secretary for the group.

As of August 2, 2010, the new Board of Directors of Renato Corporation is re-structuring the company’s corporate business plan and is evaluating all existing negotiations and agreements.

www.renatocorp.com, www.renatocorp.de

About Renato Corporation

At Renato Corporation it is the company’s objective to provide diverse early detection diagnostic technologies utilizing its current experience, reputation and expertise within the international health care industry. Introducing and making available these non-invasive technologies through private health care firms and health and wellness centres in an affordable manner is our immediate focus.

The company’s mission is to carefully select where these advanced diagnostic technologies will be placed to ensure unparalleled delivery of customer service and satisfaction in the field of non-invasive early detection disease diagnosis and management.

Innovative information technology platforms are enabling new models for more efficient, effective and safer healthcare delivery. It is inevitable that the economic strain on today’s health care systems worldwide will realize the ever increasing need for early detection diagnostic devices and services.

Disclaimer & Safe Harbor Statement:
This release includes forward looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise. “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995.

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – August 4, 2010) – www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today announced the decision to close
the US headquarters of NicOx Inc. with effect from August 31, 2010. The
decision follows a review of the Group’s structure and requirements after
the US Food and Drug Administration (FDA) said it could not approve its
lead drug candidate naproxcinod, which is expected to at least
significantly delay any potential US launch.

NicOx plans to discuss possible next steps as early as possible with the
FDA and to continue to pursue the European regulatory process for
naproxcinod. NicOx will also actively seek to enter into partnerships for
naproxcinod in Europe and the rest of the world as well as for other
products in its pipeline whilst also pursuing appropriate in-licensing and
M&A opportunities.

The Company had cash and cash equivalents of ?128.4 million at June
30, 2010, and no long-term debt. It also has development partnerships on
its pipeline with Bausch + Lomb, Merck & Co. Inc and Ferrer Grupo.

Michele Garufi, Chief Executive Officer of NicOx, commented: “We very much
regret having to close our operations in the US and we are grateful for the
hard work and dedication of all our employees over the past few years. They
have played a major role in raising awareness among scientists and
clinicians of naproxcinod’s potential medical and clinical value. As we
seek to work out possible next steps for naproxcinod in the US and to
pursue the approval process in Europe, it is essential that we manage our
resources in the most effective manner.”

Risks factors which are likely to have a material effect on NicOx’s
business are presented in the 4th chapter of the ” Document de
référence, rapport financier annuel et rapport de gestion 2009 ”
filed with the French Autorité des Marchés Financiers (AMF) on
March 5, 2010 and available on NicOx’s website (www.nicox.com) and on the
AMF’s website (www.amf-france.org).

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the U.S. Food and Drug
Administration (FDA) provided a Complete Response Letter to the New Drug
Application (NDA) for naproxcinod stating that it does not approve the
naproxcinod application. The naproxcinod Marketing Authorization
Application (MAA) submitted by NicOx in December 2009 is currently under
review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although
the Company believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from
those anticipated in the forward-looking statements.

For a discussion of risks and uncertainties which could cause actual
results, financial condition, performance or achievements of NicOx S.A. to
differ from those contained in the forward-looking statements, please refer
to the Risk Factors (“Facteurs de Risque”) section of the Document de
Reference filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on NicOx S.A.’s website
(http://www.nicox.com).

This information is provided by HUGIN

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Aug. 3, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (“ALDA” or “the Company”) announces that it is seeking an extension of the exercise period of an aggregate of 6,000,000 outstanding share purchase warrants issued as part of the non-brokered private placement of common share units which closed on September 16, 2009. Pursuant to the proposed extension, the applicable exercise period will be extended by one further year, from September 16, 2010 to September 16, 2011. The warrant exercise price of $0.40 per share will remain the same. Insiders of the Company hold 50,000 of the outstanding share purchase warrants subject to the proposed amendment.

The proposed extension is subject to the warrant holders entering into definitive amendment agreements and the acceptance of the TSX Venture Exchange. The amendment provides ALDA with an extended opportunity to receive funding for general corporate purposes from existing warrant holders.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

DENVER, CO–(Marketwire – August 3, 2010) –  Microsoft recently published a case study demonstrating how executives at Denver Health increased performance and strategic focus using Microsoft Outlook and productivity models developed by McGhee Productivity Solutions (McGhee).

The case study describes a situation where executives at the helm of a large hospital serving 25 percent of Denver’s population found themselves spending too many hours trying to manage the influx of messages and meeting requests that flow through the medical center each day. Chief Information Officer at Denver Health, Gregory Veltri, stated, “I was working 12-hour days and spending about three and a half hours per day on just e-mail.”

McGhee provided desk-side productivity coaching to executives and their assistants to increase their strategic focus, performance, and work/life balance. The program provided proven theories and models for improving knowledge-worker efficiency, creating behavioral change, and implementing an Integrated Management System using Microsoft Outlook. Results included a more powerful partnership, reductions in non value-added tasks, and an increase in time spent on objectives. As recorded in the case study, the executives and their assistants have reclaimed time and gained control of their workday with positive shifts in overall accountability and integrity.

Veltri, who previously found it difficult to find the time to plan for departmental growth, now spends much more time planning and developing the IT strategy for his team and for Denver Health. “I can consistently assess how my team’s goals contribute to the overall strategy and make timely adjustments as necessary,” stated Veltri following the coaching.

All Denver Health participants in the McGhee coaching program have said that their ability to balance work and their personal lives has improved significantly. Executives improved planning, strategic focus, boosted their daily productivity, and are now able to spend more time on strategic tasks. When they were asked to quantify the improvement, employees and senior management reported increased satisfaction rates of up to 20 percent.

“The strategic partnership between Microsoft and McGhee goes back several decades. Our collective offerings complement each other to drive business results for enterprise clients, and we are very proud of our work with Denver Health and this acknowledgement,” said McGhee CEO, Sally McGhee.

Read the full case study at http://www.mcgheepro.com/executive-management-productivity-strategies-case-studies.aspx

McGhee Productivity Solutions, Inc. (McGhee) provides consulting services, tools, and education to increase performance and work/life balance. Based in Denver, CO, McGhee integrates its proven methods and protocols with Microsoft technology to deliver innovative action-management strategies to individuals, teams, and organizations worldwide. From the boardroom to the knowledge worker, the McGhee approach drives accountability, maximizes technology investments, and improves job satisfaction to help organizations create a true culture of productivity. McGhee is in the process of becoming a Certified Woman-Owned Business www.mcgheepro.com.

Click here to see all recent news from this company

MUNDELEIN, IL–(Marketwire – August 3, 2010) – Medline Industries, Inc., the company that produced the original Pink Glove Dance, is looking for breast cancer survivors and caregivers in the Chicago area who want to be part of the next Pink Glove Dance video. The original video has become an internet sensation, generating more than 11 million views on YouTube since its release last November. The video features healthcare workers at Providence St. Vincent Medical Center in Portland, Ore. dancing while wearing pink gloves. Medline, based in Mundelein, Ill., is the largest privately held manufacturer and distributor of healthcare supplies in the country.

When and where will it be?
Filming will take place Sunday, August 22 at 9:00 a.m. at Northerly Island (formerly Meigs Field), just south of Adler Planetarium and east of Soldier Field.

What are the qualifications to participate?
Participants need to be breast cancer survivors or healthcare workers and willing to dance wearing pink gloves. No special dancing skills required. A choreographer will be there to teach simple routines.

How long will it take?
Approximately two hours.

How do I sign up?
Details of the video shoot and registration can be found online at www.pinkglovedance.com.
Although participants can just show up on the day of the event, participants are encouraged to register online. 

Why is this video being made?
The first video was created to help spread the word about breast cancer awareness and the importance of the healthcare worker who takes care of breast cancer patients. It was so successful and generated so much positive attention that hospitals around the country inquired about participating in the next video. So the idea of a sequel was developed that not only included hospital workers but breast cancer survivors too. 

Why pink exam gloves?
As a way to extend Medline’s breast cancer awareness campaign, the company developed a pink glove called Generation Pink™. Gloves are also the first point of contact between the healthcare worker and the patient. And, the fact the glove is pink, Medline hoped would get people talking about breast cancer. When the gloves were launched in October, Medline committed to donating $1 of every case purchased to the National Breast Cancer Foundation to fund mammograms for individuals who cannot afford them. In the past five years, Medline has donated almost $500,000 to the National Breast Cancer Foundation. 

NEW YORK, NY–(Marketwire – August 3, 2010) –  A robust over-the-counter (OTC) drug market exists in less developed regions, where OTC is often the most practical distribution method, according to medical market research publisher Kalorama Information. According to “The Worldwide Over-the-Counter (OTC) Drug Market,” a recent Kalorama report, non-prescription pharmaceutical sales account for between 8% and 30% of total pharmaceutical markets around the globe, with higher ratios of OTC sales in developing nations. Kalorama estimates the OTC drug market in Asia-Pacific and Africa is worth $21 billion with an average growth of 4% annually.

In 2009, the OTC drug market in the developing BRIC nations (Brazil, Russia, India, and China) claimed a higher percentage of total pharmaceutical sales compared to more developed nations such as the United States, which had an OTC market share of 8%. India paced the quartet of burgeoning world powers with an OTC market share of 33%. China (23%), Russia (19%), and Brazil (17%) followed suit with double-digit OTC share claims.

Developed nations Japan and Australia are also important international players in the OTC market, though the greatest opportunities for growth and expansion remain in China, India, Singapore, Malaysia, and Indonesia, among other developing nations.

“It’s simply easier to work around regulatory and distribution issues in these countries by distributing product direct to consumers where it is medically possible,” said Melissa Elder, analyst for Kalorama Information. “It’s not a new trend, but we see sales to developing nations continuing to drive up the portion of all Pharma sales that are OTC.”

Additionally, in nations such as China the general population has an increasing ability to purchase products due to staggering increases in per capita Gross National Income between 2000 and 2005. Combined with the large population of China, there is now a more significant market opportunity for companies to sell products, especially OTC products. In comparison, the U.S. experienced a mere fraction of China’s per capita GNI growth during the same period, while Latvia was the only country with a greater GNI increase than China.

The state of the economy, lifestyles, cultures, and the condition of medical care all contribute to the percentage of people that seek to self-medicate. People are highly influenced by the cost of healthcare and will purchase OTC products in order to save money. Because a large number of consumers in India are uninsured, the majority of the population is forced to be conscious of health spending. As an example the report says that nearly 80% of India’s population actively self-medicates according to the report. In Kenya nearly 60% of the population actively self-medicates for similar reasons.

“The Worldwide Over-the-Counter (OTC) Drug Market” investigates the strategies pharmaceutical companies are using in the international OTC market. The report includes market sizes and forecasts in five general segments. For further information visit:
http://www.kaloramainformation.com/redirect.asp?progid=79415&productid=2661910.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

WESTPORT, CT–(Marketwire – August 3, 2010) –  Save the Children deployed its rapid response team to the worst-affected and hardest to reach communities in Pakistan’s Swat Valley, where record-breaking monsoon rains have triggered deadly floods and mudslides. The team had to navigate the rushing waters using rafts linked to ropes and pulleys in order to distribute temporary shelters and supplies to stranded children and their families.

The Information Minister of the worst affected province of Khyber Pakthunkhwa, Mian Ifthikar Hussain, estimates 1,500 have been killed by the floods nationwide. Now, officials fear an outbreak of disease among the millions left homeless and without clean water supplies. 

“In nearly all the flood-affected areas, water supplies have been contaminated,” said Annie Foster, Save the Children’s associate vice president for humanitarian response. “There are confirmed reports of diarrhea and cholera that may spread rapidly among the hundreds of thousands who have lost their homes. In this type of environment, children — especially those under five years of age — are the most vulnerable to severe illness and even death.”

Save the Children sent mobile health teams to provide emergency medical aid to treat more than 1,400 people in DI Khan, Buner and the Swat Valley area. The teams travelled by boat and often had to hike many kilometers to remote villages, where roads and bridges had been washed away.

The floods are now heading towards Muzaffargarh, Layyah and DG Khan and Rajanpur, in Punjab. Heavy rains predicted for the first two weeks of August are expected to increase the difficulty of delivering humanitarian aid.

“People are stranded and are rapidly using up their supplies of stored food,” said Foster. “There is a critical need to get more clean water, food and medical assistance to thousands of children and their families in the next few days.”

Save the Children has been working with the children of Pakistan and their families for more than 30 years, and provided assistance to those affected by Tropical Storm Phet in June, the conflict in Khyber-Pakhtunkhwa Province in 2009 and the massive earthquake in 2005.

Donate Now to the Pakistan Children in Emergency Fund or call (800) 728-3843.

Save the Children is the leading, independent organization that creates lasting change for children in need in the United States and around the world. 

NEWPORT BEACH, CA–(Marketwire – August 3, 2010) –  Nationwide Health Properties, Inc. (NYSE: NHP) announced today that its Board of Directors declared a quarterly common stock cash dividend of $0.46 per share, a $0.01 increase from the prior quarterly dividend of $0.45 per share. The dividend will be paid on September 3, 2010 to stockholders of record on August 20, 2010.

Nationwide Health Properties, Inc. is a real estate investment trust (REIT) that invests primarily in healthcare real estate in the United States. As of June 30, 2010, the Company’s portfolio of properties, including mortgage loans and properties owned by unconsolidated joint ventures, totaled 628 properties among the following segments: 283 senior housing facilities, 206 skilled nursing facilities, 120 medical office buildings, 11 continuing care retirement communities, 7 specialty hospitals and 1 asset held for sale. For more information on Nationwide Health Properties, Inc., visit our website at http://www.nhp-reit.com.

NEW YORK, NY–(Marketwire – August 3, 2010) –  United Treatment Centers, Inc. (PINKSHEETS: UTRM)

Dear Fellow shareholders:

It has been three months since the company has issued a press release and we, UTRM management, wanted to inform investors on the progress of the company’s business plan.

The company was notified that Glaxo Smithkline had filed a trademark infringement lawsuit which precluded the advisability of shipping any product with the contested name. There was no way of knowing how long the legal process would be, and weeks became months. The company is diligently working to resolve the issue with Glaxo and will inform investors on any progress immediately. “We feel this lawsuit has only delayed the company’s ability to ship product and will ultimately be finalized,” said Todd Spinelli Vice President of Business Development. He added, “This proprietary product brings sanitary brushing, convenience and the first ever waterless toothbrush to the forefront of a 47 Billion Dollar global industry.”

The company continues to pursue contracts and business relationships in anticipation of the resolution of the lawsuit. The company has ordered product parts without the “Aquafree” name to fulfill any new orders and will announce any shipments. UTRM management does not feel that the success of the Waterless Toothbrush is dependent upon the “Aquafree” name and is anxious to move forward in following up with promising initiatives with a number of government agencies and international distributors.

UTRM has discovered, and is targeting, a very promising sector for the Waterless Toothbrush in the United States — municipalities in states that face severe challenges with water conservation initiatives.

Significantly for the long term future of UTRM, the company has been approached by well-known retail merchants but it has been determined that it would be advisable that the company “grow” into accepting these larger orders from these large potential customers. Financing larger orders too early in the company’s financial history can be limiting and restrict our flexibility, but we anticipate closing on these larger accounts in the next six to twelve months.

UTRM management is confident that our business plan is solid and the company will continue to sign contracts with significant marketing partners within the next few weeks. We apologize for the inadvertent delays in executing our business plan, but we are excited by the future of the company and our groundbreaking product. We already know there is a great deal of interest by green technology firms, governmental and non-governmental organizations (NGO’s) and international distributors.

As shareholders too, we understand your frustration with recent delays, but we thank all shareholders for their patience and support. You can visit us at www.thewaterlesstoothbrush.com

Sincerely,
UTRM Management

To be included in the company’s database for company updates, press releases and industry developments, investors and shareholders should send their e-mails to [email protected].

About United Treatment Centers, Inc.
UTRM is a dental health and green technology company which developed and is now marketing a revolutionary new, patented and patent pending oral care product which will change the way people perform their daily dental hygiene task-brushing teeth. UTRM will oversee out-sourced production of a patent pending consumer product focused on the $4.8 billion United States oral care market segment comprised of toothbrushes and toothpaste. The Waterless Tooth Brush is unique with significant advantages over existing and traditional toothbrushes: it cleans and prevents cavities 35% better than traditional brushing because it uses liquid dentifrice (Journal of American Dental Association [JADA:135(7): pp.1023-1029]), so toothpaste is no longer required to brush, allowing the user to brush virtually anywhere at any time with no water required. The company’s corporate website is http://www.unitedtreatmentcenters.com/.

This document includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or beliefs, and are subject to uncertainty and changes in circumstances changes in economic, business, competitive, technological and/or regulatory factors.

Safe Harbor

Statements about the Company’s future expectations and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. When used in this document, the words “anticipate,” “estimate,” “expect,” “intend,” “plans,” “projects,” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.

SOUTH SAN FRANCISCO, CA–(Marketwire – August 3, 2010) –  Two leading non-profit providers of mental health and addiction recovery counseling services are merging their organizations to provide better care and more comprehensive, holistic counseling to those in need, it was announced today.

Pyramid Alternatives of Pacifica, which provides counseling on mental health, substance abuse, domestic violence, and trauma services, will merge with Sitike Counseling Center of South San Francisco, a provider of addiction recovery services. The merged organizations will continue to be housed in their respective locations in Pacifica, South San Francisco, San Bruno and Half Moon Bay.

Rhonda Ceccato, executive director of Sitike Counseling Center, believes that by combining the two organizations, those in need will get more comprehensive, holistic counseling. “Two years ago, Janeen Smith and I began talking about our mutual concerns for the future,” she said. “The economic climate and the challenges of serving a more diverse and complex population, together with the need to attract and retain qualified staff, drove us to seriously consider a merger.”

Janeen Smith, executive director of Pyramid Alternatives, explained that the merger will result in better care for the organization’s clients. “Our new organization will be an important safety net for the San Mateo community, providing valuable services to an especially vulnerable population in this economy,” said Smith.

Ceccato and Smith both believe that the increasing emphasis on co-occurring or complex disorders as well as the desire among funders for larger, more comprehensive providers makes the merger a logical progression. An added benefit for staff will be the opportunity for quality training and career advancement. No layoffs are planned at this time, said Ceccato and Smith.

When the merger is completed, Rhonda Ceccato will serve as Executive Director and Janeen Smith will be Deputy Director. The respective Boards of both organizations will be combined to form a single Board of Directors.

Pyramid Alternatives has been serving clients in San Mateo County since 1973 and Sitike Counseling Center first opened its doors in 1988. The newly merged group will announce its new name by December 2010.

Rhonda Ceccato has more than 30 years of experience in the San Francisco Bay Area’s non-profit sector. Substance abuse treatment is both her passion and her area of expertise. Since 1993, Rhonda has served as Executive Director of Sitike Counseling Center, a community-based treatment center that provides a variety of recovery services for adult men and women. In 1995 Rhonda co-founded the San Mateo County Alcohol and Drug Providers’ Coalition, which recently merged with the San Mateo County Mental Health Contractors to form the Behavioral Health & Recovery Contractors Association. Prior to beginning her tenure at Sitike, Rhonda was Executive Director for the San Francisco Chapter of the National Council on Alcoholism and Drug Dependence and from 1977 to 1992 Rhonda worked in various capacities, including Interim Executive Director for the Women’s Alcoholism Center in San Francisco. She played a key role in planning and designing the Bay Area’s first intensive outpatient and residential programs for pregnant and parenting women, Lee Woodward Counseling Center and Pomeroy House. Rhonda Ceccato was elected in 2002 to the San Mateo County Board of Education and serves as a Trustee for South San Francisco Unified School District. Rhonda also lends her expertise as an active participant in other community organizations and currently serves as a consultant to the Nurse Diversion Evaluation Board for the State of California Board of Registered Nursing.

Janeen Smith is a Licensed Marriage and Family Therapist (MFT) with 20 years of experience in the field of mental health, substance abuse and violence prevention. She began her career in residential treatment at Bay Area Youth Centers in Hayward, California, in 1991. In 1995, she began work as a Case Manager for Edgewood Children’s Center in San Francisco after which she joined the Counseling Clinic at San Francisco State University. In 1997, she interned at Rape Trauma Services in Burlingame and began work at Pyramid Alternatives and has been there ever since. While at Pyramid, Janeen began as a staff counselor, was promoted from Outpatient Coordinator to Alternatives to Violence Manager and when licensed, became a clinical supervisor. In 2006, she was promoted to Deputy Director, and finally took over as Executive Director in 2007. Janeen’s passion is in partnerships and collaboration to improve services to the community. She is a co-founder of the North County Outreach Collaborative, (NCOC), and a co-founder of the Bayshore Community Prevention Project. Janeen is a member of the Co-Occurring Steering Committee of San Mateo County, the Daly City Partnership and Pacifica Collaborative. Janeen received a Masters of Counseling degree from San Francisco State University and her Bachelor of Science degree from San Diego State University.

Sitike Counseling Center
306 Spruce Avenue
South San Francisco, CA 94080
650-589-9305
www.sitike.org

Pyramid Alternatives
480 Manor Plaza
Pacifica CA 94044
650-355-8787
www.pyramidalternatives.org

Click here to see all recent news from this company

BETHESDA, MD–(Marketwire – August 3, 2010) – GetWellNetwork, Inc. today announced that Comer Children’s Hospital at the University of Chicago is using GetWell Town™, the industry’s leading pediatric interactive patient care solution, to advance patient engagement, education and safety. GetWell Town is also helping children ease into their hospital stay with high quality entertainment features including password-protected, parent-controlled access to the Internet, Pandora, Hollywood movies, games and more. 

“GetWell Town is the perfect bedside solution to complement our vision of children and family-centered care,” said Jeffrey Finesilver, Vice President of University of Chicago Medical Center and Director of Comer Children’s Hospital. “We are very excited to provide our families and young patients with a new interactive approach to learning about their health and to access the hospital’s resources from the bedside.”

One of the first initiatives at the hospital has been to provide patients and families with direct access to services such as housekeeping, patient relations, hospital chaplain and more. Rather than calling their nurse to make service requests, patients can simply use their beside remote control and keyboard to communicate their needs via the GetWell Town system. This streamlines service requests, expedites the response, frees nurses for care tasks, and empowers young patients to feel independent and make their own choices.

GetWell Town offers exclusive KidsHealth® content with more than 170 videos of specific conditions and medical procedures — all in child-friendly language.

Comer Children’s Hospital will be enhancing patient education and influencing clinical outcomes through innovative programs such as the GetWell Town Asthma Care Plan. The GetWell Town Asthma Care Plan prepares patients and families for managing their condition at home with fewer visits to the hospital.

GetWellNetwork will also integrate with the hospital’s EpicCare Inpatient Clinical System to enable bi-directional flow of patient information. Nurses will be able to order education content specific to a child’s diagnosis, keep track of their progress and have it automatically documented into the patient’s record. This will help save nursing hours, meet regulatory compliance, and reduce the potential for human errors.

“Comer Children’s Hospital is focused on providing the optimal patient care experience for their patients and families.” said Shannon O’Neil, MSW, Director of Pediatrics, GetWellNetwork, Inc. “We are honored to be working with them in leveraging bedside technology to truly educate and engage families throughout the care process, and to help in driving key hospital initiatives.”

About GetWell Town
GetWell Town was developed in collaboration with GetWellNetwork’s National Children’s Hospital Task Force, comprised of 15 pediatric facilities across the U.S. as well as direct input from pediatric patients and their families. GetWell Town is designed to complement the kid-friendly spaces that children’s hospitals have worked hard to create and features exclusive content in partnership with KidsHealth®, part of The Nemours Foundation’s Center for Children’s Health Media.

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

Click here to see all recent news from this company

SEATTLE, WA–(Marketwire – August 3, 2010) –  Mindbloom, Inc. today announced a strategic partnership with Sacramento State ‘s health and wellness facility, also known as The WELL (Wellness, Education, Leisure, Lifestyle), that will leverage Mindbloom technology to enhance the effectiveness of the campus’ 7 Dimensions of Wellness Program. 

The Well serves approximately 28,000 faculty, staff and students and is designed to support health-promoting behaviors and healthy life-balance choices. Mindbloom’s enterprise platform enables The WELL to insert its proprietary content into the Mindbloom platform to create a customized experience that encourages users to make their healthy behaviors an everyday priority.

“The WELL’s program is a perfect fit for our enterprise platform,” said Chris Hewett, Mindbloom’s founder and executive producer. “By fusing great content within an easy-to-use format, we’ve created a wellness and personal development experience that’s simple, fun and effective. The combination of the university’s framework and our Life Game™ platform will deeply engage students, faculty and staff in ways that can actually establish and sustain healthy habits.” 

Mindbloom.com is a social Life Game — a new genre of online experiences that motivate and activate people in their quest for health and wellness, life balance and meaningful relationships. By combining proven personal development concepts with gaming mechanics and social networking support, Mindbloom creates an immersive, personalized, online experience where users choose and accomplish small steps that produce meaningful results. Its enterprise platform allows content providers, wellness programs, and health-oriented communities to embed the Mindbloom experience into their own website, customize their users’ experience, incorporate their proprietary content, and extend both their core philosophy and their brand.

“Incorporating the Mindbloom enterprise platform takes our 7 Dimensions of Wellness Program to a higher level,” said Mirjana Gavric, director of The WELL. “It helps us personalize our information and its experiential engagement and social networking support make it a perfect fit for the members of the Sacramento State community.”

Mindbloom Launches Enterprise Platform

The WELL at Sacramento State is a 151,000-square-foot-facility that’s scheduled to open September 2, 2010. Its 7 Dimensions of Wellness Program helps participants explore and balance all aspects of their lives, toward creating and maintaining optimal wellness. 

“Mindbloom’s enterprise platform is an important part of our business model,” said Brent Poole, Mindbloom’s CEO. “Partnering with academically grounded and well developed programs like The 7 Dimensions of Wellness allows us to connect with people who have decided they want to take more responsibility for their own health, and who want a little extra help to take small steps toward things that they care about.” 

Because the Mindbloom experience is effective in motivating and supporting people to make and sustain personal change, Mindbloom’s enterprise platform will be attractive to any company, association, organization, or community seeking to support its members to make personal change toward healthier lifestyles. It is an excellent business solution for corporate wellness companies, employee benefit departments, health systems, insurance networks, and wellness programs. 

About Mindbloom

Mindbloom, Inc. is located in Seattle, Wash. and was founded in 2008. The company provides an online service, The Mindbloom Life Game™, which offers an interactive, fun and rewarding way to focus priorities around health and wellness. The service includes components of casual gaming, social networking and personal media sharing. It was built by former executives and developers from Amazon, Monolith, AOL, Microsoft, Vulcan and Adobe. Users have found Mindbloom to be an effective way to manage personal intentions and goal setting. The mission of the company and the game itself is to inspire and motivate people to live a healthy, balanced and meaningful life. Mindbloom offers a free-to-play version which requires the user to “earn” their way through the experience and a Professional version in which users are able to add content (actions, images, goals) at will. There are currently two subscription levels for this service priced at $39/year or $89 for a lifetime. Mindbloom also offers completely customized and white-label solutions for enterprise organizations. For more information, please visit www.mindbloom.com

About The WELL at California State University, Sacramento

The WELL will be a 151,000-square-foot multi-use facility with multi-activity courts, weight and fitness rooms, climbing wall, indoor track, and a new student health center. Sacramento State students will be able to exercise, participate in group recreational activities, access healthcare services, study and socialize. The WELL mission statement, “Lifetime wellness through collaboration, education and innovation sets the tone for a renewed and vibrant campus life. It will also be a resource for faculty and staff as it offers a host of cutting-edge fitness, recreation, and athletic opportunities. For more information about The WELL, please visit http://www.thewell.csus.edu/

VICTORIA, BRITISH COLUMBIA–(Marketwire – Aug. 3, 2010) – CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm” or the “Company”) today announced that it has entered into a loan agreement and general security agreement with MD Primer Inc. (“MDP”) under which MDP has agreed to extend to CardioComm a $200,000 line of credit secured against CardioComm’s assets, which CardioComm may use on an as-needed basis as it continues to implement its 2010/2011 business strategies. Any amounts drawn by CardioComm on the line of credit will bear simple interest at 6% per year and will be repayable on or before July 28, 2012. MDP is under the direction of Dr. Anatoly Langer, CardioComm’s Chairman. As MDP is a related party of CardioComm, Dr. Langer abstained from voting on the transaction when the transaction received board approval.

CardioComm also announced an amendment to its GEMS 4.0 software development agreement with MDP, dated November 1, 2009 and announced in a November 16, 2009 press release, involving the development and release of a new, multi -language compatible software platform of the GlobalCardio™, GEMS™ GEMS™ Air/HL7/Auto Attendant modules and other pipeline software systems. CardioComm was resticted to a five year time frame to purchase exclusive software rights. The amendment removes CardioComm’s purchase restriction clause, while continuing CardioComm’s perpetual, non-exclusive license to the software.

“With this amendment, we remain on track for our most significant software release which will keep us in step with emerging wireless technologies, and expansion into international markets. In addition, CardioComm is able to review its co-license agreement with MDP at its discretion,” reports Etienne Grima, CardioComm’s CEO.

The Company also announced that it granted an aggregate of 750,000 incentive stock options pursuant to its Omnibus Share Compensation Plan as follows: 500,000 options were granted to Etienne Grima, the Company’s CEO; and 250,000 options were granted to Wendy Hsieh, the Company’s CFO. The options are exercisable at $0.10 per share for five years from the date of grant, will vest equally over a period of 18 months and are subject to a four month hold period. The grant of options will be subject to the provisions of the Company’s Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws.

About CardioComm Solutions, Inc.

CardioComm’s patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (EKGs), for diagnosis and management of cardiac patients. The Company’s products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time EKG viewer. CardioComm is the first company to provide a real-time means of viewing EKGs over a network (LAN, WAN or Internet). This tool enables EKGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global EKG Management System (GEMS™) and GlobalCardio™. CardioComm’s software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

Anatoly Langer, Chairman of the Board

LIVINGSTON, NJ–(Marketwire – August 3, 2010) –  A newly published report underscores the importance of technology and skilled technique in the practice of preimplantation genetic diagnosis (PGD). PGD has been a hotly debated topic in recent years due to the inconsistent conclusions from numerous trials.

Downloadable photos and other supporting materials available here: http://www.multimedianewscenter.com/reprogenetics/new-report-bolsters-support-for-pgd

The paper, published in the July issue of Fertility and Sterility, identifies numerous factors that contribute to the procedure’s success. Data show that PGD success appears to correlate with access to the appropriate technology and the level of skill and technique used by the embryologists.

“Our analysis of available research shows that clinics using optimal methodology, highly skilled technicians and the most advanced chromosomal assessment techniques have consistently shown an improvement in assisted reproductive technology results with PGD,” said Santiago Munné, Ph.D., founder of Reprogenetics and one of the nation’s leading experts on PGD. “PGD remains a viable option for many couples who are at risk of passing on certain genetic diseases to their children or who have been unsuccessful with assisted reproduction to help increase their chance of having a healthy baby.”

In his review, Dr. Munné identified that widely varying biopsy and chromosome analysis procedures were used, leading to conflicting results. Additionally, poor training and limited experience in these delicate procedures may also contribute to reduced embryo implantation following PGD.

According to Dr. Munné, the formula for successful PGD includes: Identifying the appropriate patient by considering maternal age and evaluating the number of embryos available, using an experienced laboratory with trained scientists reduces the risk of not obtaining a result, taking a biopsy of a single cell from the embryo, processing of the cell appropriately, analyzing a minimum of eight important chromosomes as well as working with a PGD laboratory that has an error rates below 10% with extensive experience and showing positive outcomes in PGD. 

The technique used to analyze the extracted chromosomes may play an important role in embryo selection. Array comparative genome hybridization (array CGH) is a newer technique capable of accurately determining total or partial abnormalities affecting any of the 24 different types of chromosomes, compared to more traditional FISH testing which analyzes just 5-12 chromosomes. Data presented at the last American Society of Reproductive Medicine meeting demonstrated that using CGH analysis resulted in a highly statistically significant increase in implantation rates in women with an average age of 38 and with one to 10 prior failed IVF cycles.

About PGD
In PGD, embryos created through in-vitro fertilization are tested for chromosomal abnormalities prior to replacement in a woman’s uterus. This process allows the reproductive endocrinologist to select only chromosomally healthy embryos for replacement with the goal of increasing the chance of successful implantation, reducing spontaneous abortion, reducing the chance for a fetus to have a chromosomal abnormality and in some cases improving delivery rates for assisted reproduction.

Chromosome abnormalities are the primary cause of miscarriage and more than 50%. This percentage increases with maternal age, and studies have shown that 82% of embryos from woman 40 years and older will be chromosomally abnormal.

About Reprogenetics
Reprogenetics is a private genetics laboratory specializing in Preimplantation Genetic Diagnosis (PGD). Dr. Santiago Munné and Dr. Jacques Cohen founded Reprogenetics in the year 2000 after extensive experience in PGD and IVF. Reprogenetics offers a comprehensive and personalized service to its referring IVF centers and their patients. Genetic counselors are intricately involved in the process and interact routinely with the patients pursuing all PGD tests. 

MELVILLE, NY–(Marketwire – August 3, 2010) –  FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, announced the purchase of an UPRIGHT® Multi-Position™ MRI by Medserena, of Germany. It is the fourth purchase by Medserena. The Other UPRIGHT® MRI scanners in Germany owned by Medserena are located in Cologne, Hanover and Munich.

Matthias Schulz, CEO of Medserena, said, “The first three UPRIGHT® MRI centers have had great success. With physicians all over Germany asking about this technology, it has become imperative for us to expand and install a fourth UPRIGHT® scanner. This is in spite of an intensely active MRI market in Germany, where there are already many conventional lie-down MRI’s installed. The large number of requests coming from our physicians in Germany,” Mr. Schulz said, “are arising because of the special medical need for FONAR’s unique technology.” 

“The German people have a long history in science and technology innovation,” Mr. Schulz reported, “so we tend to recognize the potential of any new technology quickly. We have been very successful in Germany with the FONAR UPRIGHT® Multi-Position™ MRI and its power for scanning patients in multiple upright and recumbent positions because our physicians have quickly appreciated the benefits of this new technology and want their patients to have access to those benefits as soon as possible. With 50% of MRI’s being of the spine, it is self-evident that to make a satisfactory imaging diagnosis of the spine, the spine needs to be supporting its normal weight load which the conventional lie-down MRI does not permit. In addition, the FONAR UPRIGHT® is able to avoid anesthesia for the imaging of young children in many cases, diagnose the fallen cerebellar tonsils (CTE, cerebellar tonsillar ectopia) that occur from whiplash injuries and diagnose scoliosis in young women without the x-rays that give rise to an increased incidence of breast cancer in scoliosis patients.”

Mr. Schulz continued, “The FONAR UPRIGHT® Multi-Position™ MRI is a most unique MRI scanner. We firmly believe that it will become a standard for MRI diagnostics in Europe, especially in evaluating the spine. No other medical technology can put together in one scanner the ability to achieve detailed images of the patient in any and all of the positions that can give rise to his pain. Our basic marketing strategy is to educate the medical community about the unique diagnostic capabilities of the FONAR unit.”

Mr. Schulz commented, “Automobile whiplash injuries are just as much a problem in Germany as they are in any other industrialized nation. It was with great pleasure that we learned of the July 2010 article in “Brain Injury,” that will now make it possible for physicians to visualize these injuries so that the most expedient medical treatment can be provided. This is a huge advantage for the FONAR UPRIGHT® Multi-Position™ MRI when it competes with other MRI scanners.”

“The July 2010 scientific study in “Brain Injury” is a big study,” Mr. Schulz said. “1200 neck pain patients were scanned by MRI. They were divided into 4 groups, consisting of 2 control neck pain groups that did not experience whiplash trauma and 2 neck pain groups that did. The radiologists who read the study images were blinded as to which images were the patient images and which were the control images. The patients were examined in both the upright and recumbent positions. The recumbent MRI images were obtained in a conventional lie-down MRI and the upright images were obtained in the FONAR UPRIGHT® Multi-Position™ MRI. As a result of this study the fallen cerebellar tonsils of a whiplash injury patient can now be reliably visualized by using the FONAR UPRIGHT® Multi-Position™ MRI. From our point of view, here in Germany, the newly published 1200 patient study in “Brain Injury” sets a “new standard of care” for whiplash injury patients.

The sale of the UPRIGHT® MRI was facilitated by Tecserena, GmbH, which was established as a distributor for FONAR’s MRI products in Europe. For additional information about Tecserena, visit www.tecserena.com, or call +49 221 340 289 0.

For FONAR investor and other information visit: www.fonar.com.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, pMRI™, Dynamic™, Multi-Position™, True Flow™, The Proof is in the Picture™, Spondylography™ Spondylometry™ and Upright Radiology™ are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company’s financial results may be found in the company’s filings with the Securities and Exchange Commission.

JERICHO, NY–(Marketwire – August 3, 2010) – SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (“TRDX” or the “Company”) (PINKSHEETS: TRDX) today announces that Preferred Distribution, Inc., the Company’s medical and dental products subsidiary, has signed a Letter of Intent (“LOI”) to acquire the exclusive licensing rights to SoleCare®, an innovative, patent pending, podiatry product.

SoleCare® is a unique new product for the removal of calluses by pedicurists.

The Company expects the continuing negotiations to result in a definitive agreement in the near term.

Dr. Gary Wallach, the inventor of SoleCare®, stated: “I am very excited about the decision to work with SciMeDent on the development and distribution of my SoleCare line of products.”

Dr. Stahl, CEO of TRDX, commented: “We advanced our discussions from a distribution relationship to an exclusive license deal. Having a license makes us more of a partner with Dr. Wallach and the SoleCare® team.”

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company’s business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

NEW YORK, NY–(Marketwire – August 3, 2010) – Allied Healthcare International Inc. (NASDAQ: AHCI) (AIM: AHI), a leading provider of flexible healthcare staffing
services in the United Kingdom, today issued financial results for its
fiscal 2010 third quarter ended June 30, 2010.

To provide investors with a better understanding of the Company’s
performance and because of fluctuations in foreign exchange rates, Allied
is discussing its revenue, gross profit, selling, general & administrative
(SG&A) expenses and operating income at constant exchange rates, which are
calculated using the comparable prior period weighted average exchange
rates. In addition, as the Company’s revenue and gross profit are
generated in the United Kingdom, an analysis, which is contained in the
Historical Revenue and Gross Profit table at the end of this press release,
is included of the last eleven quarters’ revenue and gross profit in pounds
sterling to enable investors to fully understand the underlying trends over
these periods without the effects of currency exchange rates.

Fiscal Third Quarter Results

                                    Three Months Ended
                                         June 30,
                                 ------------------------
                                                      %
                                   2010      2009   Change
                                 --------  -------- -----
                                         Revenue
                                 ------------------------

Homecare                         $ 59,270  $ 52,801  12.3%
Nursing Homes                       4,237     5,774 -26.6%
Hospitals                           4,551     4,528   0.5%
                                 --------  -------- -----
Total, at constant exchange
 rates                             68,058    63,103   7.9%
Effect of foreign exchange         (2,310)        -  -3.7%
                                 --------  -------- -----
Total, as reported               $ 65,748  $ 63,103   4.2%
                                 ========  ======== =====


                                        Three Months Ended June 30,
                                 -----------------------------------------
                                                                       %
                                   2010       %       2009     %     Change
                                 --------  -------  -------- ------  -----
                                               Gross Profit
                                 -----------------------------------------

Homecare                         $ 18,023     30.4% $ 16,272   30.8%  10.8%
Nursing Homes                       1,368     32.3%    1,843   31.9% -25.8%
Hospitals                           1,078     23.7%    1,058   23.4%   2.0%
                                 --------           --------         -----
Total, at constant exchange
 rates                             20,469     30.1%   19,173   30.4%   6.8%
Effect of foreign exchange           (701)                 -          -3.7%
                                 --------           --------         -----
Total, as reported               $ 19,768           $ 19,173           3.1%
                                 --------           --------         -----


                                                    SG&A
                                 -----------------------------------------
SG&A, at constant exchange rates
 & excluding acquisition costs   $ 17,114           $ 16,276           5.1%
Acquisition costs, at constant
 exchange rates                       595                  -           3.7%
                                 --------           --------         -----
SG&A, at constant exchange rates   17,709             16,276           8.8%
Effect of foreign exchange           (533)                 -          -3.3%
                                 --------           --------         -----
Total SG&A, as reported          $ 17,176           $ 16,276           5.5%
                                 --------           --------         -----


                                              Operating Income
                                 -----------------------------------------
Operating Income, at constant
 exchange rates & excluding
 acquisition costs               $  3,355           $  2,897          15.8%
Acquisition costs, at constant
 exchange rates                      (595)                 -         -20.5%
                                 --------           --------         -----
Operating Income, at constant
 exchange rates                     2,760              2,897          -4.7%
Effect of foreign exchange           (168)                 -          -5.8%
                                 --------           --------         -----
Operating Income, as reported    $  2,592           $  2,897         -10.5%
                                 ========           ========         =====


                                     Net income attributable to Allied
                                 -----------------------------------------
                                      Basic and            Basic and
                                     Diluted EPS          Diluted EPS
                                 -----------------------------------------
Net income attributable to
 Allied, excluding acquisition
 costs                           $ 2,270     $  0.05    $ 2,388    $  0.05
Acquisition costs                   (610)   -$  0.01          -          -
                                 -------     -------    -------    -------
Net income attributable to
 Allied                          $ 1,660     $  0.04    $ 2,388    $  0.05
                                 =======     =======    =======    =======

For the third quarter of fiscal 2010, total revenue increased 7.9%, to
$68.0 million, compared with $63.1 million reported during the same period
in fiscal 2009. Allied’s Homecare revenue grew 12.3% to $59.3 million. The
acquisition completed in this quarter contributed 4.0%, or $2.1 million, to
the increase in Homecare revenues. Nursing Homes revenue declined 26.6% to
$4.2 million and Hospitals revenue increased 0.5% to $4.5 million. After
the unfavorable impact of currency exchange of $2.3 million, revenue
increased 4.2% year over year to the reported $65.7 million.

Total gross profit for the third fiscal quarter increased 6.8% to $20.5
million, from $19.2 million for the comparable quarter in fiscal 2009.
Gross profit as a percentage of revenue was 30.1%, compared with 30.4% for
the comparable prior-year period. Foreign exchange decreased gross profit
by $0.7 million to the reported $19.8 million for the 2010 third fiscal
quarter.

SG&A, excluding acquisition costs, for the third fiscal quarter was $17.1
million (25.1% of revenues), an increase of 5.1%, from $16.3 million (25.8%
of revenues) reported last year. The Company also incurred acquisition
costs of $0.6 million. Foreign exchange decreased costs by $0.5 million to
the reported $17.2 million for the 2010 third fiscal quarter.

Operating income, before acquisition costs, for the third quarter of fiscal
2010 increased by 15.8% to $3.4 million from $2.9 million a year ago.
Acquisition costs decreased operating income by $0.6 million. Foreign
exchange decreased operating income by $0.2 million to the reported $2.6
million for the 2010 third fiscal quarter.

Income attributable to Allied, excluding acquisition costs, for the third
quarter of fiscal 2010 was $2.3 million, or $0.05 per diluted share. Net
income attributable to Allied for the third quarter of fiscal 2010 was $1.7
million, or $0.04 per diluted share, compared with $2.4 million, $0.05 per
diluted share, reported during the 2009 third fiscal quarter.

Fiscal Nine Months Results

                                 Nine Months Ended June 30,
                                 --------------------------
                                                       %
                                   2010      2009    Change
                                 --------- --------- ------
                                          Revenue
                                 --------------------------

Homecare                         $ 167,474 $ 145,497  15.1%
Nursing Homes                       13,471    19,295 -30.2%
Hospitals                           14,451    15,173  -4.8%
                                 --------- --------- ------
Total, at constant exchange
 rates                             195,396   179,965   8.6%
Effect of foreign exchange           5,266         -   2.9%
                                 --------- --------- ------
Total, as reported               $ 200,662 $ 179,965  11.5%
                                 ========= ========= ======


                                         Nine Months Ended June 30,
                                 -----------------------------------------
                                                                       %
                                   2010       %       2009     %    Change
                                 --------  -------  -------- ------  -----
                                               Gross Profit
                                 -----------------------------------------

Homecare                         $ 51,380     30.7% $ 45,283   31.1%  13.5%
Nursing Homes                       4,330     32.1%    6,027   31.2% -28.2%
Hospitals                           3,292     22.8%    3,842   25.3% -14.3%
                                 --------           --------         -----
Total, at constant exchange
 rates                             59,002     30.2%   55,152   30.6%   7.0%
Effect of foreign exchange          1,591                  -           2.9%
                                 --------           --------         -----
Total, as reported               $ 60,593           $ 55,152           9.9%
                                 --------           --------         -----


                                                    SG&A
                                 -----------------------------------------
SG&A, at constant exchange rates
 & excluding acquisition costs   $ 48,743           $ 46,224           5.4%
Acquisition costs, at constant
 exchange rates                       595                  -           1.3%
                                 --------           --------         -----
SG&A, at constant exchange rates   49,338             46,224           6.7%
Effect of foreign exchange          1,264                  -           2.8%
                                 --------           --------         -----
Total SG&A, as reported          $ 50,602           $ 46,224           9.5%
                                 --------           --------         -----


                                                Operating Income
                                 -----------------------------------------
Operating Income, at constant
 exchange rates & excluding
 acquisition costs               $ 10,259           $  8,928          14.9%
Acquisition costs, at constant
 exchange rates                      (595)                 -          -6.7%
                                 --------           --------         -----
Operating Income, at constant
 exchange rates                     9,664              8,928           8.2%
Effect of foreign exchange            327                  -           3.6%
                                 --------           --------         -----
Operating Income, as reported    $  9,991           $  8,928          11.9%
                                 ========           ========         =====


                                     Net income attributable to Allied
                                 -----------------------------------------
                                      Basic and            Basic and
                                     Diluted EPS          Diluted EPS
                                 -----------------------------------------
Income from continuing
 operations attributable to
 Allied, excluding acquisition
 costs                           $ 7,766     $  0.17    $ 6,999    $  0.15
Acquisition costs                   (610)   -$  0.01          -          -
                                 -------     -------    -------    -------
Net income attributable to
 Allied                          $ 7,156     $  0.16    $ 6,999    $  0.15
                                 =======     =======    =======    =======

For the nine months of fiscal 2010 total revenue increased 8.6%, to $195.4
million, compared with $180.0 million for the same period in fiscal 2009.
Allied’s Homecare revenue grew 15.1% to $167.5 million. The acquisition
completed in the third quarter of fiscal 2010 contributed 1.4%, or $2.1
million, to the increase in Homecare revenues. Nursing Homes revenue
declined 30.2% to $13.5 million and Hospitals revenue declined 4.8% to
$14.4 million. After the favorable impact of currency exchange of $5.3
million, revenue increased 11.5% year over year to the reported $200.7
million for the fiscal 2010 nine-month period.

Total gross profit for the nine months of fiscal 2010 increased 7.0% to
$59.0 million, from $55.2 million for the comparable period in fiscal 2009.
Gross profit as a percentage of revenue was 30.2%, compared with 30.6% for
the comparable prior-year period. Foreign exchange increased gross profit
by $1.6 million to the reported $60.6 million for the fiscal 2010
nine-month period.

SG&A, excluding acquisition costs, for the nine months of fiscal 2010 was
$48.7 million (24.9% of revenues), an increase of 5.4%, from $46.2 million
(25.7% of revenues) reported last year. We also incurred acquisition
costs of $0.6 million. Foreign exchange increased costs by $1.3 million to
the reported $50.6 million for the fiscal 2010 nine month period.

Operating income, before acquisition costs, for the nine months of fiscal
2010 increased by 14.9% to $10.3 million from $8.9 million a year ago.
Acquisition costs decreased operating income by $0.6 million. Foreign
exchange increased operating income by $0.3 million to the reported $10.0
million for the fiscal 2010 nine month period.

Income attributable to Allied, excluding acquisition costs, for the nine
months of fiscal 2010 was $7.8 million, or $0.17 per diluted share. Income
attributable to Allied for the nine months of fiscal 2010 was $7.2 million,
or $0.16 per diluted share, compared with $7.0 million, $0.15 per diluted
share, reported during the fiscal 2009 nine month period.

Cash balances as of June 30, 2010 were $37.0 million (£24.5 million) as
compared to $41.6 million (£27.6 million) as of March 31, 2010. The
decrease was primarily due to payments on acquisition and the Company’s
share buy back program.

For the fiscal nine months ended June 30, 2010, depreciation and
amortization was $3.2 million (£2.0 million), capital expenditures were
$2.4 million (£1.6 million). Days Sales Outstanding was 27 days at June 30,
2010 (42 days including unbilled account receivables), and 24 days at June
30, 2009 (46 days including unbilled account receivables).

Management Discussion

Sandy Young, Chief Executive Officer of Allied, commented, “Allied’s
Homecare revenue increased by 12.3% year over year. This is less than
previous growth levels and includes a 4.0% contribution from our newly
acquired Homecare business in Ireland. We are pleased with the transaction
progress and see opportunities to share our knowledge of Continuing Care
and learn from the Irish experience of supported living. We anticipate that
the contribution from our Irish business will exceed £10 million in revenue
and £1.2 million in EBITDA in the coming fiscal year. We believe the low
level of outsourcing in the Republic of Ireland will accelerate as the
government tries to extract the best value for taxpayers.

“There is no doubt that with the new budget year, which commenced in April,
Local Authorities have been controlling their spending. We have not seen
any significant decline so far, but local authority social care only
increased by 5.4%. In contrast, Continuing Care, which is funded by the
National Health Services (NHS) Primary Care Trusts (PCT’s), grew by 18%,
resulting in total growth in our Homecare business of 8.3% before the
benefits of Ireland.

“It has been reported that NHS spending will be protected over the life of
the parliament and we expect new outsourcing opportunities to emerge.
Although there will be a change from NHS Primary Care Trusts (about 150
nationally) to General Practitioner Consortia (about 500 nationally) within
two years, we do not see why that will restrict growth. At present PCT’s
outsource only a proportion of their spending and more care will be joint
commissioned as they try to bridge the gap between Healthcare and Social
Care. We are very well positioned to capitalize on these changes in the
industry.

“We have significant scope to increase our Continuing Care business as only
60 of our 113 total branches provide Continuing Care. Further, only about
12 branches provide the full range of Continuing Care, which includes high
intensity patients. We currently have plans to increase our sales and
marketing expenditures to promote these opportunities. We are also
exploring new service lines and during the quarter we piloted the Rapid
Intervention Service for End-of-life care (RISE) launched by NHS
Oxfordshire in July.

“The service aims to make first contact with a patient within 20 minutes at
times of crisis. The team operates between 8.00 am and 10.00 pm seven days
a week and can offer care and support for a maximum of six days. If
patients require overnight care, then the service will link with Marie
Curie Night Service or Out of Hours services. Furthermore, if ongoing care
is required, the RISE team also works to make sure other services are
involved so care can be continued if necessary.

“While we are positive about health spending, we can see there may be some
slowing in Local Authority spending. However, we believe that the larger
dynamics in this business will continue to have a positive impact.
Firstly, there is the steady increase because of the ageing profile of the
population. Secondly, a number of Local Authorities have not outsourced
care to the private sector. Thirdly, the reduction in the number of
suppliers used by each Authority will favor the larger players.

“Finally, quality is a major driver and we are delighted that we now have
91% of our branches rated by the Government (CQC) as good or excellent. In
the provision of such a sensitive service, quality is paramount.

“In the last month, we have won a 1,000 hours per week contract in Wales,
an 1,100 hour per week extra care scheme in London, and a place on the West
London Alliance which could be significantly more than 1,000 hours per
week.

“So we are still winning business but cannot quantify the effects of
savings in other areas. We are well placed to benefit from volume deals and
some of the smaller providers may find the temporary volume restrictions
hard.

“Overall I would hope that our Homecare business (before the benefit of
Ireland) can continue to grow in the 5% to 10% range rather than the 10% to
15% range previously highlighted. I think the 5% to 10% growth level will
be a feature of the medium term as the Local Authorities and PCT’s adjust,
but thereafter I see no reason why we will not return to the higher levels
of growth, particularly given the reinforced emphasis on outsourcing. There
are already other outsourcing opportunities Allied can initiate.

“Our Nursing Home activities continued to decline and we do not foresee any
immediate change. However, with Hospital Staffing we have posted a small
growth of 1%. We have also started to extract this business from our
Homecare network to allow for more focus. It now reports in to our
Commercial Director.”

Mr. Young concluded, “To support our commitment to providing our customers
with one of the highest levels of quality care in our industry and to
enhancing our leadership, Professor Raymond J. Playford has been appointed
to the new post of Medical Advisor to our Board. Professor Playford has
more than 25 years of experience in the medical field, specialising in
clinical research, and we look forward to benefiting from his profound
health care expertise, particularly in this environment.”

Dr. Jeff Peris, Chairman of Allied, commented, “Looking forward, we will
focus on executing our business strategy and building value for our
shareholders through organic growth, new service opportunities, strategic
acquisitions, as well as through our share buyback program. As of July 30,
2010 we had repurchased 1.1 million shares, or approximately $2.8 million,
of our stock under the $10 million stock repurchase program announced in
May 2010.”

Conference Call Information: August 3, 2010 at 10:00 AM Eastern Time /
3:00 PM UK Time

Allied will host a call and webcast today at 10:00 AM Eastern Time / 3:00
PM UK Time, to discuss its financial results. To join the call, please dial
(877) 407-8031 for domestic participants and (201) 689-8031 for
international participants. Participants may also access a live webcast of
the conference call through the “Investors” section of Allied Healthcare’s
Website: www.alliedhealthcare.com. A telephone replay will be available
until August 31st following the call by dialing (877) 660-6853 for domestic
participants and (201) 612-7415 for international participants. When
prompted, please enter account number 286 and conference ID number 353906.
A webcast replay will also be available and archived on the Company’s
website for ninety days.

Reconciliation of GAAP and Non-GAAP Data

In addition to disclosing results of operations that are determined in
accordance with generally accepted accounting principles (“GAAP”), this
press release also discloses non-GAAP results of operations that exclude or
include certain charges. These non-GAAP measures adjust for foreign
exchange effects and acquisition costs. Management believes that the
presentation of these non-GAAP measures provides useful information to
investors regarding the Company’s results of operations, as these non-GAAP
measures allow investors to better evaluate ongoing business performance.
Investors should consider non-GAAP measures in addition to, and not as a
substitute for, financial measures prepared in accordance with GAAP. A
reconciliation of the non-GAAP measures disclosed in this press release
with the most comparable GAAP measures are included in the financial tables
included in this press release.

ABOUT ALLIED HEALTHCARE INTERNATIONAL INC.

Allied Healthcare International Inc. is a leading provider of flexible
healthcare staffing services in the United Kingdom. Allied operates a
community-based network of approximately 115 branches with the capacity to
provide carers (known as home health aides in the U.S.), nurses, and
specialized medical personnel to locations covering approximately 90% of
the U.K. population. Allied meets the needs of private patients, community
care, nursing and care homes, and hospitals. For more news and information
please visit: www.alliedhealthcare.com.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release may be forward-looking
statements. These forward-looking statements are based on current
expectations and projections about future events. Actual results could
differ materially from those discussed in, or implied by, these
forward-looking statements. Factors that could cause actual results to
differ from those implied by the forward-looking statements include:
general economic and market conditions; the effect of the change in the
U.K. government and the impact of proposed changes in recent policy making
related to health and social care that may reduce revenue and
profitability; Allied’s ability to continue to recruit and retain flexible
healthcare staff; Allied’s ability to enter into contracts with local
government social services departments, NHS Trusts, hospitals, other
healthcare facility clients and private clients on terms attractive to
Allied; the general level of demand and spending for healthcare and social
care; dependence on the proper functioning of Allied’s information systems;
the effect of existing or future government regulation of the healthcare
and social care industry, and Allied’s ability to comply with these
regulations; the impact of medical malpractice and other claims asserted
against Allied; the effect of regulatory change that may apply to Allied
and that may increase costs and reduce revenues and profitability; Allied’s
ability to use net operating loss carry forwards to offset net income; the
effect that fluctuations in foreign currency exchange rates may have on our
dollar-denominated results of operations; and the impairment of goodwill,
of which Allied has a substantial amount on the balance sheet, may have the
effect of decreasing earnings or increasing losses. Other factors that
could cause actual results to differ from those implied by the
forward-looking statements in this press release include those described in
Allied’s most recently filed SEC documents, such as its most recent annual
report on Form 10-K, all quarterly reports on Form 10-Q and any current
reports on Form 8-K filed since the date of the last Form 10-K. Allied
undertakes no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events, or
otherwise.

ALLIED HEALTHCARE INTERNATIONAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)

                                  Three Months Ended    Nine Months Ended
                                --------------------- --------------------
                                 June 30,   June 30,   June 30,   June 30,
                                   2010       2009       2010       2009
                                ---------  ---------- ---------  ---------
Revenues:
  Net patient services          $  65,748  $   63,103 $ 200,662  $ 179,965
                                ---------  ---------- ---------  ---------

Cost of revenues:
  Patient services                 45,980      43,930   140,069    124,813
                                ---------  ---------- ---------  ---------

     Gross profit                  19,768      19,173    60,593     55,152

Selling, general and
 administrative expenses           17,176      16,276    50,602     46,224
                                ---------  ---------- ---------  ---------

     Operating income               2,592       2,897     9,991      8,928

Interest income                        84          76       275        453
Interest expense                      (10)          -       (10)       (12)
Foreign exchange (loss) income        (46)        307      (259)       (60)
                                ---------  ---------- ---------  ---------

     Income before income
      taxes and discontinued
      operations                    2,620       3,280     9,997      9,309

Provision for income taxes            903         892     2,784      2,310
                                ---------  ---------- ---------  ---------

     Income from continuing
      operations                    1,717       2,388     7,213      6,999
                                ---------  ---------- ---------  ---------

Discontinued operations:
Income from discontinued
 operations, net of taxes               -           -         -        367
                                ---------  ---------- ---------  ---------

Net income                          1,717       2,388     7,213      7,366

Less: Net income attributable
 to noncontrolling interest           (57)          -       (57)         -
                                ---------  ---------- ---------  ---------

Net income attributable to
 Allied Healthcare
 International Inc.             $   1,660  $    2,388 $   7,156  $   7,366
                                =========  ========== =========  =========

Amounts attributable to Allied
 Healthcare International Inc.:
     Income from continuing
      operations, net of tax    $   1,660  $    2,388 $   7,156  $   6,999
     Discontinued operations,
      net of tax                        -           -         -        367
                                ---------  ---------- ---------  ---------
     Net income                 $   1,660  $    2,388 $   7,156  $   7,366
                                =========  ========== =========  =========

Earnings per share - basic and
 diluted attributable to Allied
 Healthcare International Inc.
 common shareholders
     Income from continuing
      operations                $    0.04  $     0.05 $    0.16  $    0.15
     Discontinued operations            -           -         -       0.01
                                ---------  ---------- ---------  ---------
Net income attributable to
 Allied Healthcare
 International Inc.
 common shareholders            $    0.04  $     0.05 $    0.16  $    0.16
                                =========  ========== =========  =========

Weighted average number of
 common shares outstanding:
     Basic                         45,045      44,986    45,102     44,986
                                =========  ========== =========  =========
     Diluted                       45,269      44,998    45,363     44,990
                                =========  ========== =========  =========





ALLIED HEALTHCARE INTERNATIONAL INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)

                                                    June 30,  September 30,
                                                      2010         2009
                                                  (Unaudited)
                                                  -----------  -----------
ASSETS

Current assets:
  Cash and cash equivalents                       $    36,954  $    35,273
  Accounts receivable, less allowance for
   doubtful accounts of $694 and $839,
   respectively                                        19,584       19,594
  Unbilled accounts receivable                         10,970       11,572
  Deferred income taxes                                   403          389
  Prepaid expenses and other assets                     1,501        1,188
                                                  -----------  -----------
         Total current assets                          69,412       68,016

Property and equipment, net                             9,303        7,756
Goodwill                                               98,114       95,649
Other intangible assets, net                            3,699        1,646
                                                  -----------  -----------
         Total assets                             $   180,528  $   173,067
                                                  ===========  ===========

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
  Accounts payable                                $     1,099  $     1,186
  Current maturities of debt and capital leases           567            -
  Accrued expenses, inclusive of payroll and
   related expenses                                    24,866       24,304
  Taxes payable                                           970          201
                                                  -----------  -----------
         Total current liabilities                     27,502       25,691

Long-term debt and capital leases,
 net of current maturities                                394            -
Deferred income taxes                                   1,425          103
Other long-term liabilities                               294            -
                                                  -----------  -----------
         Total liabilities                             29,615       25,794
                                                  -----------  -----------

Commitments and contingencies

                                                  -----------  -----------
Noncontrolling interest                                 4,028            -
                                                  -----------  -----------

Shareholders' equity:
  Preferred stock, $.01 par value; authorized
   10,000 shares, issued and outstanding - none             -            -
  Common stock, $.01 par value; authorized 80,000
   shares, issued 45,721 and 45,571 shares,
   respectively                                           457          456
  Additional paid-in capital                          242,312      241,555
  Accumulated other comprehensive loss                (21,403)     (14,418)
  Accumulated deficit                                 (70,870)     (78,026)
                                                  -----------  -----------
                                                      150,496      149,567
  Less cost of treasury stock (1,089 and 585
   shares, respectively)                               (3,611)      (2,294)
                                                  -----------  -----------
         Total shareholders' equity                   146,885      147,273
                                                  -----------  -----------
         Total liabilities and shareholders'
          equity                                  $   180,528  $   173,067
                                                  ===========  ===========





ALLIED HEALTHCARE INTERNATIONAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

                                                        Nine Months Ended
                                                        June 30,  June 30,
                                                          2010      2009
                                                        --------  --------
Cash flows from operating activities:
  Net income                                            $  7,213  $  7,366
  Adjustments to reconcile net income to net
   cash provided by operating activities:
     Income from discontinued operations                       -      (367)
     Depreciation and amortization                         2,242     1,880
     Amortization of intangible assets                       952       921
     Foreign exchange gain                                    (2)     (221)
     (Decrease) increase in provision for
      allowance for doubtful accounts                        (24)      100
     (Gain) loss on sale of fixed assets                      (2)       11
     Stock based compensation                                471       366
     Deferred income taxes                                   102      (246)
  Changes in operating assets and liabilities,
   excluding the effect of businesses acquired and
   sold:
     Increase in accounts receivable                        (335)     (518)
     Decrease (increase) in prepaid expenses
      and other assets                                       671    (1,137)
     Increase in accounts payable and other
      liabilities                                          1,693     2,875
                                                        --------  --------

        Net cash provided by continuing
         operations                                       12,981    11,030
                                                        --------  --------

Cash flows from investing activities:
  Capital expenditures                                    (2,428)   (2,152)
  Proceeds from sale of business                               -       114
  Proceeds from sale of property and equipment                62         1
  Acquisition of controlling interest,
   net of cash acquired                                   (5,812)        -
  Payments on acquisitions payable                             -      (171)
                                                        --------  --------

        Net cash used in investing activities             (8,178)   (2,208)
                                                        --------  --------

Cash flows from financing activities:
  Stock options exercised                                    288         -
  Borrowings under invoice discounting facility, net         248         -
  Repayments of debt and capital lease obligations          (121)        -
  Treasury shares acquired                                (1,317)        -
                                                        --------  --------

        Net cash used in financing activities               (902)        -
                                                        --------  --------

Effect of exchange rate on cash                           (2,220)   (1,361)
                                                        --------  --------

Increase in cash                                           1,681     7,461

Cash and cash equivalents, beginning of period            35,273    26,199
                                                        --------  --------

Cash and cash equivalents, end of period                $ 36,954  $ 33,660
                                                        ========  ========

Supplemental cash flow information:
  Cash paid for interest                                $     10  $    300
                                                        ========  ========

  Cash paid for income taxes, net                       $  1,025  $    137
                                                        ========  ========

Supplemental disclosure of non-cash investing
 and financing activities:
  Capital expenditures included in accrued expenses
   and other long-term liabilities                      $    609  $      -
                                                        ========  ========

  Details of business acquired in purchase
   transactions:
     Fair value of assets acquired                      $ 12,430
                                                        ========

     Liabilities assumed or incurred                    $  2,694
                                                        ========

     Noncontrolling interest                            $  3,888
                                                        ========

     Cash paid for acquisitions                         $  5,848
     Cash acquired                                            36
                                                        --------

     Net cash paid for acquisitions                     $  5,812
                                                        ========





ALLIED HEALTHCARE INTERNATIONAL INC.
HISTORICAL REVENUE AND GROSS PROFIT
(In thousands, except foreign exchange rate)
(Unaudited)

                                             Revenue
                                ---------- ---------- ----------
                                    Q3         Q2         Q1
                                  2010       2010       2010
                                ---------- ---------- ----------

Homecare                        GBP 38,323 GBP 35,860 GBP 35,903
Nursing Homes                        2,731      2,864      3,261
Hospitals                            2,933      3,235      3,330
                                ---------- ---------- ----------
Total                           GBP 43,987 GBP 41,959 GBP 42,494
Foreign Exchange rate                 1.49       1.56       1.63
                                ---------- ---------- ----------
                                $   65,748 $   65,530 $   69,384
                                ========== ========== ==========


                                                 Revenue
                                ---------- ---------- ---------- ----------
                                    Q4         Q3         Q2         Q1
                                  2009       2009       2009       2009
                                ---------- ---------- ---------- ----------

Homecare                        GBP 35,763 GBP 34,162 GBP 30,858 GBP 30,620
Nursing Homes                        3,986      3,716      4,159      4,808
Hospitals                            2,956      2,914      3,448      3,612
                                ---------- ---------- ---------- ----------
Total                           GBP 42,705 GBP 40,792 GBP 38,465 GBP 39,040
Foreign Exchange rate                 1.64       1.55       1.44       1.58
                                ---------- ---------- ---------- ----------
                                $   69,845 $   63,103 $   55,334 $   61,528
                                ========== ========== ========== ==========


                                                 Revenue
                                ---------- ---------- ---------- ----------
                                    Q4         Q3         Q2         Q1
                                  2008       2008       2008       2008
                                ---------- ---------- ---------- ----------

Homecare                        GBP 30,218 GBP 29,130 GBP 27,561 GBP 27,358
Nursing Homes                        5,140      4,969      5,373      5,730
Hospitals                            4,088      3,926      4,358      3,473
                                ---------- ---------- ---------- ----------
Total                           GBP 39,446 GBP 38,025 GBP 37,292 GBP 36,561
Foreign Exchange rate                 1.90       1.97       1.98       2.05
                                ---------- ---------- ---------- ----------
                                $   74,968 $   75,024 $   73,815 $   74,770
                                ========== ========== ========== ==========



                                          Gross Profit
                                ---------- ---------- ----------
                                    Q3         Q2         Q1
                                  2010       2010       2010
                                ---------- ---------- ----------

Homecare                        GBP 11,651 GBP 11,083 GBP 11,041
Nursing Homes                          882        931      1,033
Hospitals                              696        755        712
                                ---------- ---------- ----------
Total                           GBP 13,229 GBP 12,769 GBP 12,786
Foreign Exchange rate                 1.49       1.56       1.63
                                ---------- ---------- ----------
                                $   19,768 $   19,948 $   20,877
                                ========== ========== ==========


                                               Gross Profit
                                ---------- ---------- ---------- ----------
                                    Q4         Q3         Q2         Q1
                                  2009       2009       2009       2009
                                ---------- ---------- ---------- ----------

Homecare                        GBP 10,951 GBP 10,525  GBP 9,753  GBP 9,487
Nursing Homes                        1,257      1,187      1,298      1,477
Hospitals                              745        679        874        973
                                ---------- ---------- ---------- ----------
Total                           GBP 12,953 GBP 12,391 GBP 11,925 GBP 11,937
Foreign Exchange rate                 1.64       1.55       1.44       1.58
                                ---------- ---------- ---------- ----------
                                $   21,196 $   19,173 $   17,166 $   18,813
                                ========== ========== ========== ==========


                                               Gross Profit
                                ---------- ---------- ---------- ----------
                                    Q4         Q3         Q2         Q1
                                  2008       2008       2008       2008
                                ---------- ---------- ---------- ----------

Homecare                         GBP 9,447  GBP 9,294  GBP 8,476  GBP 8,491
Nursing Homes                        1,554      1,531      1,596      1,706
Hospitals                            1,050        888      1,009        767
                                ---------- ---------- ---------- ----------
Total                           GBP 12,051 GBP 11,713 GBP 11,081 GBP 10,964
Foreign Exchange rate                 1.90       1.97       1.98       2.05
                                ---------- ---------- ---------- ----------
                                $   22,911 $   23,120 $   21,931 $   22,423
                                ========== ========== ========== ==========

IRVINE, CA–(Marketwire – August 3, 2010) –  Sun Healthcare Group, Inc. (NASDAQ: SUNH) today announced that it plans to offer 19,300,000 shares of its common stock in an underwritten public offering through an existing shelf registration statement. In connection with the offering, Sun expects to grant the underwriters a 30-day option to purchase up to 2,895,000 additional shares of its common stock to cover any over-allotments, if applicable.

Sun intends to use the net proceeds from this offering to repay a portion of the outstanding term loans under its existing credit facility.

Jefferies & Company, Inc., Credit Suisse Securities (USA) LLC and J.P. Morgan Securities Inc. are the joint book-running managers for this offering.

This press release does not constitute an offer to sell or a solicitation of any offer to buy the shares of Sun’s common stock described herein, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. The offering may be made only by means of the prospectus supplement and the related prospectus relating to the proposed offering, copies of which may be obtained, when available, by written request to Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12^th Floor, New York, NY 10022, by telephone at (877) 547-6340, or by e-mail at [email protected]; or Credit Suisse Securities (USA) LLC, Attention: Credit Suisse Prospectus Department, One Madison Avenue, New York, NY 10010 or by telephone at (800) 221-1037.

About Sun Healthcare Group, Inc.

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing, rehabilitative and related specialty healthcare services principally to the senior population in the United States. Sun’s core business is providing, through its subsidiaries, inpatient services, primarily through 166 skilled nursing centers, 16 combined skilled nursing, assisted and independent living centers, 10 assisted living centers, two independent living centers and eight mental health centers. On a consolidated basis, Sun has annual revenues of $1.9 billion and approximately 30,000 employees in 46 states. At June 30, 2010, SunBridge centers had 23,209 licensed beds located in 25 states, of which 22,427 were available for occupancy. Sun also provides rehabilitation therapy services to affiliated and non-affiliated centers through its SunDance subsidiary, medical staffing services through its CareerStaff Unlimited subsidiary and hospice services through its SolAmor subsidiary. 

Forward-Looking Statements 

Statements made in this release that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995) that involve risks and uncertainties and are subject to change at any time. These forward-looking statements may include, but are not limited to, statements containing words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “hope,” “intend,” “may” and similar expressions. Factors that could cause actual results to differ are identified in the public filings made by the Company with the Securities and Exchange Commission and include our ability to successfully complete the offering on terms and conditions satisfactory to us, as well as other risks and uncertainties, including those detailed from time to time in our Securities and Exchange Commission filings. More information on factors that could affect our business and financial results are included in our public filings made with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on Sun’s web site, www.sunh.com. The forward-looking statements involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control. We caution investors that any forward-looking statements made by Sun are not guarantees of future performance. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.

NASHVILLE, TN–(Marketwire – August 2, 2010) – Vanguard Health Systems, a Nashville-based healthcare company, today announced that affiliates of Vanguard have acquired two acute care hospitals and associated outpatient facilities in Illinois from Resurrection Health Care. Located in the western suburbs of Chicago, the hospitals are 234-bed West Suburban Medical Center in Oak Park, Illinois and 225-bed Westlake Hospital in Melrose Park, Illinois. 

This transaction supports Vanguard’s strategy of developing urban-based health care delivery networks by expanding its presence in the western suburbs where the company has served the community through its ownership of MacNeal Hospital since 2000. By achieving scale in urban markets, Vanguard is able to further its vision of providing health and health care to the communities it serves.

“We are committed to the Chicago-area as evidenced by our decade long involvement with Berwyn and neighboring communities through our ownership of MacNeal Hospital and want to expand our service to West Suburban Medical Center and Westlake Hospital,” said Charlie Martin, Chairman and CEO of Vanguard. “We look forward to bringing the necessary capital and strategic expertise needed to sustain and build upon the great clinical care provided by the employees, nurses and physicians at these two organizations.”

About Vanguard
 Vanguard owns and operates 17 acute care hospitals with 4,594 licensed beds and complementary facilities and services in Chicago, Illinois; Phoenix, Arizona; San Antonio, Texas; and Massachusetts. Vanguard’s total revenues for its last fiscal year ended June 30, 2009, were approximately $3.2 billion. Vanguard’s strategy is to develop locally branded, comprehensive healthcare delivery networks in urban markets. Vanguard will pursue acquisitions where there are opportunities to partner with leading delivery systems in new urban markets. Upon acquiring a facility or network of facilities, Vanguard implements strategic and operational improvement initiatives including expanding services, strengthening relationships with physicians and managed care organizations, recruiting new physicians and upgrading information systems and other capital equipment. These strategies improve quality and network coverage in a cost effective and accessible manner for the communities we serve.

This press release contains forward-looking statements within the meaning of the federal securities laws, which are intended to be covered by the safe harbors created thereby. These forward-looking statements include all statements that are not historical statements of fact and those statements regarding Vanguard’s intent, belief or expectations. Do not rely on any forward-looking statements as such statements are subject to numerous factors, risks and uncertainties that could cause Vanguard’s actual outcomes, results, performance or achievements to be materially different from those projected. These factors, risks and uncertainties include, among others, Vanguard’s high degree of leverage and interest rate risk; Vanguard’s ability to incur substantially more debt; operating and financial restrictions in Vanguard’s debt agreements; Vanguard’s ability to generate cash to service its debt; potential liability related to disclosures of relationships between physicians and Vanguard’s hospitals; Vanguard’s ability to grow its business and successfully implement its business strategies; Vanguard’s ability to successfully integrate any future acquisitions; the potential that acquisitions could be costly, unsuccessful or subject Vanguard to unexpected liabilities; post-payment claims reviews by governmental agencies that could result in additional costs to Vanguard; conflicts of interest that may arise as a result of Vanguard’s control by a small number of stockholders; the highly competitive nature of the healthcare business; governmental regulation of the industry including Medicare and Medicaid reimbursement levels; changes in Federal, state or local regulation affecting the healthcare industry; the potential impact to us of the significant Federal healthcare reform enacted by Congress in March 2010 and potential additional Federal or state healthcare reform; pressures to contain costs by managed care organizations and other insurers and Vanguard’s ability to negotiate acceptable terms with these third party payers; the ability to attract and retain qualified management and personnel, including physicians and nurses; claims and legal actions relating to professional liabilities or other matters; the impacts of weakened economic conditions and volatile capital markets on Vanguard’s results of operations, financial position and cash flows; Vanguard’s failure to adequately enhance its facilities with technologically advanced equipment could adversely affect its revenues and market position; Vanguard’s exposure to the increased amounts of and collection risks associated with uninsured accounts and the co-pay and deductible portions of insured accounts; Vanguard’s ability to maintain or increase patient membership and control costs of its managed healthcare plans; the geographic concentration of Vanguard’s operations; the technological and pharmaceutical improvements that increase the cost of providing healthcare services or reduce the demand for such services; the timeliness of reimbursement payments received under government programs; the potential adverse impact of known and unknown government investigations; and those factors, risks and uncertainties detailed in Vanguard’s filings from time to time with the Securities and Exchange Commission, including, among others, Vanguard’s Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q.

Although Vanguard believes that the assumptions underlying the forward-looking statements contained in this press release are reasonable, any of these assumptions could prove to be inaccurate, and, therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, you should not regard the inclusion of such information as a representation by Vanguard that its objectives and plans anticipated by the forward-looking statements will occur or be achieved, or if any of them do, what impact they will have on Vanguard’s results of operations and financial condition. Vanguard undertakes no obligation to publicly release any revisions to any forward-looking statements contained herein to reflect events and circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.

LEXINGTON, MA–(Marketwire – August 2, 2010) –   Imprivata®, Inc., the company that simplifies and secures user access, today announced the general availability of Imprivata OneSign 4.5. With breakthrough features such as OneSign Secure Walk-Away, and capabilities such as strong authentication for Citrix and RDP sessions, enhanced support for virtualized desktops and FIPS 140-2 compliance, the new release solves the critical workflow and security challenges organizations face by strengthening user authentication, streamlining application access and simplifying compliance reporting.

“Imprivata OneSign has grown to the point that our users see it as another service we offer to make their lives easier,” said Jack Thompson, senior customer support tech, Southwest Washington Medical Center. “When your product is able to provide security and productivity at the same time, you’re doing something right.” 

IMPROVED END-USER WORKFLOW

OneSign 4.5 delivers enhancements to many of the existing features that have made the product the leader in its category, and introduces new features that change the way organizations think about secure access to applications.

• Automatic Desktop Locking via OneSign Secure Walk-Away uses intelligent computer vision technology with active presence detection to secure unattended desktops without changing end-user behavior. This removes the security burden from the user and reduces the time and frustration associated with logging on/off of applications. Secure Walk-Away is particularly useful in healthcare, where clinicians who constantly log on/off of electronic medical records (EMR) and other applications are now free to focus on improving patient care rather than IT security. 
• One-touch Roaming and Location Awareness enables desktops to follow users throughout the organization, making the electronic data they need available to them wherever they are with just the touch of a finger or the tap of a proximity card. Imprivata OneSign can be configured to be fully location aware, meaning application, default printer and user privileges are configured dynamically based on the particular workstation being accessed by the user. Imprivata OneSign complements desktop virtualization from VMware View and Oracle Sun Ray, by adding the capabilities to enable secure roaming including strong authentication, single sign-on (SSO), session management and location-aware desktop personalization and customization. 

INCREASED IT SECURITY

• Transparent Screen Locking secures a computer desktop from unauthorized access while at the same time maintaining the desktop/applications’ visibility for monitoring purposes. This feature is critical to healthcare, where particular sessions must be locked, while patient status remains visible to care givers. 
• Enhanced Transaction-based Authentication supports additional workflows through OneSign ProveID, Imprivata’s unique feature being used by leading EMR vendors for ePrescribing. 
• Fingerprint Identification Enhancements enable scalability to accommodate the largest organizations.

ENHANCED DELIVERY/PACKAGING OPTIONS

• The OneSign Virtual Appliance is a self contained software implementation of the OneSign server that is functionally equivalent to the hardware appliance. OneSign virtual appliances are formatted using the industry standard Open Virtualization Format (OVF). Heterogeneous enterprises can be deployed with both virtual and hardware OneSign Appliances.
• FIPS 140-2 compliance
• Windows 7 support

“Improving user productivity and securing data are inherently competing goals,” commented Omar Hussain, president and CEO at Imprivata. “As our customers rely increasingly on fast access to digital data to be successful, security and compliance requirements across industries around the world are making access to that data more and more difficult. Imprivata has earned its leadership position by anticipating customer needs and continuing to deliver new and unique technologies that simplify and secure access to corporate data. Imprivata OneSign 4.5 is the latest proof that user productivity and IT security do not have to be mutually exclusive.” 

Centrally managed from a single administrative console, Imprivata OneSign secures access across Windows, host-based, Citrix and virtual desktop environments. OneSign empowers organizations to balance the need for stronger security with improved user workflow and productivity. The solution also reduces the time and complexity of complying with regulated access control requirements and password management costs that consume IT help desk resources.

About Imprivata
Imprivata is the leading independent vendor focused on simplifying and securing user access. By strengthening user authentication, streamlining application access and simplifying compliance reporting across multiple computing environments, customers realize substantial IT helpdesk and administration cost savings, while achieving the security standards they demand.

Imprivata has received numerous product awards and top review ratings from leading industry publications and analysts. Headquartered in Lexington, Mass., Imprivata partners with over 200 resellers, and serves the access security needs of more than 1,000 customers around the world. For more information, please visit www.imprivata.com.

Imprivata is a registered trademark of Imprivata, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

RSS Feed to Imprivata News: http://feeds.feedburner.com/ImprivataNews
Follow Imprivata on Twitter: https://twitter.com/Imprivata

id=”nav_links”>

MOUNTAIN VIEW, CA–(Marketwire – August 2, 2010) –  NCP engineering, Inc. today announced that American Hospice has selected the NCP Secure Enterprise Solution to protect patient data reported by its 180 home healthcare employees. Staff now use NCP’s remote access software to connect their Windows Mobile-based devices to American Hospice’s network, and access and update patient information in real time from anywhere, securely and in full compliance with HIPAA regulations.

NCP’s technology also allows American Hospice and its home healthcare staff to maximize efficiency and improve patient care while on the road. Previously, employees’ recordkeeping was a manual, paper-based system, which often took a week or more to process. Today, staff can safely check their patients’ medical records and home visit schedules, track their travel mileage and immediately provide patient status updates. The NCP Secure Enterprise Solution secures all of the information on the devices themselves and while in transit to the hospice’s network, a key HIPAA requirement.

Key Facts:

• American Hospice is a national leader in the delivery of hospice services. Its interdisciplinary teams, including physicians, nurses, hospice aides, pharmacists, medical social workers, spiritual care specialists, bereavement counsellors and hospice volunteers, serve several thousand patients every day.

• The NCP Secure Enterprise Solution was rolled out in May 2010, with NCP engineering meeting American Hospice’s five-day deployment deadline — taking only three days.

• 180 home healthcare employees stationed throughout Arizona, Georgia, New Jersey, Oklahoma and Virginia use NCP’s one-click IPsec VPN client to synchronize and securely transmit patient data from their Windows Mobile-based devices to the hospice’s server.

• The NCP Secure Enterprise Management System provides American Hospice’s IT staff with a single point of administration for the hospice management company’s entire VPN network, as well as full NAC management. Network administrators can easily control user and device provisioning, and distribute plug-in updates and configuration settings.

Supporting Quotes:

• “Our team tested several VPN solutions, but the NCP Secure Enterprise Solution was the only one able to fully meet our remote access needs,” said Fred Cruz, IT director, American Hospice. “We were extremely impressed with the company’s technology and support during the deployment phase. The stability to ensure a secure communications environment for our healthcare staff has become a cornerstone of our mission to provide the highest quality care to our patients and their families.”

• “American Hospice required a complete, flexible and user-friendly VPN solution for its mobile workforce,” said H. Peter Felgentreff, president and CEO, NCP engineering, Inc. “We are pleased to have fit the bill, and helped the healthcare customer not only rethink its secure remote access but also maximize employee productivity and reduce its operational costs.” 

Resources:

• For more information about American Hospice, please visit www.americanhospice.com.

• For more information about NCP engineering, please visit www.ncp-e.com. Reach the company on its blog, VPN Haus, or on Twitter.

• To learn how NCP engineering enables its customers to rethink remote access with its “Next Generation Network Access Technology”, please visit http://www.ncp-e.com/en/solutions/rethink-remote-access.html.

Tags:
NCP engineering, American Hospice, remote access, VPN, healthcare, HIPAA, security, network, enterprise

About NCP engineering, Inc.
Since its inception in 1986, NCP engineering has delivered innovative software that allows enterprises to rethink their secure remote access, and overcome the complexities of creating, managing and maintaining network access for staff.

NCP’s award-winning product line spans the spectrum of remote access, from IPSec / SSL VPN to endpoint firewalls and network access control (NAC) functions. The company’s products support organizations with complex remote user needs, who want to leverage the latest end-devices to increase staff productivity, reduce network administration and adapt policy changes on-the-fly. Each solution is interoperable with existing third-party software or hardware.

Headquartered in the San Francisco Bay Area, the company serves 30,000-plus customers worldwide throughout the healthcare, financial, education and government markets, as well as many Fortune 500 companies. NCP has established a network of national and regional technology, channel and OEM partners to serve its customers. For more information, visit www.ncp-e.com.

id=”nav_links”>

KANKAKEE, IL–(Marketwire – August 2, 2010) – Riverside Medical Center’s recent investment in a new state-of-the art Interventional Radiology (IR) system, greatly expands the advanced services it can now offer the Kankakee Illinois healthcare community. Riverside saw an opportunity to re-engineer the patient experience and improve workflow around the Kankakee County hospital and they jumped at the chance.

Riverside’s IR room underwent a complete remodel and expansion. The new room, which cost nearly $2 million, features positive air pressure making it operating room compatible. The room now uses Toshiba’s Infinix-i-x-ray system. This new imaging system has greatly impacted the quality of care and safety for the patient that this south Chicago healthcare giant can provide. Being able to control the amount of radiation administered is extremely important to the patient, radiologists and staff. This new system equips the physicians and radiologists with a comprehensive dose management package that allows for greater control, superior precision and less exposure to radiation. 

The equipment, which was once controlled in a separate room, can now be completely controlled in one area, allowing the staff to remain with the patient for added safety. In addition, Riverside Medical Center has paired the x-ray system with Toshiba’s 12″x12″ mid-sized flat panel detector. Together, they offer a wider field-of-view and provide increased visualization and optimal access, helping radiologists more quickly and accurately diagnose and treat patients.

Radiologists are now also able to view the patient’s images on a live feed and can immediately pull up a patient’s previous scans and display them on the monitors for comparison. Doctors now have immediate access to angiograms, physiological monitoring, CT and MRI scans, and many other imaging or patient specific data that can be displayed throughout the entire procedure. Clearer, sharper images and enhanced system utilization are all important features of today’s interventional radiology room.

Previously, a patient was literally moved in many different directions in order to perform the procedure. With Riverside’s advanced new technology, the unit moves to the patient. When combining the five-axis positioner with the tilting and cradling features of the table, physicians are able to obtain optimal angles for interventional procedures without re-positioning the patient. With these modern updates, Riverside is caring for patients in new and exciting ways.

To learn more about the quality services offered by Riverside Medical Center, visit www.RiversideMC.net or call (815) 933-1671.

Click here to see all recent news from this company

SPRINGFIELD, OH–(Marketwire – August 2, 2010) –  AdCare Health Systems, Inc. (NYSE Amex: ADK), an Ohio-based long-term care, home care and management company, has closed on a previously announced agreement to lease five privately held nursing homes in South Georgia that is expected to more than double its revenue.

The five facilities have been leased under a five-year term from the owner, with an extension option for an additional five years. The facilities have on aggregate 615 beds that generate approximately $35 million in annualized revenue.

AdCare’s upfront cost for the transaction was $700,000 in cash, plus legal and accounting closing costs. At closing, the company assumed approximately $1.3 million in negative working capital and purchased for $2 million approximately $5.5 million in existing receivables due to these facilities. In addition, AdCare provided the lessor $1.16 million, comprised of the first month’s lease payment and a security deposit that includes an amount equal to two months lease payment.

With the close of this transaction, AdCare estimates its revenue run-rate will exceed $61 million annually, representing an increase of more than 120% over the company’s 2009 revenues.

“This lease is the first major transaction we closed since we began our acquisition campaign at the end of last year,” said Chris Brogdon, AdCare’s vice chairman and chief acquisitions officer. “We expect these facilities to be very profitable for AdCare, especially as they come under our more capable management and benefit from the economies of scale we bring to the table.”

AdCare also reported it signed an agreement to lease an additional five nursing homes in Georgia that produce annualized revenues of approximately $37 million, which it plans to close on September 30, 2010.

“We are also now moving quickly toward closing the other two acquisitions we announced in the first half of 2010,” noted Brogdon. “As we have outlined in our M&A strategy, we are also continuing to evaluate foreclosures and other poorly run facilities that we can secure at below-market prices, as well as target acquisitions of both profitable and turnaround properties to grow our business.”

Brogdon joined AdCare last September when the company announced a new M&A growth strategy to build upon its strong reputation for operational efficiency and high-quality living environments.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) develops, owns and manages assisted living facilities, nursing homes and retirement communities and provides home healthcare services. Prior to becoming a publicly traded company in November of 2006, AdCare operated as a private company for 18 years. AdCare’s 900 employees provide high-quality care, management services and other services for patients and residents residing in 19 facilities, seven of which are assisted living facilities, 11 skilled nursing centers and one independent senior living community. The company owns eight of those facilities. In the ever-expanding marketplace of long-term care, AdCare’s mission is to provide quality healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Safe Harbor Statement
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law, which can be identified by the use of forward-looking terminology, such as “believes,” “expects,” “plans,” “anticipates” or similar expressions. Statements in this announcement that are forward-looking include, but are not limited to, statements that with the closing of this transaction, AdCare estimates its revenue run-rate will exceed $61 million annually, representing an increase of more than 120% over the company’s 2009 revenues; that the leased facilities mentioned in this release will be very profitable for AdCare; that it plans to close the newly announced additional five leases on September 30, 2010; and that the company is moving quickly toward closing the other two acquisitions it announced in the first half of 2010. Such forward-looking statements reflect management’s beliefs and assumptions, and are based on information currently available to management. The forward-looking statements involve known and unknown risks that may make the results, performance or achievements of the company differ materially from those expressed or implied in such statements. Such factors are also identified in the public filings made by the company with the U.S. Securities and Exchange Commission, and they include, but are not limited to, the company’s ability to secure lines of credit and/or an acquisition credit facility, find suitable acquisition properties at favorable terms, changes in the health care industry because of political and economic influences, changes in regulations governing the industry, changes in reimbursement levels including those under the Medicare and Medicaid programs, and changes in the competitive marketplace. There can be no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements.

CARMEL, IN–(Marketwire – August 2, 2010) –  Clinical Architecture today announced that UMass Memorial Health Care, the largest healthcare system in Central and Western Massachusetts, has selected Clinical Architecture’s Symedical™ interoperability solution. UMass Memorial is using Symedical™ to re-code patient data from various locations and terminologies into a central data repository using a single terminology set. “Merging patient data from disparate sources is a significant undertaking,” said John Poikonen, PharmD, Director of Clinical Informatics at UMass Memorial Medical Center. “Symedical has proven to be a pragmatic and efficient tool that allows us to focus on accuracy.”

Providing the highest quality of care requires access to a consistently accurate representation of the patient’s clinical context. Symedical™ enables clinical applications to maintain the continuity of meaning by sharing patient information as actionable discrete data. “It is no longer enough to offer read only access to medical records stored in various places throughout the healthcare enterprise,” said Charlie Harp, Chief Executive Officer of Clinical Architecture. “We’re pleased to be working with UMass Memorial as they leverage Symedical to deliver a more meaningful and actionable information exchange.”

About Clinical Architecture

Clinical Architecture specializes in meeting the integration and interoperability needs of healthcare through niche consulting and application development. The company was formed around the extensive clinical integration experience of its staff and has consistently succeeded in addressing complex problems with effective pragmatic solutions. The company is located just north of Indianapolis in Carmel, Indiana. For additional information on Clinical Architecture, contact John Wilkinson at (317) 580-8417 or visit www.clinicalarchitecture.com. Informative discussions of interoperability topics are available at the company’s Healthcare IT Blog; www.clinicalarchitecture.com/healthcare_technology_informatics_blog/.

About UMass Memorial Health Care

UMass Memorial Health Care is Central Massachusetts’ largest not-for-profit health care delivery system, covering the complete health care continuum with UMass Memorial Medical Center, its academic medical center, member and affiliated community hospitals, freestanding primary care practices, ambulatory outpatient clinics, home health agencies, hospice programs, a rehabilitation group and mental health services. UMass Memorial is the clinical partner of the University of Massachusetts Medical School. Visit www.umassmemorial.org for additional information. Follow UMass Memorial on Twitter at http://twitter.com/umassmemorial.

IRVING, TX–(Marketwire – August 2, 2010) – VHA Inc., the national health care network, will showcase its VHA SupplyLYNX™ portal and its array of analytics offerings at the annual meeting of the Association for Healthcare Resource & Materials Management Conference on August 1-4, in Denver.

VHA SupplyLYNX offers hospitals the ability to analyze every aspect of their purchasing activities for both products and services and gives them the data they need to accelerate the pace at which hospitals can reduce spending and maximize contract savings.

“VHA SupplyLYNX enables hospitals to fully optimize data throughout the organization and delivers unparalleled insight into the hospital’s performance,” said Scott Downing, executive vice president, Supply Chain Management at VHA. “Cost reduction is a daily focus and is essential to offset anticipated cuts in Medicare reimbursement that will decrease hospital revenues and potentially stifle the bottom line.”

In addition to the recently introduced VHA SupplyLYNX Web portal, attendees can participate in demonstrations of VHA PriceLYNX™ 2.0, the industry’s leading price benchmarking service. VHA PriceLYNX provides benchmarking analysis that arms decision makers with factual information that enables the organization to view long- and short-term market trends and respond to immediate price fluctuations. Ultimately, this information better equips the purchasing team during vendor negotiations. From January 2009 through June 2010, members using VHA PriceLYNX have identified an average savings of $4 million per quarter. 

AHRMM marks the public debut of VHA PriceLYNX mobile. VHA anticipates that mobile access via devices such as smart phones will give hospital personnel the opportunity to make faster decisions when it comes to switching products or accessing lower pricing on the products they already purchase. VHA recently launched its VHA SupplyLYNX mobile platform, built in conjunction with McLean, Va.-based MicroStrategy, to provide mobile access to its suite of analytical products and services. 

“Beginning with our leadership around data standards and e-commerce in 2001, VHA has led other analytics competitors by providing accurate, timely and actionable supply chain information to members, backed by the largest data set in health care,” continued Downing. “What sets us apart is our core belief in price transparency, a data warehouse that provides superior accuracy and a categorization methodology that ensures quality reporting every time.”

About VHA — VHA Inc., based in Irving, Texas, is a national network of not-for-profit health care organizations that work together to drive maximum savings in the supply chain arena, set new levels of clinical performance and identify and implement best practices to improve operational efficiency and clinical outcomes. In 2009, VHA delivered record savings and value of $1.47 billion to members. Formed in 1977, through its 16 regional offices, VHA serves more than 1,400 hospitals and more than 28,000+ non-acute care providers nationwide. VHA was ranked by Modern Healthcare as the 7th best place to work in health care in 2009.

GILBERT, AZ–(Marketwire – August 2, 2010) – As your boss reminds you that this is your third sick day in two months due to your “back pain excuse,” you hang up the phone frustrated. You aren’t playing hooky. You’d honestly rather be at work than flat on your back in pain. But taking painkillers makes it hard for you to function properly — and it merely masks the pain, instead of solving the problem. If only there was a solution that didn’t involve a knife and more time off work.

“When I treat patients with the one-two punch of spinal decompression and deep tissue laser therapy, they are able to return to their favorite activities, such as gardening, walking, dancing and tennis,” says Brian Self, D.C., a chiropractor with Arizona Pain & Wellness Centers. “And with 6.5 million people stuck in bed each day because of back pain, literally millions could benefit from this affordable, effective, permanent pain relief. While both procedures require multiple visits, most patients feel relief from their pain after their first few sessions.”

Spinal decompression is a revolutionary new technology that treats the symptoms of disc herniations, disc degeneration, sciatica and low back and neck pain. Patients simply lie on their backs while a specialized belt is placed comfortably around their waist. An advanced computer system is then set to focus on each patient’s specific problem area. As disc bulges or herniations are drawn in, or as the discs begin to regenerate, pressure is taken off the nerves and surrounding structures relieving the patient of pain and inflammation. In fact, Dr. Self says that the spinal decompression treatments are so gentle; he’s had patients become so relaxed, they fall asleep during it.

Most patients undergoing spinal decompression will also receive deep tissue laser therapy; because Dr. Self has found that these two treatments work best in tandem. “Our deep tissue laser works by flooding the tissues with photons, energizing the damaged cells and increasing circulation to the painful area,” he says. “This produces a cascade of healing responses in your body, reducing inflammation, thereby reducing or even eliminating your pain. There are no known side effects, it’s noninvasive and nonsurgical — and treatment simply feels like a deep, gentle warmth.”

To put an end to your neck and back pain without medications, injections or surgery, visit www.arizonapainandwellness.com

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 30, 2010) –  Increased demand for testing, new technologies and emerging markets have trumped the economic situation in the world in vitro diagnostics (IVD) market, according to the seventh edition of Kalorama Information’s biennial report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition.” The healthcare market research publisher reported a $44.3 billion market in 2009, and expects growth to be at a rate of six percent for the next five years. 

According to Kalorama the market has already weathered price declines and as a result developed innovative technologies and approaches. This has dulled the impact of a recession which has hurt other industries. Digital pathology, multiplex assays, automation and test service commercialization represent areas where the industry has developed new approaches. The market changes described in the report were on display at the American Association for Clinical Chemistry (AACC) convention in Anaheim, CA this week.

“The convention reflected what we’ve said in the report; that despite economic hard times, the IVD industry is on an upswing,” said Shara Rosen, senior diagnostic analyst for Kalorama Information and author of the study. “A number of world events bode well for the future of testing.”

Trends such as the use of biomarkers and molecular approaches to testing have only increased since the last edition of the report. Consolidation has been a factor in an industry that is dominated by Roche, Siemens, and Abbott. The report notes that 72 percent of the revenue in 2009 was earned by just 18 companies. This hasn’t stopped scores of new companies with unique approaches from competing in diagnostics, according to Kalorama.

The report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition,” has more information on segment market sizes, forecasts, company analyses, and test product development. The report can be found at Kalorama Information at: http://www.kaloramainformation.com/redirect.asp?progid=79398&productid=2613362.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

OAKBROOK TERRACE, IL–(Marketwire – July 30, 2010) –  Each year, millions of people — from elderly nursing home residents to hospitalized children to women who have just given birth — are injured by falls in health care facilities and homes. The Joint Commission today launched a national campaign to help Americans reduce the risk of falling.

The new education campaign, which is part of The Joint Commission’s award-winning Speak Up™ program, recognizes that falls are a serious problem. Statistics from the Centers for Disease Control and Prevention (CDC) show that falls are the second leading cause of injury-related deaths for people ages 65 and older, and are the most common cause of injuries and hospital admissions among the elderly. (Source: CDC, NCHS. Mortality Data Tapes. Hyattsville, MD: the Center, 1998.) Reducing injuries, disabilities and deaths from falls has even been included as part of the Healthy People 2010 program. The national Healthy People 2010 objectives from the U.S. Department of Health and Human Services identify the most significant preventable threats to health and establish national goals to reduce these threats.

“Falls can cause serious to life-threatening injuries; however, there are steps people can take at home or in a health care facility to reduce their risk of falling. We want people to be aware of these simple yet important precautions and avoid preventable injuries,” says Mark R. Chassin, M.D., M.P.P., M.P.H., president, The Joint Commission.

The new Speak Up™ campaign offers tips and actions that will help people reduce the risk of falling, whether at home or in a medical facility. Among the topics are:

• Taking care of your health — this includes exercise to improve strength and balance, staying hydrated, having an eye exam regularly and talking to your doctor about any side effects from medications that might cause drowsiness or confusion.
• Taking extra precautions — simple actions such as turning on the lights when entering a room, keeping walkways clear, using handrails on stairs, and wearing proper shoes can make a difference.
• Making small changes to your home — using motion sensors or timers for lights, placing nightlights in bedrooms and bathrooms, removing throw rugs, and applying non-slip decals on stairs and in bathtubs to reduce the risk of falls. Home care agencies, personal care and support agencies, or community programs may be available to help you accomplish these tasks if you are older or disabled.
• Taking extra precautions in the hospital or nursing home, for example, people in health care facilities should use the call button to ask for help to get out of bed or go to the bathroom, wear non-slip socks, lower the height of the bed and bed rails, and tell the nurse or doctor if medicine is making you feel dizzy or sick.

The framework of the Speak Up™ program urges patients to:

• Speak up if you have questions or concerns, and if you don’t understand, ask again. It’s your body and you have a right to know.
• Pay attention to the care you are receiving. Make sure you’re getting the right treatments by the right health care professionals. Don’t assume anything.
• Educate yourself about your diagnosis, the medical tests you are undergoing, and your treatment plan.
• Ask a trusted family member or friend to be your advocate.
• Know what medications you take and why you take them. Medication errors are the most common health care errors.
• Use a hospital, clinic, surgery center, or other type of health care organization that has undergone a rigorous on-site evaluation against established state-of-the-art quality and safety standards, such as that provided by The Joint Commission.
• Participate in all decisions about your treatment. You are the center of the health care team.

Speak Up™ brochures also are available on preventing errors in medical care for children, finding pain relief, understanding caregivers, understanding medical tests, recovering after leaving the hospital, preventing medication mistakes, preventing infections, preparing to become a living organ donor, avoiding wrong site surgery and preventing errors in care. Brochures can be found at http://www.jointcommission.org/PatientSafety/SpeakUp/. All of the Speak Up™ brochures are available in an easy-to-read format and in Spanish.

Founded in 1951, The Joint Commission seeks to continuously improve health care for the public, in collaboration with other stakeholders, by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value. The Joint Commission evaluates and accredits more than 17,000 health care organizations and programs in the United States, including more than 9,500 hospitals and home care organizations, and more than 6,300 other health care organizations that provide long term care, behavioral health care, laboratory and ambulatory care services. In addition, The Joint Commission also provides certification of more than 1,000 disease-specific care programs, primary stroke centers, and health care staffing services. An independent, not-for-profit organization, The Joint Commission is the nation’s oldest and largest standards-setting and accrediting body in health care. Learn more about The Joint Commission at www.jointcommission.org.

To view this release in a media-rich format, go to: http://www.pwrnewmedia.com/2010/jointcommission_00728_Fall_Prevention/index.html

Click here to see all recent news from this company

HOUSTON, TX–(Marketwire – July 30, 2010) –  Bederra Corporation (PINKSHEETS: BEDA) management announced that the company has attained Pinksheet Current Information status on otcmarkets.com. Management had previously announced its intention to satisfy the “Alternative Reporting Standard” of public transparency in the company’s efforts to further investor relations and voluntarily make adequate and current information publicly available.

Management also noted that it remains currently in discussions with several potential acquisition candidates both in the medical area and outside this market. While the company remains dedicated to further growth in the medical services industry, management had recently announced its decision to explore diversification options in the interest of shareholders until further information regarding the overall direction of the recently passed healthcare legislation is announced. 

About Bederra Corp.
http://www.bederra.com
Bederra Corporation provides multiple modality diagnostic medical services to the greater Houston area and the world famous Texas Medical Center. The Company’s business strategy is to continue to expand its current operations and seek out additional acquisitions that will complement its core offerings.

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products and services in development, including any planned acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements might not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company’s plans or expectations.

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – July 30, 2010) – www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today reported its financial results
for the six months ended June 30, 2010 and provided a business update on
its activities.

Michele Garufi, Chairman and CEO of NicOx, declared: “This has been both an
active and a challenging first half for NicOx, as we worked with regulators
in the United States and Europe on the marketing applications for
naproxcinod. We will collaborate closely with both regulatory authorities
in the coming months. We will also focus on securing potential licensing
agreements for naproxcinod in Europe and the rest of the world, ensuring
the continued success of our existing partnerships and prioritizing our
research programs. We will continue to manage our cash resources in the
most cost-effective manner to ensure the future growth of the Company
whilst also pursuing appropriate in-licensing and M&A opportunities.”

Key events of the first six months of 2010:

– NicOx and Bausch + Lomb signed a Worldwide Licensing Agreement for the
glaucoma candidate NCX 116

– The European Medicines Agency (EMA) validated the Marketing Authorization
Application (MAA) for naproxcinod

– Joint Advisory Committee of the U.S. Food and Drug Administration (FDA)
voted that they did not have sufficient evidence to support the approval of
naproxcinod for the relief of the signs and symptoms of osteoarthritis

– Additional clinical data for naproxcinod and preclinical results for NCX
434 and NCX 1236, two of the Company’s nitric oxide (NO)-donating New
Molecular Entities, were presented at scientific and medical conferences

– NicOx and TOPIGEN Pharmaceuticals Inc. mutually terminated their
collaboration for TPI 1020 as a result of the acquisition of TOPIGEN

Post reporting period:

– On July 22, 2010, NicOx announced the receipt of a Complete Response
Letter from the U.S. Food and Drug Administration (FDA), stating that it
could not approve the New Drug Application (NDA) for naproxcinod. NicOx
plans on discussing the Complete Response Letter and potential next steps
with the FDA, as early as possible.

Eric Castaldi, Chief Financial Officer of NicOx, declared: “NicOx has a
strong cash position, with no long-term debt and cash and cash equivalents
totaling ?128.4 million at the end of June 2010. We will continue to
ensure careful conservation of our funds.”

Financial summary for the first half of 2010:

Revenues for the first half of 2010 were ?7.4 million, compared to
?1.1 million during the same period in 2009. These revenues correspond
to the initial license payment received from Bausch + Lomb in the first
quarter of the year, as per the agreement signed in March 2010.

For the first six months of 2010, operating expenses were ?36.4
million, compared to ?32.7 million for the same period in 2009. These
expenses correspond principally to personnel costs related to the
regulatory processes for naproxcinod both in the United States and in
Europe, investments in naproxcinod’s supply chain and costs related to the
anticipated cancellation of certain manufacturing and pre-commercial
activities following the decision of the FDA.

NicOx recorded a total net loss for the period of ?27.5 million for
the first six months of 2010, compared to a corresponding net loss of
?27.2 million for the same period in 2009. On June 30, 2010, NicOx had
cash and cash equivalents of ?128.4 million, compared to ?148.3
million on December 31, 2009.

Review of the first six months of 2010:

Signature of a Worldwide Licensing Agreement with Bausch + Lomb

In March 2010, NicOx and Bausch + Lomb signed a Worldwide Licensing
Agreement granting Bausch + Lomb exclusive rights to develop and
commercialize NCX 116, an NO-donating prostaglandin F2-alpha analog for the
potential treatment of glaucoma and ocular hypertension. Both companies
have already held an initial meeting to agree on the next steps for the
development of NCX 116. Under the terms of this agreement, NicOx received
an initial license payment of $10 million and stands to receive potential
milestones totaling $169.5 million, as well as tiered double-digit
royalties on the sales of NCX 116.

Regulatory status of naproxcinod in the United States

A Joint Advisory Committee of the FDA, including the Arthritis Drugs
Advisory Committee and the Drug Safety and Risk Management Advisory
Committee, voted by 16 to 1 with 1 abstention on May 12, 2010 that they did
not have sufficient evidence at that time to support the approval of
naproxcinod for the relief of the signs and symptoms of osteoarthritis.

On July 22, 2010, NicOx announced the receipt of a Complete Response Letter
from the U.S. Food and Drug Administration (FDA) related to the New Drug
Application (NDA) for naproxcinod. The FDA informed NicOx that its review
of the NDA was complete and that it did not approve the naproxcinod
application. The FDA recommended conducting one or more long-term
controlled studies to assess the cardiovascular and gastrointestinal safety
of naproxcinod. Additional studies to demonstrate a clinically meaningful
therapeutic benefit attributable to the nitric oxide donation were also
recommended. No clinical efficacy studies were requested. NicOx plans to
discuss the Complete Response Letter and potential next steps as early as
possible with the FDA.

Regulatory status of naproxcinod in Europe

In January 2010, the European Medicines Agency (EMA) validated the
Marketing Authorization Application (MAA) for naproxcinod, which was
submitted through the centralized procedure in December 2009. NicOx is
seeking approval for an indication for the relief of the signs and symptoms
of primary osteoarthritis. The Medicinal Products for Human Use (CHMP)
opinion is expected by mid-2011, the exact timing depending on the
interactions needed with the health authorities in the last phase of the
review process.

Presentation of scientific results for naproxcinod

Detailed results from the 301 study were published in the May issue of
Osteoarthritis and Cartilage. Additional clinical data for naproxcinod were
presented in May at the American Society of Hypertension Annual Scientific
Meeting and Exposition in New York and in June at the European Meeting on
Hypertension in Olso and the Annual European Congress of Rheumatology in
Rome.

Presentation of promising preclinical results in international conferences

Preclinical results obtained with two of NicOx’s NO-donating New Molecular
Entities (NMEs) were presented in congresses in the first half of 2010. In
May, preclinical findings obtained with NCX 1236, a lead compound for the
potential treatment of Neuropathic Pain, were presented at the
International Congress on Neuropathic Pain in Athens. Preclinical results
for NCX 434, a potential preclinical candidate in Diabetic Macular Edema
(DME), were presented in May at the Ocular Diseases & Drug Discovery
conference in Boston and in June at the Retina International World Congress
in Stresa.

Review of the consolidated financial results for the six months ended June
30, 2010 and 2009:

Revenues

NicOx’s revenues totaled ?7.4 million for the six months ended June
30, 2010 compared to ?1.1 million for the six months ended June 30,
2009.

This significant increase results from the recognition as revenues during
the first quarter of 2010 of ?7.4 million corresponding to the initial
license payment received from Bausch + Lomb following the signature of a
licensing agreement in March 2010 that granted Bausch + Lomb exclusive
worldwide rights to develop and commercialize NCX 116. This amount has been
immediately recognized in revenues because the Company will not have
continuing involvement in the future development of the compound which is
subject of this collaboration agreement. No revenues have been recorded in
the second quarter of 2010.

Operating expenses

For the six months ended June 30, 2010, operating expenses totaled
?36.4 million, compared to ?32.7 million for the six months ended
June 30, 2009, of which, 74% was attributable to research and development
expenses and 26% attributable to selling and administrative expenses in the
first semester of 2010, compared to 77% and 23% respectively in the first
semester of 2009.

Research and development expenses were ?26.9 million during the first
semester of 2010, compared to ?25.1 million during the first semester
of 2009 (including ?0.1 million allocated to cost of sales in 2009
corresponding to the expenses incurred by NicOx in performing research
activities under the contract signed with Pfizer). In the first semester of
2010, research and development expenses correspond principally to personnel
expenses related to the activities performed in relation with the
naproxcinod New Drug Application and Marketing Authorization Application
submitted respectively in the US and in Europe and to investment expenses
in dedicated manufacturing facilities of its active ingredient supplier DSM
in order to increase the naproxcinod supply chain capacity and flexibility.
Following the decision in July 2010 of the FDA not to approve the marketing
application for naproxcinod in the US, indemnities in an amount of
?6.9 million have been booked as research and development expenses in
the accounts as of June 30, 2010, to be paid to suppliers involved in the
manufacturing of naproxcinod for the anticipated cancellation of purchase
orders. The Company employed 79 people in research and development on June
30, 2010, compared to 93 people at the same date in 2009.

General and administrative expenses were ?3.2 million in the first
semesters of 2010 and 2009 and include personnel expenses in administrative
and financial functions, as well as the remuneration of corporate officers,
including stock option, free share and warrant attributions. Selling and
corporate development expenses totaled ?6.2 million during the first
six months ended June 30, 2010 compared to ?4.4 million during the
same period in 2009 and correspond to market research and analysis
activities for naproxcinod, as well as the business development and
communication activities of the Company. The Company employed 48 people in
its selling, general and administrative departments on June 30, 2010,
compared to 39 people on June 30, 2009.

Other income

Other income totaled ?1.6 million during the first semester of 2010
compared to ?3.1 million in the first semester of 2009. Other income
corresponds mainly to the operational subsidies from the research tax
credits in France and in Italy.

Operating result

The operating loss amounted to ?27.4 million in the six months ended
June 30, 2010, compared to ?28.5 million in the same period in 2009.

Other results

Net financial income totaled ?0.1 million during the first semester of
2010, compared to ?1.3 million during the first semester of 2009, and
represents mainly the returns on the financial investments of the Company’s
cash, cash equivalents.

The income tax expense incurred by NicOx during the first six months of
2010 relates to tax from its US and Italian subsidiaries and totaled
?0.3 million, compared to ?0.1 million during the same period in
2009.

Total net loss of the period

The total net loss for the period was ?27.5 million on June 30, 2010,
compared to ?27.2 million on June 30, 2009. Notwithstanding the strong
increase of the revenues recognized in the first six months of 2010
following the initial license payment received from Bausch + Lomb, the
total net loss on June 30, 2010 remains at the same level as last year due
to the impact of the anticipated cancellation of manufacturing and pre-
commercial activities related to naproxcinod following the decision of the
FDA not to approve the application of the product in the United States.

Consolidated statement of financial position

The indebtedness incurred by NicOx is mainly short-term operating debt. On
June 30, 2010, the Company’s current liabilities totaled ?16.6
million, including ?12.0 million in accounts payable to suppliers and
external collaborators (including ?5.9 million with respect to the
cancellation of orders of naproxcinod active drug substance), ?2.5
million in accrued compensation for employees, ?1.9 million in other
contingencies and liabilities (corresponding to the costs related to the
anticipated cancellation of certain manufacturing and pre-commercial
activities following the decision of the FDA) and ?0.2 million for
other liabilities.

The Company’s cash and cash equivalents were ?128.4 million on June
30, 2010, compared to ?148.3 million on December 31, 2009, and
?76.8 million on June 30, 2009. In late 2009, the Company completed a
two step capital increase and received a total of ?94.6 million
corresponding to the net proceeds of the following operations: ?29.4
million from a private placement of shares to institutional investors
completed on November 23, 2009, and ?65.2 million from a rights issue
completed on December 23, 2009.

NicOx will continue to pursue the European regulatory process for
naproxcinod and follow-up with the FDA after the Complete Response Letter.
NicOx will actively seek to enter into partnerships for naproxcinod. The
Company’s cash position is strong and NicOx is taking all necessary steps
to preserve it.

Risks factors which are likely to have a material effect on NicOx’s
business are presented in the 4th chapter of the ” Document de
référence, rapport financier annuel et rapport de gestion 2009 ”
filed with the French Autorité des Marchés Financiers (AMF) on
March 5, 2010 and available on NicOx’s website (www.nicox.com) and on the
AMF’s website (www.amf-france.org).

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the U.S. Food and Drug
Administration (FDA) provided a Complete Response Letter to the New Drug
Application (NDA) for naproxcinod stating that it does not approve the
naproxcinod application. The naproxcinod Marketing Authorization
Application (MAA) submitted by NicOx in December 2009 is currently under
review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although
the Company believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from
those anticipated in the forward-looking statements. For a discussion of
risks and uncertainties which could cause actual results, financial
condition, performance or achievements of NicOx S.A. to differ from those
contained in the forward-looking statements, please refer to the Risk
Factors (“Facteurs de Risque”) section of the Document de Reference filed
with the AMF, which is available on the AMF website (http://www.amf-
france.org) or on NicOx S.A.’s website (http://www.nicox.com).

+-------------------------+-+--------------------+-+---------+
|                         | |For the period ended| |         |
|                         | |June 30,            | |         |
+-------------------------+-+--------------------+-+---------+
|                         | |2010                | |    2009 |
+-------------------------+-+--------------------+-+---------+
|                         | |(in thousands of EUR| |         |
|                         | |except for per share| |         |
|                         | |data)               | |         |
+-------------------------+-+--------------------+-+---------+
|Revenues                 | |7,423               | |   1,119 |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Cost of sales            | |-                   | |    (75) |
|                         | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Research and development | |(26,924)            | |(25,031) |
|expenses                 | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Administrative expenses  | |(3,214)             | | (3,234) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Selling expenses         | |(6,241)             | | (4,403) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Other income             | |1,600               | |   3,130 |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Operating loss           | |(27,356)            | |(28,494) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Finance income           | |183                 | |   1 388 |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Finance expense          | |(70)                | |    (54) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Loss before income tax   | |(27,243)            | |(27,160) |
|                         | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Income tax expense       | |(257)               | |    (77) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Net loss of the          | |(27,500)            | |(27,237) |
|period                   | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Exchange differences on  | |(38)                | |     (1) |
|translation of foreign   | |                    | |         |
|operations               | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Other comprehensive      | |(38)                | |     (1) |
|income (loss) for the    | |                    | |         |
|period, net of tax       | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Total comprehensive      | |(27,538)            | |(27,238) |
|income (loss) for the    | |                    | |         |
|period, net of tax       | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Attributable to:         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|- Equity holders of the  | |(27,538)            | |(27,238) |
|parent                   | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|- Non-controlling        | |-                   | |       - |
|interests                | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Basic and diluted loss   | |(0.38)              | |  (0.57) |
|per share attributable to| |                    | |         |
|equity holders of the    | |                    | |         |
|parent                   | |                    | |         |
+-------------------------+-+--------------------+-+---------+

+----------------------+--------------------+-+------------------+--------+
|                      |   June 30, 2010    | |December 31, 2009 |        |
+----------------------+--------------------+-+------------------+--------+
|                      |(in thousands       | |                  |        |
|                      | of EUR)            | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|ASSETS                |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Non-current assets    |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Property, plant &     |              2,782 | |                  |  2,772 |
|equipment             |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Intangible assets     |                794 | |                  |    797 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Government subsidies  |                936 | |                  |    477 |
|receivable            |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other financial assets|                267 | |                  |    238 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Deferred income tax   |                  - | |                  |    156 |
|assets                |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total non-current     |              4,779 | |                  |  4,440 |
|assets                |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Current assets        |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Government subsidies  |              3,263 | |                  |  2,597 |
|receivable            |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other current assets  |                988 | |                  |  1,329 |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Prepaid expenses      |              1,213 | |                  |    784 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Cash and cash         |            128,448 | |                  |148,275 |
|equivalents           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total current assets  |            133,912 | |                  |152,985 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|TOTAL ASSETS          |            138,691 | |                  |157,425 |
+----------------------+--------------------+-+------------------+--------+
|EQUITY AND LIABILITIES|                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Common shares         |             14,505 | |                  | 14,434 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other reserves        |            103,046 | |                  |128,444 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Non-controlling       |                  - | |                  |      - |
|interests             |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total Equity          |            117,551 | |                  |142,878 |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Non-current           |                    | |                  |        |
|liabilities           |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other contingencies   |              4,369 | |                  |  4,069 |
|and liabilities       |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Deferred income tax   |                 98 | |                  |     91 |
|liabilities           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Finance lease         |                 44 | |                  |      6 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total non-current     |              4,511 | |                  |  4,166 |
|liabilities           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Current liabilities   |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other contingencies   |              1,890 | |                  |      - |
|and liabilities       |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Finance lease         |                 18 | |                  |      7 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Trade payables        |             12,034 | |                  |  6,136 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Current income tax    |                  - | |                  |     19 |
|payable               |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Social security and   |              2,504 | |                  |  3,909 |
|other taxes           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other liabilities     |                183 | |                  |    310 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total current         |             16,629 | |                  | 10,381 |
|liabilities           |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|TOTAL EQUITY AND      |            138,691 | |                  |157,425 |
|LIABILITIES           |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|NicOx S.A.,           |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Les Taissounières-Bât |                    | |                  |        |
|HB4 - 1681 route des  |                    | |                  |        |
|Dolines - BP313, 06906|                    | |                  |        |
|Sophia Antipolis cedex|                    | |                  |        |
|France.               |                    | |                  |        |
|Tel.                  |                    | |                  |        |
|+33 (0)4 9724 53 00   |                    | |                  |        |
|Fax                   |                    | |                  |        |
|+33 (0)497 24 53 99   |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
+----------------------+--------------------+-+------------------+--------+

This information is provided by HUGIN

SAN DIEGO, CA–(Marketwire – July 29, 2010) –  Medistem Inc. (PINKSHEETS: MEDS) announced today publication of a peer reviewed paper identifying a molecule found on the company’s lead product, the universal donor Endometrial Regenerative Cell (ERC), as a key component of cellular escape from immune attack. The study, titled “Resistance of neonatal porcine Sertoli cells to human xenoantibody and complement-mediated lysis is associated with low expression of alpha-Gal and high production of clusterin and CD59,” was published in the journal Xenotransplantation as a collaboration between Medistem and the Institute of Organ Transplantation, Tongji Hospital, in Wuhan, China.

The study found that CD59, a molecule made by ERC, plays an important role in protecting cells from immune rejection when placed in contact with immune components from another species. The ERC is a mesenchymal-like stem cell that Medistem discovered in 2007 capable of generating heart, lung, brain, muscle, blood vessel, pancreas, liver, fat and bone tissue. The original description of this cell, which won the “Publication of the Year Award” may be found at http://www.translational-medicine.com/content/pdf/1479-5876-5-57.pdf.

“One of the fundamental aspects of Medistem’s lead product, the Endometrial Regenerative Cell (ERC), is its ability to function without the need for tissue matching. In other words, the ERC stem cells act as universal donors. We have previously published that human ERC are effective in treating mice having a condition that resembles critical limb ischemia (see paper http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf). We now believe that expression of the molecule CD59 on ERC may be one of the mechanisms by which these human cells can be used not only as a universal donor for humans, but also for the treatment of numerous diseases across a variety of animal species,” said Thomas Ichim, CEO of Medistem.

Medistem has filed an IND with the FDA for treatment of critical limb ischemia (severe obstruction of the arteries that leads to decreased blood flow to the extremities) with ERC. Currently the company is in the process of completing additional experiments requested by the FDA before clinical trials can commence. Through physician-initiated compassionate use mechanisms Medistem has already published on human use of ERC in treatment of heart failure, Duchenne Muscular Dystrophy, and multiple sclerosis. A recent peer-reviewed paper describing ERC in treatment of heart failure may be found at http://www.intarchmed.com/content/pdf/1755-7682-3-5.pdf.

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. 

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

id=”nav_links”>

MADISON, WI–(Marketwire – July 29, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), producer of the Hi*Art® treatment system and other products for
advanced radiation therapy, today released financial results for the second
quarter ended June 30, 2010.

Second Quarter Results

Second quarter 2010 revenue was $47.6 million, an increase of 16% from
$41.1 million in the second quarter of 2009. Revenue from product sales
was $34.2 million in the second quarter of 2010, up 12% compared to the
same quarter last year, and revenue from service and other was $13.4
million in the second quarter of 2010, up 27% compared to the same quarter
last year. The company reported a second quarter 2010 loss from operations
of $8.4 million, a 14% decrease from the $9.7 million loss from operations
for the same period last year.

The company incurred a net loss attributable to shareholders of $6.9
million, or $0.13 per share, for the second quarter of 2010, compared to a
net loss of $7.1 million, or $0.14 per share, for the second quarter of
2009.

As of June 30, 2010, the company had $145.7 million of cash, cash
equivalents and short-term investments, representing a $3.0 million
decrease from March 31, 2010, and minimal debt. During the quarter, there
were no borrowings against the company’s credit facility.

As of June 30, 2010, the company had a revenue backlog of $139.2 million, a
4% increase from the $134.2 million backlog as of March 31, 2010. The
backlog includes $42.5 million of equipment orders received during the
second quarter of 2010. One order was removed from backlog during the
second quarter due to uncertainty surrounding the project schedule.
Backlog includes only firm orders that the company believes are likely to
ship within the next two years. Backlog does not include any revenue from
service contracts, which represents a growing portion of the company’s
overall revenue.

“Our second quarter financial results were in line with our internal
expectations and represent a solid improvement over the same period last
year,” said Fred Robertson, TomoTherapy’s CEO. “In addition, we are
pleased with the 13% increase in revenue from the first quarter of 2010 and
the $5.0 million net increase to our backlog since March 31, 2010.
Specifically, we realized a rise in new orders, which we believe reflects
the strength of our new product offerings as well as enhanced global sales
and marketing efforts. On the service side, revenue increased
significantly compared to the same period last year, due to continued
growth in the number of service contracts, and we again achieved strong
customer service rankings. We continue to take steps to enhance our
financial performance and drive toward profitability while still investing
in key product development initiatives. Importantly, our capital position
remained strong in the quarter despite the continuing challenges in the
global economy.”

Six-Month Results

For the six months ended June 30, 2010, revenue was $89.7 million, a 25%
increase from $71.7 million for the six months ended June 30, 2009.
Revenue from product sales was $63.5 million in the first half of 2010, up
23% compared to the first half of 2009, and revenue from service and other
was $26.2 million in the first half of 2010, up 31% compared to the first
half of 2009.

The company reported a year-to-date 2010 loss from operations of $14.4
million, a 39% decrease from the loss from operations of $23.7 million
during the first six months of 2009. The company incurred a net loss
attributable to shareholders of $11.6 million, or $0.22 per share, for the
six months ended June 30, 2010, compared to a net loss attributable to
shareholders of $20.1 million, or $0.40 per share, for the same period last
year.

During the first half of 2010, the company’s cash, cash equivalents and
short-term investments decreased by $8.7 million. The company’s backlog
increased by $3.4 million during the first half of 2010, from $135.8 as of
December 31, 2009 to $139.2 million as of June 30, 2010.

Outlook

The company reaffirms its revenue and earnings guidance for full-year 2010.
Management still expects 2010 revenue to be comparable to 2009 revenue of
$160 million to $180 million, with a net loss attributable to shareholders
in the range of $0.65 to $0.85 per share. Consistent with prior years,
management is not providing specific quarterly guidance. However, similar
to 2009, management anticipates that the timing of expected customer
deliveries will result in 2010 second half revenues being heavily weighted
toward the fourth quarter.

Robertson concluded, “Given our second quarter performance and expectations
for the balance of the year, we remain on track to deliver results in line
with our previously announced guidance. While there is still uncertainty
with respect to macro conditions, particularly in Europe, we are encouraged
by recent performance in North America and Asia. We also continue to make
good progress on several key initiatives, including diversifying our
product line-up and expanding our business both in North America and other
global markets. With significant interest in our TomoDirect™ and
TomoHD™ offerings, entry into new markets, and greater access to many
hospitals through new strategic Group Purchasing Organization agreements,
we believe TomoTherapy is well positioned to capitalize on the substantial
opportunity in the growing global radiation therapy market.”

Investor Conference Call

TomoTherapy will conduct a conference call regarding its second quarter
2010 results at 5:00 p.m. EDT today, July 29, 2010 (4:00 p.m. CDT). To
hear a live Webcast or replay of the call, visit the Investor Relations page at TomoTherapy.com, where it will
be archived for two weeks. To access the call via telephone, dial
1-800-260-8140 from inside the United States or
1-617-614-3672 from outside the United States, and enter pass code
35309628. The replay can be accessed by dialing 1-888-286-8010 from inside
the United States or 1-617-801-6888 from outside the United States and
entering pass code 64325104. The telephone replay will be available
through 11:59 p.m. CDT on August 5, 2010.

About TomoTherapy Incorporated

TomoTherapy Incorporated develops, markets and sells advanced radiation
therapy solutions that can be used to efficiently treat a wide variety of
cancers, from the most common to the most complex. The ring gantry-based
TomoTherapy® platform combines integrated CT imaging with conformal
radiation therapy to deliver sophisticated radiation treatments with speed
and precision while reducing radiation exposure to surrounding healthy
tissue. TomoTherapy’s suite of solutions includes its flagship Hi*Art®
treatment system, which has been used to deliver more than three million
CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment
fractions; the TomoHD™ treatment system, designed to enable cancer centers
to treat a broader patient population with a single device; and the
TomoMobile™ relocatable radiation therapy solution, designed to improve
access and availability of state-of-the-art cancer care. TomoTherapy’s
stock is traded on the NASDAQ Global Select Market under the symbol “TOMO.”
To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Statements
concerning market acceptance of the company’s technology; growth drivers;
the company’s orders, revenue, backlog or earnings growth; future financial
results and any statements using the terms “should,” “believe,” “outlook,”
“expect,” “anticipate” or similar statements are forward-looking statements
that involve risks and uncertainties that could cause the company’s actual
results to differ materially from those anticipated. Such risks and
uncertainties include: demand for the company’s products; impact of sales
cycles and competitive products and pricing; the effect of economic
conditions and currency exchange rates; the company’s ability to develop
and commercialize new products; its reliance on sole or limited-source
suppliers; its ability to increase gross margins; the company’s ability to
meet U.S. Food and Drug Administration (FDA) and other regulatory agency
product clearance and compliance requirements; the possibility that
material product liability claims could harm future revenue or require the
company to pay uninsured claims; the company’s ability to protect its
intellectual property; the impact of managed care initiatives, other health
care reforms and/or third-party reimbursement levels for cancer care;
potential loss of key distributors or key personnel; risk of interruptions
to the company’s operations due to terrorism, disease or other events
beyond the company’s control; and the other risks listed from time to time
in the company’s filings with the U.S. Securities and Exchange Commission,
which by this reference are incorporated herein. TomoTherapy assumes no
obligation to update or revise the forward-looking statements in this
release because of new information, future events or otherwise.

                TOMOTHERAPY INCORPORATED AND SUBSIDIARIES

              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                 (In thousands, except per share data)
                                (unaudited)



                                 Three Months Ended     Six Months Ended
                                      June 30,              June 30,
                                --------------------  --------------------
                                  2010       2009       2010       2009
                                ---------  ---------  ---------  ---------

Revenue:
 Product                        $  34,242  $  30,552  $  63,471  $  51,685
 Service and other                 13,388     10,528     26,239     20,018
                                ---------  ---------  ---------  ---------
  Total revenue                    47,630     41,080     89,710     71,703
                                ---------  ---------  ---------  ---------
Cost of revenue:
 Product                           17,354     14,253     30,139     25,998
 Service and other                 17,818     18,312     34,509     34,651
                                ---------  ---------  ---------  ---------
  Total cost of revenue            35,172     32,565     64,648     60,649
                                ---------  ---------  ---------  ---------
   Gross profit                    12,458      8,515     25,062     11,054
                                ---------  ---------  ---------  ---------
Operating expenses:
  Research and development          8,960      7,020     16,500     12,869
  Selling, general and
   administrative                  11,910     11,224     22,944     21,876
                                ---------  ---------  ---------  ---------
   Total operating expenses        20,870     18,244     39,444     34,745
                                ---------  ---------  ---------  ---------
Loss from operations               (8,412)    (9,729)   (14,382)   (23,691)
Other income (expense):
  Interest income                     416        695        947      1,392
  Interest expense                    (12)       (15)       (23)       (29)
  Other expense, net                 (578)      (107)    (1,026)      (363)
                                ---------  ---------  ---------  ---------
   Total other income (expense)      (174)       573       (102)     1,000
                                ---------  ---------  ---------  ---------
Loss before income tax and
 noncontrolling interests          (8,586)    (9,156)   (14,484)   (22,691)
  Income tax expense (benefit)         10       (318)       (34)      (418)
                                ---------  ---------  ---------  ---------
Net loss                           (8,596)    (8,838)   (14,450)   (22,273)
  Noncontrolling interests          1,673      1,715      2,849      2,151
                                ---------  ---------  ---------  ---------
Net loss attributable to
 shareholders                   $  (6,923) $  (7,123) $ (11,601) $ (20,122)
                                =========  =========  =========  =========

Weighted-average common shares
 outstanding -
 basic and diluted                 51,713     50,592     51,640     50,592
                                =========  =========  =========  =========

Loss per common share - basic
 and diluted                    $   (0.13) $   (0.14) $   (0.22) $   (0.40)
                                =========  =========  =========  =========





                TOMOTHERAPY INCORPORATED AND SUBSIDIARIES

                  CONDENSED CONSOLIDATED BALANCE SHEETS
                              (In thousands)
                                (unaudited)


                                                    June 30,   December 31,
                                                      2010         2009
                                                  ------------ ------------

                                  ASSETS
Cash and cash equivalents                         $     99,240 $     76,108
Short-term investments                                  46,434       78,225
Receivables, net                                        32,915       33,559
Inventories, net                                        53,204       47,669
Prepaid expenses and other current assets                5,507        3,633
                                                  ------------ ------------
 Total current assets                                  237,300      239,194
Property and equipment, net                             18,198       18,628
Other non-current assets, net                           10,588       12,429
                                                  ------------ ------------
 TOTAL ASSETS                                     $    266,086 $    270,251
                                                  ============ ============

                           LIABILITIES AND EQUITY
Accounts payable                                  $     11,896 $      6,269
Accrued expenses                                        20,273       19,588
Accrued warranty                                         3,776        4,173
Deferred revenue                                        31,506       34,145
Customer deposits                                       11,145       13,266
                                                  ------------ ------------
 Total current liabilities                              78,596       77,441
Other non-current liabilities                            4,404        5,475
                                                  ------------ ------------
 TOTAL LIABILITIES                                      83,000       82,916

Total shareholders' equity                             175,498      183,424
Noncontrolling interests                                 7,588        3,911
                                                  ------------ ------------
 TOTAL EQUITY                                          183,086      187,335

                                                  ------------ ------------
 TOTAL LIABILITIES AND EQUITY                     $    266,086 $    270,251
                                                  ============ ============

WAYNE, PA–(Marketwire – July 29, 2010) –  Clinical and Laboratory Standards Institute (CLSI) unveiled the release of StatisPro^™, its new method evaluation software package for the evaluation, verification, and validation of performance characteristics of laboratory test methods at the AACC/ASCLS Annual Meeting this week.

StatisPro software delivers a feature-rich tool designed to perform the statistical analysis necessary to meet regulatory and accreditation requirements. Hospitals, physician office laboratories, reference laboratories, and customer support departments of in vitro diagnostic manufacturers can benefit from using this new method evaluation software.

David Grenache, PhD, DABCC, FACB, Associate Professor, Department of Pathology, University of Utah, ARUP Laboratories, and beta-tester for StatisPro, says, “The benefits of StatisPro are its ease-of-use and intuitive interface. When validating a new method, replacing equipment, or preparing for accreditation or regulatory inspections, StatisPro makes advanced statistical analysis easier regardless of the size of the laboratory using it.”

Developed in conjunction with Analyse-it^®, StatisPro can produce reports on analytical accuracy, precision, linearity, limit of detection and quantitation, and reference intervals and is entirely based on the most up-to-date CLSI guidelines.

With StatisPro, laboratories can:

• Verify comparability of new methods and systems.
• Ensure comparable results across measuring systems.
• Establish reference intervals or transfer intervals between methods and laboratories.

James Huntington, Co-founder, Analyse-it^®, describes the importance of evaluating and verifying method performance, saying, “Laboratories must ensure method performance is as expected to meet regulatory or accreditation requirements. As the statistics necessary to determine method performance become more complex, software such as StatisPro is essential to ensure accurate, correct, determination of method performance.”

CLSI partnered with Analyse-it because of its excellent reputation and proven experience in creating statistically based software, as well as its similar culture and values to CLSI, explains Glen Fine, MS, MBA, CAE, CLSI Executive Vice President. “Since StatisPro is based on CLSI’s world-renowned best practices, it will inspire user confidence. This is the only software package available that streamlines implementation of CLSI’s latest method evaluation guidelines. StatisPro allows staff of laboratories of any size to produce advanced statistical calculations and display reports quickly and accurately in order to ensure the highest quality patient care,” says Fine. 

StatisPro is available directly from CLSI. For more information, please visit www.StatisPro.org or call 877.477.1888.

CLSI is a volunteer-driven, membership-supported, nonprofit organization dedicated to developing standards and guidelines for the health care and medical testing community through a consensus process that balances the perspectives of industry, government, and the health care professions. For additional information visit the CLSI website at www.clsi.org or call 610.688.0100.

Analyse-it Software, Ltd. formed in 1997 to develop statistical analysis and charting software for Microsoft^® Excel^™, and built its flagship product, Analyse-it, through work with some of the world’s largest in vitro diagnostic companies. Now with more than 20,000 customers, Analyse-it is highly respected in the scientific and research community, and is used and cited in thousands of peer-reviewed published papers. For additional information, visit the Analyse-it website at www.analyse-it.com.

Click here to see all recent news from this company

KELLER, TX–(Marketwire – July 29, 2010) – In less time than it takes for a single lunch hour, employees can learn, for free, how to save a life through Cardiopulmonary Resuscitation (CPR). This because Dallas-based non-profit Mission CPR (www.MissionCPR.org) has launched its “Spend 45 Minutes, Save a Life” initiative offering workplace CPR awareness and basic skills training to area businesses and organizations completely free of charge. Mission CPR has launched this program as part of the American Heart Association’s overriding “CPR Anytime” campaign created to increase the incidence of bystander CPR by making training more accessible.

“A full 93.6 percent of sudden cardiac arrest victims die simply because the vast majority of those witnessing the arrest do not know how to perform CPR and are reluctant to even try,” says Jeff D. Hill, CEO of Mission CPR, whose own life was saved by CPR at age 3 and who has since saved a life using CPR through his work as an EMT. “Our organization aims to not only raise awareness about the vital importance of bystander CPR, but also actually save lives by providing local groups with basic, easily absorbed training in a convenient on-site workplace setting — at no cost to the employee, group member or organization.” 

“The session lasts only 45 minutes and very little time is needed to organize the presentation,” Hill underscores. “This program is an invaluable employee benefit that has nothing but upside for all involved — the company, employee, their families and the Dallas/Fort Worth community at large.”

At the age of 3, Hill’s own life was saved by bystander CPR. Left briefly unattended, he fell in a pool and drowned. Hill had no heartbeat and had stopped breathing completely. A visiting relative heard his mother screaming once she pulled Hill from the pool, and he jumped in to try to help. This relative had received CPR training years before and was unsure if he was “doing it right,” but he TRIED his best, revived Hill’s heartbeat, and kept him alive long enough until the EMS arrived to take over. This experience exemplifies why even the most basic understanding of CPR is important and how those skills can prove critical in an emergency situation.

Hill notes, “The reality is many people in distress that need CPR do not get the help because bystanders are not trained or are afraid to try. Indeed, in my prior work as a firefighter and EMT, most bystanders waited until we arrived to attempt CPR and, most often, it was too late. Even the most basic skills training can give someone the knowledge and confidence needed to attempt CPR until medical professionals arrive, and can mean the difference between life and death.”

In addition to its free “Spend 45 Minutes, Save a Life” training program, Mission CPR also offers interested and key employees full certification-based CPR and First Aid training at a reduced cost, with proceeds used to purchase additional American Heart Association CPR training kits to support and prolong the organization’s free training efforts. Mission CPR sessions are available for company meetings and conferences, “lunch and learns,” health fairs, benefits enrollment periods or any other time that best suits the business or organization. 

Interested parties may visit www.MissionCPR.org to learn more about Mission CPR’s free and reduced-fee certification programs. More information about the American Heart Association’s “CPR Anytime” campaign may be accessed online at http://www.trihealth.com/aus/srv/CPR_Anytime.aspx.

About Mission CPR
Based in Keller, Texas, Mission CPR is a non-profit organization dedicated to raising awareness about the vital importance of bystander CPR in both a local and nationwide effort to save lives. The organization provides free CPR awareness presentations and basic skills training, and reduced-cost CPR and First Aid certifications, to businesses and organizations of all types throughout the Dallas/Fort Worth region. Mission CPR is spearheaded by CPR recipient and survivor Jeff D. Hill who himself, as a former EMT, has saved the life of another using CPR. Contact Mission CPR at 817-509-0004 or [email protected], or learn more about the organization online at www.MissionCPR.org.

Click here to see all recent news from this company

HALIBURTON, ON–(Marketwire – July 29, 2010) – Patient News, a leading dental marketing company in the US and Canada, was recognized for its outstanding newsletter design and layout in the 22nd Annual Awards for Publication Excellence Competition (APEX). Judged by a panel of experienced writers and editors, the APEX 2010 awards are based on excellence in graphic design, editorial content, and the ability to achieve overall communications excellence. Despite an exceptionally intense competition with more than 3,700 entries, Patient News received an Award for Publication Excellency by Apex 2010 for Dr. Randy G. Fussell’s Fall 2009 dental marketing newsletter “Smile! Pass It on!”

“At Patient News we take great pride in our highly skilled editorial, design, and production teams who work together to create engaging, innovative, and personable patient marketing and potential patient marketing materials that speak directly to our clients’ targeted audience,” said Karen Galley, President of Patient News. “As the industry leader, our customized marketing methods are proven, reliable, professional, and diverse.”

Patient News offers a variety of innovative dental marketing products including dental email newsletters, patient newsletters, direct mail newsletters, dental postcards, patient referral cards and patient satisfaction surveys. All products are tailored to help achieve the specific goals of each client. With nearly 20 years of business and over 100 million newsletters and postcards later, Patient News provides health care specialists with measurably effective practice marketing. In addition to the APEX 2010 Award for Publication Excellency, Patient News has received a number of other awards, including Entrepreneur of the Year, Large Business of the Year, and the American Graphic Design Award.

Patient News has been producing dental marketing materials for almost 20 years in North America and the UK. For additional information on dental marketing from Patient News, call 800.667.0268 or visit www.patientnews.com. To read more on this topic, visit: http://www.patientnews.com/pressreleases/dental-marketing-excellency-award.html.

About Patient News:
 Patient News is North America’s most comprehensive and innovative dental marketing solutions provider. Founded in Canada in 1992, the company produces award-winning healthcare and dental marketing products in Canada, the United States, and the United Kingdom. The company has been named a Top 100 employer for four consecutive years, and has officially added environmental sustainability to its core values within the company vision.
Contact:

Click here to see all recent news from this company

WAYNE, PA–(Marketwire – July 29, 2010) –  Kenexa (NASDAQ: KNXA), a global provider of business solutions for human resources, today announced that a trio of executives from global and regional healthcare-related companies will share their unique perspectives on talent acquisition and employee engagement during the upcoming 2010 Kenexa World Conference. Gina Nardone, Manager of Talent Acquisition for Baxter Healthcare; Kristy Rigot, System Director of Human Resources for Lee Memorial Health System; and Cathy Fraser, Senior Vice President of Human Resources for Tenet Healthcare Corporation will add their voices to the conference, sharing best practices that are changing the face of HR.

In a session titled “The Effective Great Unknown: Global Expansion in a Decentralized Talent Acquisition Organization,” Nardone will focus on Baxter’s global implementation of Kenexa Recruiter® BrassRing, highlighting the company’s specific challenges, including the initial absence of a strong global talent acquisition presence across the organization. Nardone will explain how Baxter has achieved 85% implementation across the organization, with a goal of 100% by the end of 2011. Recommendations on conducting Delta Workshops, language implementation, dealing with HR turnover, working with limited budgets and post-implementation involvement also will be discussed.

Improving recruitment productivity is not about doing things faster and harder. It is about streamlining work process, standardizing, modifying behaviors, optimizing technology and staying focused on key recruitment workforce metrics. During her presentation of “Soar with the Eagles: Improving Recruitment Productivity,” Rigot will provide an overview of Lee Memorial Health System’s focus on performance improvement strategies and goals based on continuous analysis of candidate pipeline, workflow and performance metrics.

In a presentation titled “Achieving Impact by ‘Under-thinking’ Traditional HR,” Fraser will share how textbook HR does not always make sense, describing different thinking in the traditional towers of talent management, performance management, employee engagement, and anti-unionization, tuned at achieving impact. During this intriguing session, Fraser will highlight the importance of context and organizational readiness, with the backdrop of Tenet Healthcare’s business turnaround.

The fifth annual Kenexa World Conference promises to transform HR through outliers, helping organizations move beyond potential to drive business performance. To reveal true human potential to improve business results, companies must identify and nurture high performers and create the right environment for them to thrive. Attendees of the conference will come to understand how the right individuals in the right environment lead to ultimate success.

Happening Tuesday, September 21 through Thursday, September 23, 2010, in Philadelphia, Pa., the Kenexa World Conference will give companies the information they need to transform HR and move from potential to performance. The 2010 Kenexa World Conference will be held at The Sheraton Society Hill Hotel, One Dock Street, Philadelphia, Pa. For more information or to register, visit www.kenexa.com.

About Kenexa
Kenexa® provides business solutions for human resources. We help global organizations multiply business success by identifying the best individuals for every job and fostering optimal work environments for every organization. For more than 20 years, Kenexa has studied human behavior and team dynamics in the workplace, and has developed the software solutions, business processes and expert consulting that help organizations impact positive business outcomes through HR. Kenexa is the only company that offers a comprehensive suite of unified products and services that support the entire employee lifecycle from pre-hire to exit. Additional information about Kenexa and its global products and services can be accessed at www.kenexa.com.

Click here to see all recent news from this company

TUSTIN, CA–(Marketwire – July 29, 2010) –  US-based Radient Pharmaceuticals Corporation (NYSE Amex: RPC) announced today Perceptive Imagineering has launched a Spanish language website (www.perceptive-imagineering.com/onko-sure) adapted for the Latin American culture in support of the product commercialization for RPC’s proprietary, USFDA-approved Onko-Sure® in vitro diagnostic (IVD) cancer test. 

As RPC’s distribution partner for Central America, South America, Mexico and the Caribbean, Perceptive Imagineering is responsible for commercialization efforts, including product registration, marketing, sales and support for the licensing and distribution of Onko?Sure in these regions. The newly launched site is a companion to RPC’s corporate websites: Radient-Pharma.com and Onko-Sure, and delivers detailed information on Radient Pharmaceuticals, Onko-Sure and Onko-Sure product sales and distribution in Latin American and surrounding regions. This website also includes a valuable FAQ section with answers to the most commonly asked questions about Onko-Sure, scientific literature regarding the test, basic information about cancer and cancer testing in Latin America, RPC’s CLIA laboratory testing resources and general information on cancer screening, testing and treatment.

According to Douglas MacLallan, Chairman and CEO of Radient Pharmaceuticals, “The launch of this new site supports our commercialization efforts in Latin America and serves as a critical communication tool in this geographical region. The site is an invaluable resource to educate our key Latin American audiences, which include cancer patients, the medical and healthcare community at large, existing and prospective investors, partners and suppliers on the Company and Onko-Sure and Onko-Sure’s merits as a non-invasive, simple blood test for cancer screening and testing.”

Perceptive specializes in assisting US medical companies in bringing their products into Latin America. Perceptive Imagineering, LLC is led Dr. Nancy Alvarez, and, under her leadership, her company is well?suited to lead the licensing, distribution and commercialization efforts for RPC’s Onko?Sure cancer test in this market.

Onko-Sure IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure™ is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test.

About Radient Pharma:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is a US-based pharmaceutical company specializing in the research, development and sales of In Vitro Diagnostic Cancer tests. The Company’s focus is on the discovery, development & commercialization of unique high?value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Our Onko?Sure™ IVD cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. For additional information on RPC and its portfolio of cancer products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

UTICA, NY–(Marketwire – July 29, 2010) – CONMED Corporation (NASDAQ: CNMD) today announced
financial results for the second quarter of 2010.

Sales for the second quarter ended June 30, 2010 were $181.1 million
compared to $164.6 million in the same quarter of 2009, an increase of 10
percent. GAAP diluted earnings per share were $0.25 compared to $0.05 in
the second quarter of 2009. Non-GAAP diluted earnings per share equaled
$0.32 compared to non-GAAP diluted earnings per share of $0.17 in the 2009
second quarter. As discussed below under “Use of Non-GAAP Financial
Measures,” the Company presents various non-GAAP financial measures in this
release. Investors should consider non-GAAP measures in addition to, and
not as a substitute for, or superior to, financial performance measures
prepared in accordance with GAAP. Please refer to the attached
reconciliation between GAAP and non-GAAP financial measures.

For the six months ended June 30, 2010, sales were $357.5 million compared
to $328.6 million in the first six months of 2009, an increase of 8.8
percent. GAAP diluted earnings per share were $0.50 for year-to-date June
2010 compared to $0.20 in the same period of 2009. Non-GAAP diluted
earnings per share were $0.60 for the 2010 six-month period compared to
$0.36 in 2009.

“The results of the 2010 second quarter improved upon the positive
performance of the first quarter of the year,” commented Mr. Joseph J.
Corasanti, President and Chief Executive Officer. “Single-use product
sales, once again, produced solid year-over-year growth, while capital
product sales experienced significant growth, 18.9 percent in constant
currency, over the second quarter of last year. This overall sales growth,
together with the continued realization of cost efficiencies from ongoing
restructuring initiatives, resulted in substantially improved earnings
compared to a year ago.”

International sales in the second quarter of 2010 were $87.9 million,
representing 48.5% of total sales, and $172.9 million for the six-months
ended June 30, 2010. Favorable currency exchange rates in 2010 led to an
increase in sales of $3.2 million compared to exchange rates in the second
quarter of 2009, and $11.1 million for the six-month period of 2010.

Cash provided from operating activities outpaced net income in the second
quarter of 2010 and amounted to $18.5 million, or 10.2 percent of sales.
The cash was used to repay debt and repurchase the Company’s common stock,
as further explained below.

Outlook

Mr. Corasanti added, “We believe that the results of the second quarter of
2010, as well as what we are hearing from our sales force, indicates that
our customers are returning to historical purchasing trends as compared to
the instability experienced in 2009 due to the global economic crisis.
Consequently, we expect that sales in the third quarter of 2010 will
experience a normal seasonal sequential reduction from the second quarter
2010 and that the sales of the fourth quarter of 2010 should be the
strongest of the year, as we’ve seen historically. For the third quarter
of 2010, we expect sales to approximate $174 – $179 million with non-GAAP
diluted earnings per share of $0.25 – $0.30. For the full year of 2010, we
are reiterating our previously communicated guidance, with sales estimated
to be $715 – $725 million and non-GAAP diluted earnings per share of $1.20
– $1.30.”

The sales and earnings forecasts have been developed using July 2010
currency exchange rates and take into account the currency hedges entered
into by the Company. We estimate that 80% of the currency exposure is
hedged for the third quarter 2010 and 60% hedged for the fourth quarter.

The non-GAAP estimates for the year and the third quarter exclude the
additional non-cash interest expense required by recently issued Financial
Accounting Standards Board (“FASB”) guidance, the loss on repurchase and
retirement of our Convertible Notes and all of the manufacturing and
administrative restructuring costs expected to be incurred in 2010.

Restructuring costs

During the second quarter of 2010, the Company consolidated various
administrative functions in its CONMED Linvatec division and continued the
transfer of additional product lines to its Mexican manufacturing facility.
Expenses associated with these activities, including severance and
relocation costs, amounted to $2.0 million in the second quarter of 2010
and $2.5 million for the six months ended June 30, 2010. These charges are
included in the GAAP earnings per share set forth above and are excluded
from the non-GAAP results. CONMED expects additional restructuring charges
for the remainder of 2010 to approximate $1.5 million; these costs are
excluded from non-GAAP earnings estimates.

Stock and bond repurchase

During the second quarter of 2010, utilizing the Company’s current cash
flow, CONMED repurchased approximately 475,000 shares of its common stock,
amounting to $9.5 million, and also repurchased and retired $3.0 million
face value of its 2.5 percent Convertible Notes at a discount of
approximately 3 percent. The remaining availability under the Board of
Directors’ authorization for stock repurchases currently amounts to $37.3
million, and additional shares under this authority may be repurchased
using the Company’s cash flow.

Convertible note interest expense

As previously disclosed, and in accordance with guidance recently issued by
the FASB, the Company is now required to record non-cash interest expense
related to its convertible notes to bring the effective interest rate to a
level approximating that of a non-convertible note of similar size and
tenor. In the second quarters of 2010 and 2009, CONMED recorded additional
non-cash pre-tax interest charges of $1.1 million and $1.0 million,
respectively. For the first six-months of 2010 and 2009, such charges
amounted to $2.1 million in each period. These charges are included in the
GAAP earnings per share set forth above, and excluded from the non-GAAP
amounts.

Accounts receivable financing — change in accounting

As previously disclosed, recently issued FASB guidance requires that
CONMED’s accounting for its accounts receivable financing facility be
changed as of January 1, 2010. Previously, the sale of accounts receivable
to a bank removed the sold receivables from the Company’s balance sheet.
In 2010 and future years, the new guidance requires that the receivables
remain on CONMED’s balance sheet and that the financing transaction be
recorded as a liability. Usage of the facility amounted to $31.0 million
at June 30, 2010. Accordingly, as of June 30, 2010, compared to the
previous off-balance sheet accounting, accounts receivable is $31.0 million
greater because the full amount of receivables remains on the balance
sheet, and the current portion of long-term debt includes the $31.0 million
usage of the receivable facility. Further, cash provided by operating
activities on the June 30, 2010 statement of cash flows is reduced by $29.0
million as a result of the change in accounting. See the attached
reconciliation of cash flow provided by operating activities. This
accounting change had no effect on the consolidated statement of income.

Use of Non-GAAP Financial Measures

Management has disclosed financial measurements in this press announcement
that present financial information that is not in accordance with Generally
Accepted Accounting Principles (“GAAP”). These measurements are not a
substitute for GAAP measurements, although Company management uses these
measurements as aids in monitoring the Company’s on-going financial
performance from quarter-to-quarter and year-to-year on a regular basis,
and for benchmarking against other medical technology companies. Non-GAAP
net income and non-GAAP earnings per share measure the income of the
Company excluding unusual credits or charges that are considered by
management to be outside of the normal on-going operations of the Company.
Management uses and presents non-GAAP net income and non-GAAP earnings per
share because management believes that in order to properly understand the
Company’s short and long-term financial trends, the impact of unusual items
should be eliminated from on-going operating activities. These adjustments
for unusual items are derived from facts and circumstances that vary in
frequency and impact on the Company’s results of operations. Management
uses non-GAAP net income and non-GAAP earnings per share to forecast and
evaluate the operational performance of the Company as well as to compare
results of current periods to prior periods on a consistent basis.
Non-GAAP financial measures used by the Company may be calculated
differently from, and therefore may not be comparable to, similarly titled
measures used by other companies. Investors should consider non-GAAP
measures in addition to, and not as a substitute for, or superior to,
financial performance measures prepared in accordance with GAAP.

Conference call

The Company will webcast its second quarter 2010 conference call live over
the Internet at 10:00 a.m. Eastern Time on Thursday, July 29, 2010. This
webcast can be accessed from CONMED’s web site at www.conmed.com. Replays
of the call will be made available through August 6, 2010.

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices
and equipment for minimally invasive procedures and patient monitoring.
The Company’s products serve the clinical areas of arthroscopy, powered
surgical instruments, electrosurgery, cardiac monitoring disposables,
endosurgery and endoscopic technologies. They are used by surgeons and
physicians in a variety of specialties including orthopedics, general
surgery, gynecology, neurosurgery and gastroenterology. Headquartered in
Utica, New York, the Company’s 3,300 employees distribute its products
worldwide from several manufacturing locations.

Forward-Looking Information

This press release contains forward-looking statements based on certain
assumptions and contingencies that involve risks and uncertainties. The
forward-looking statements are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995 and relate to the
Company’s performance on a going-forward basis. The forward-looking
statements in this press release involve risks and uncertainties which
could cause actual results, performance or trends, to differ materially
from those expressed in the forward-looking statements herein or in
previous disclosures. The Company believes that all forward-looking
statements made by it have a reasonable basis, but there can be no
assurance that management’s expectations, beliefs or projections as
expressed in the forward-looking statements will actually occur or prove to
be correct. In addition to general industry and economic conditions,
factors that could cause actual results to differ materially from those
discussed in the forward-looking statements in this press release include,
but are not limited to: (i) the failure of any one or more of the
assumptions stated above, to prove to be correct; (ii) the risks relating
to forward-looking statements discussed in the Company’s Annual Report on
Form 10-K for the fiscal year ended December 31, 2009; (iii) cyclical
purchasing patterns from customers, end-users and dealers; (iv) timely
release of new products, and acceptance of such new products by the market;
(v) the introduction of new products by competitors and other competitive
responses; (vi) the possibility that any new acquisition or other
transaction may require the Company to reconsider its financial assumptions
and goals/targets; and/or (vii) the Company’s ability to devise and execute
strategies to respond to market conditions.

                                 CONMED CORPORATION
                            Second Quarter Sales Summary

                                  Three Months Ended June 30,
                    ------------------------------------------------------

                                                                Constant
                                                                Currency
                         2009          2010       Growth         Growth
                    ------------- ------------- ------------  ------------
                           (in millions)
Arthroscopy
   Single-use       $        46.0 $        54.4         18.3%         15.4%
   Capital                   15.6          20.5         31.4%         28.8%
                    ------------- ------------- ------------  ------------
                             61.6          74.9         21.6%         18.8%
                    ------------- ------------- ------------  ------------

Powered Surgical
 Instruments
   Single-use                19.1          19.1          0.0%         -2.6%
   Capital                   14.4          16.6         15.3%         13.2%
                    ------------- ------------- ------------  ------------
                             33.5          35.7          6.6%          4.2%
                    ------------- ------------- ------------  ------------

Electrosurgery
   Single-use                17.3          18.2          5.2%          4.0%
   Capital                    5.4           5.8          7.4%          5.6%
                    ------------- ------------- ------------  ------------
                             22.7          24.0          5.7%          4.4%
                    ------------- ------------- ------------  ------------

Endoscopic
 Technologies
   Single-use                12.5          11.9         -4.8%         -6.4%
                    ------------- ------------- ------------  ------------
Endosurgery
   Single-use and
    reposable                17.3          17.1         -1.2%         -1.7%
                    ------------- ------------- ------------  ------------
Patient Care
   Single-use                17.0          17.5          2.9%          2.4%
                    ------------- ------------- ------------  ------------

Total
   Single-use and
    reposable               129.2         138.2          7.0%          5.1%
   Capital                   35.4          42.9         21.2%         18.9%
                    ------------- ------------- ------------  ------------
                    $       164.6 $       181.1         10.0%          8.1%
                    ============= ============= ============  ============




                                  CONMED CORPORATION
                                Six-Month Sales Summary

                                  Six Months Ended June 30,
                    ------------------------------------------------------

                                                                Constant
                                                                Currency
                         2009          2010        Growth        Growth
                    ------------- ------------- ------------  ------------
                           (in millions)
Arthroscopy
   Single-use       $        92.8 $       109.3         17.8%         13.0%
   Capital                   32.6          37.8         16.0%         12.6%
                    ------------- ------------- ------------  ------------
                            125.4         147.1         17.3%         12.9%
                    ------------- ------------- ------------  ------------

Powered Surgical
 Instruments
   Single-use                37.2          39.3          5.6%          0.0%
   Capital                   29.1          31.4          7.9%          4.1%
                    ------------- ------------- ------------  ------------
                             66.3          70.7          6.6%          1.8%
                    ------------- ------------- ------------  ------------

Electrosurgery
   Single-use                34.3          35.3          2.9%          0.9%
   Capital                   10.8          11.8          9.3%          6.5%
                    ------------- ------------- ------------  ------------
                             45.1          47.1          4.4%          2.2%
                    ------------- ------------- ------------  ------------

Endoscopic
 Technologies
   Single-use                24.5          23.7         -3.3%         -5.7%
                    ------------- ------------- ------------  ------------
Endosurgery
   Single-use and
    reposable                31.8          34.2          7.5%          5.7%
                    ------------- ------------- ------------  ------------
Patient Care
   Single-use                35.5          34.7         -2.3%         -3.1%
                    ------------- ------------- ------------  ------------

Total
   Single-use and
    reposable               256.1         276.5          8.0%          4.6%
   Capital                   72.5          81.0         11.7%          8.4%
                    ------------- ------------- ------------  ------------
                    $       328.6 $       357.5          8.8%          5.4%
                    ============= ============= ============  ============ 



                            CONMED CORPORATION
                    CONSOLIDATED STATEMENTS OF INCOME
                  (in thousands except per share amounts)
                                (unaudited)

                         Three months ended         Six months ended
                              June 30,                  June 30,
                       --------------------       --------------------
                         2009         2010          2009         2010
                       --------     --------      --------     --------

Net sales              $164,569     $181,086      $328,631     $357,451

Cost of sales            83,559       86,411       168,343      170,414
Cost of sales, other
 - Note A                 3,698          992         6,624        1,559
                       --------     --------      --------     --------

Gross profit             77,312       93,683       153,664      185,478
                       --------     --------      --------     --------

Selling and
 administrative          64,147       71,494       126,000      142,046
Research and
 development              7,396        6,441        15,885       14,123
Other expense (income)
 - Note B                   734          970          (602)         970
                       --------     --------      --------     --------
                         72,277       78,905       141,283      157,139
                       --------     --------      --------     -------- 

Income from
 operations               5,035       14,778        12,381       28,339

Gain (loss) on early
 extinguishment of debt       -          (79)        1,083         (79)

Amortization of debt
 discount                 1,013        1,056         2,058        2,108

Interest expense          1,767        1,771         3,255        3,520
                       --------     --------      --------     --------

Income before income
 taxes                    2,255       11,872         8,151       22,632

Provision for income
 taxes                      846        4,566         2,257        8,007
                       --------     --------      --------     --------

Net income             $  1,409     $  7,306      $  5,894     $ 14,625
                       ========     ========      ========     ========

Per share data:

  Net Income
    Basic              $    .05     $    .25      $    .20    $    .50
    Diluted                 .05          .25           .20         .50

  Weighted average
   common shares
    Basic                29,056       29,100        29,043      29,125
    Diluted              29,082       29,295        29,071      29,342

Note A — Included in cost of sales, other in the three and six months
ended June 30, 2009 are $3.7 million and $6.6 million, respectively, in
costs related to the startup of a new manufacturing facility in Chihuahua,
Mexico and the consolidation of two of the Company’s three Utica, New York
area manufacturing facilities. Included in cost of sales, other in the
three and six months ended June 30, 2010 are $1.0 million and $1.6 million,
respectively, related to the moving of additional product lines to the
manufacturing facility in Chihuahua, Mexico.

Note B — Included in other expense (income) in the three months ended June
30, 2009 is $0.7 million related to the consolidation of the Company’s
distribution activities. Included in other expense (income) in the six
months ended June 30, 2009 is a non-cash net pre-tax pension gain of $1.9
million and $1.3 million in costs related to the consolidation of the
Company’s distribution activities. Included in other expense (income) in
the three and six months ended June 30, 2010 is $1.0 million related to the
consolidation of various administrative functions in our orthopedic
division.

                            CONMED CORPORATION
                    CONSOLIDATED CONDENSED BALANCE SHEETS
                               (in thousands)
                                (unaudited)
                                   ASSETS

                                        December 31,    June 30,
                                            2009          2010
                                         ----------    ----------
Current assets:
  Cash and cash equivalents              $   10,098    $    8,490
  Accounts receivable, net                  126,162       142,801
  Inventories                               164,275       170,816
  Deferred income taxes                      14,782        13,764
  Other current assets                       10,293        13,125
                                         ----------    ----------
    Total current assets                    325,610       348,996

Property, plant and equipment, net          143,502       142,070
Deferred income taxes                         1,953         2,002
Goodwill                                    290,505       295,111
Other intangible assets, net                190,849       192,971
Other assets                                  5,994         5,595
                                         ----------    ----------
    Total assets                         $  958,413    $  986,745
                                         ==========    ==========

                     LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
  Current portion of long-term debt       $   2,174    $   33,208
  Other current liabilities                  76,933        73,524
                                         ----------    ----------
    Total current liabilities                79,107       106,732

Long-term debt                              182,195       170,366
Deferred income taxes                        97,916       107,091
Other long-term liabilities                  22,680        24,164
                                         ----------    ----------
    Total liabilities                       381,898       408,353
                                         ----------    ----------

Shareholders' equity:
  Capital accounts                          263,550       256,911
  Retained earnings                         325,370       339,362
  Accumulated other comprehensive
   income (loss)                            (12,405)      (17,881)
                                         ----------    ----------
    Total shareholders' equity              576,515       578,392
                                         ----------    ----------

    Total liabilities and shareholders'
     equity                              $  958,413    $  986,745
                                         ==========    ==========





                             CONMED CORPORATION
               CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS
                               (in thousands)
                                (unaudited)

                                                      Six months ended
                                                          June 30,
                                                  ------------------------
                                                      2009         2010
                                                  -----------  -----------
Cash flows from operating activities:
Net income                                        $     5,894  $    14,625
Adjustments to reconcile net income
 to net cash provided by operating
 activities:
  Depreciation and amortization                        19,439       20,581
  Stock-based compensation expense                      2,090        2,082
  Deferred income taxes                                 3,129        7,239
  (Gain) loss on early extinguishment of debt          (1,083)          79
  Sale of accounts receivable to
   (collections for) purchaser                         (3,000)     (29,000)
  Increase (decrease) in cash flows from
   changes in assets and liabilities:
    Accounts receivable                                 7,999        8,718
    Inventories                                        (4,319)     (16,167)
    Accounts payable                                   (7,774)       6,100
    Income taxes payable                               (1,901)        (125)
    Accrued compensation and benefits                  (2,996)          90
    Other assets                                         (830)      (2,884)
    Other liabilities                                  (2,661)      (5,815)
                                                  -----------  -----------
Net cash provided by operating activities              13,987        5,523
                                                  -----------  -----------

Cash flows from investing activities:
  Purchases of property, plant, and
   equipment                                          (12,032)      (7,163)
  Payments related to business acquisitions              (188)      (5,157)
                                                  -----------  -----------
Net cash used in investing activities                 (12,220)     (12,320)
                                                  -----------  -----------

Cash flows from financing activities:
  Payments on debt                                     (9,519)     (14,012)
  Proceeds of debt                                      9,000            -
  Proceeds from secured borrowings, net                     -       31,000
  Repurchase of treasury stock                              -       (9,471)
  Other, net                                           (1,341)      (1,279)
                                                  -----------  -----------
Net cash provided by (used in) financing
 activities                                            (1,860)       6,238
                                                  -----------  -----------

Effect of exchange rate change on cash and cash
 equivalents                                           (1,039)      (1,049)
                                                  -----------  -----------

Net decrease in cash and cash equivalents              (1,132)      (1,608)

Cash and cash equivalents at beginning of period       11,811       10,098
                                                  -----------  -----------

Cash and cash equivalents at end of period        $    10,679  $     8,490
                                                  ===========  ===========





                           CONMED CORPORATION
        RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME
          BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT
               Three Months Ended June 30, 2009 and 2010
                (In thousands except per share amounts)
                             (unaudited)

                                                          2009      2010
                                                        --------  --------
Reported net income                                     $  1,409  $  7,306
                                                        --------  --------
New plant / facility consolidation costs included
 in cost of sales                                          3,698       992
                                                        --------  --------

CONMED Linvatec division administrative consolidation          -       970

Facility consolidation costs included in other expense
 (income)                                                    734         -
                                                        --------  --------

  Total other expense (income)                               734       970
                                                        --------  --------

Loss on early extinguishment of debt                           -        79
                                                        --------  --------

Amortization of debt discount                              1,013     1,056
                                                        --------  --------

Unusual expense (income) before income taxes               5,445     3,097

Provision (benefit) for income taxes on unusual
 expenses                                                 (1,970)   (1,125)
                                                        --------  --------

Net income before unusual items                         $  4,884  $  9,278
                                                        ========  ========

Per share data:

Reported net income
  Basic                                                 $   0.05  $   0.25
  Diluted                                                   0.05      0.25

Net income before unusual items
  Basic                                                 $   0.17  $   0.32
  Diluted                                                   0.17      0.32

Management has provided the above reconciliation of net income before
unusual items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance as
discussed in the section “Use of Non-GAAP Financial Measures” above. We
have included the amortization of debt discount in our analysis in order to
facilitate comparison with the non-GAAP earnings guidance provided in the
“Outlook” section of this and previous releases which exclude such expense.

                         CONMED CORPORATION
      RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME
         BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT
                Six Months Ended June 30, 2009 and 2010
                (In thousands except per share amounts)
                             (unaudited)

                                                          2009      2010
                                                        --------  --------

Reported net income                                     $  5,894  $ 14,625
                                                        --------  --------

New plant / facility consolidation costs included
 in cost of sales                                          6,624     1,559
                                                        --------  --------

CONMED Linvatec division administrative consolidation          -       970

Pension gain, net                                         (1,882)        -

Facility consolidation costs included in other
 expense (income)                                          1,280         -
                                                        --------  --------

      Total other expense (income)                          (602)      970
                                                        --------  --------

(Gain) loss on early extinguishment of debt               (1,083)       79
                                                        --------  --------

Amortization of debt discount                              2,058     2,108
                                                        --------  --------

Unusual expense (income) before income taxes               6,997     4,716

Provision (benefit) for income taxes on unusual
 expenses                                                 (2,538)   (1,718)
                                                        --------  --------

Net income before unusual items                         $ 10,353  $ 17,623
                                                        ========  ========

Per share data:

Reported net income
      Basic                                             $   0.20  $   0.50
      Diluted                                               0.20      0.50

Net income before unusual items
      Basic                                             $   0.36  $   0.61
      Diluted                                               0.36      0.60

Management has provided the above reconciliation of net income before
unusual items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance as
discussed in the section “Use of Non-GAAP Financial Measures” above. We
have included the amortization of debt discount in our analysis in order to
facilitate comparison with the non-GAAP earnings guidance provided in the
“Outlook” section of this and previous releases which exclude such expense.

                         CONMED CORPORATION
      IMPACT TO STATEMENT OF CASH FLOWS RELATED TO ACCOUNTING
                   CHANGE APPLIED PROSPECTIVELY
              Six Months Ended June 30, 2009 and 2010
                          (In thousands)
                            (unaudited)

                                                          2009     2010
                                                        --------  --------

Reported cash flows from operating activities           $ 13,987  $  5,523
                                                        --------  --------

Sale of accounts receivable accounting change                  -    29,000
                                                        --------  --------

Adjusted cash flows from operating activities           $ 13,987  $ 34,523
                                                        ========  ========


Reported cash flows provided by (used in) financing
 activities                                             $ (1,860) $  6,238
                                                        --------  --------

Proceeds from secured borrowings, net                          -   (31,000)
                                                        --------  --------

Adjusted cash flows provided by (used in) financing
 activities                                             $ (1,860) $(24,762)
                                                        ========  ========

Management has provided the above reconciliation of cash flow from
operations and cash flow from financing activities before the accounting
change as an additional measure that investors can use to compare operating
and financing cash flows between reporting periods. Management believes
these reconciliations provide a useful presentation of cash flows as
discussed in the section “Use of Non-GAAP Financial Measures” above.

PLEASANTON, CA–(Marketwire – July 29, 2010) –  APCO Booth #939 — As leading providers of integrated public safety solutions, Positron Front Line and its parent company Tiburon, Inc. announce a strategic partnership agreement with Intrado Inc., the leading provider of 9-1-1 technology solutions. Positron Front Line has also become Intrado’s preferred computer aided dispatch (CAD) solutions provider and will continue to deliver integrated solutions with Intrado’s call-handling applications.

As part of the agreement, Positron Front Line has committed to interoperability with Intrado’s next-generation 9-1-1 (NG9-1-1) voice and data services, ensuring that their solutions are fully compatible with approved industry standards. Through this new strategic partnership, Positron Front Line and Tiburon will work with Intrado to innovate and deliver seamless integration between Intrado’s NG9-1-1 network and value added services and the Positron Front Line VIPER CAD system, allowing NG9-1-1 capabilities and feature rich multimedia content to be accessible by public safety answering point (PSAP) operators and first responders.

NG9-1-1 represents the transformation of the legacy infrastructure of 9-1-1 based on obsolete technology first developed in the 1960s to Internet Protocol (IP) technology of the 21st century. The interoperability and integration of Positron Front Line’s CAD and Intrado’s NG9-1-1 voice and data services will be achieved using ATIS (Alliance for Telecommunications Industry Solutions) approved Emergency Services Messaging Interface (ESMI) and the Request for Assistance Interface (RFAI) standards. These standards are critical to enabling the transition from today’s legacy telecommunications systems to IP-based NG9-1-1 services in the U.S. 

“We are excited to partner with Intrado, a clear leader in next-generation 9-1-1 emergency communication services and we’re proud to be part of a partnership that will help set the standard for the future of emergency response,” said Ian Archbell, general manager of Positron Front Line. “Positron Front Line’s advanced solutions and our commitment, along with Tiburon, to improving standards and solutions for public safety agencies worldwide will further increase with this partnership.”

Intrado’s NG9-1-1 network efficiently delivers voice, text and rich media as well as hosted applications through fully-secured and redundant networks with the goal of allowing agencies and their first responders to enhance the safety, situational awareness and services they provide to their communities.

“Positron Front Line, Tiburon and Intrado are committed to supporting open standards-based technological advancements and have a shared vision about how best to enable the transformation of public safety from today’s largely legacy environments to NG9-1-1,” said Stephen Meer, chief technology officer and co-founder of Intrado. “We’re looking forward to working with Positron Front Line and Tiburon on this important integration initiative, which we believe serves the best interests of the public safety industry as a whole.”

Positron Front Line’s VIPER CAD product integrates an advanced computer aided dispatch system with flexible features, intuitive user interfaces and dynamic administrative control built on a disaster-tolerant distributed architecture. VIPER CAD enables users to manage a variety of CAD activities including tracking calls, responses and resources, changing a unit’s location and obtaining critical information such as emergency type and location. Positron Front Line’s VIPER CAD seamlessly integrates with Intrado NG9-1-1 voice and data services to provide a comprehensive emergency call-taking and dispatching capability with faster, less-costly deployment. VIPER CAD uses open standards to assure operational compatibility not only upon implementation, but throughout the future of NG9-1-1.

About Positron Front Line
As a recognized leader in advanced 9-1-1 technologies and provider of public safety solutions through hosted and traditional delivery models, Positron Front Line delivers integrated, comprehensive, cost-effective public safety solutions for dispatch, mobile communications and records management, and has more than 220 systems installed globally. A subsidiary of Tiburon, Inc., a public safety and security solution provider who serves some of the largest and most complex agencies in the world, Positron Front Line is one of the country’s leading providers of integrated public safety solutions. The company’s roots are in continuously developing, implementing and supporting automated information solutions for the public safety community since 1983. For more information, visit www.positronfrontline.com or call 877-441-4648.

About Tiburon
Established in 1980, Tiburon is the Industry-leading provider of automated public safety and security solutions to meet the demanding and complex needs of law enforcement, fire and rescue and corrections agencies. Tiburon offers fully integrated solutions including computer aided dispatch, records management, mobile data and communications, field reporting and corrections management solutions. From mission-critical conditions to daily operations, across complex multi-agency and multi-jurisdictional environments, Tiburon’s integrated solutions have set the industry standard for capability, scalability and reliability for 30 years. For more information, visit www.tiburoninc.com or call 800-428-5534.

About Intrado
In business for more than 30 years, Intrado has maintained a focus and passion for saving lives and supporting the needs of public safety. Agencies and telecommunication services providers throughout the world depend on Intrado for emergency communication services and technology. Products and services offered include emergency 9-1-1 voice call delivery, comprehensive data management, advanced call routing, emergency location and integrated call handling technologies. Intrado’s dedicated focus on emergency communications technology allows the company to continue pioneering network innovations that save lives and improve emergency response.

Click here to see all recent news from this company

MERIDIAN, ID–(Marketwire – July 29, 2010) –  MWI Veterinary Supply, Inc. (NASDAQ: MWIV) (the “Company”) announced financial results today for its third quarter ended June 30, 2010.

Highlights:

• Total revenues were $347.7 million for the quarter, 40% higher than revenues for the same period in the prior fiscal year. Of the 40% increase in total revenues, 17% was due to organic growth in the United States and 23% was related to our acquisition of Centaur Services Limited (“Centaur”). On February 8, 2010, we acquired Centaur, a supplier of animal health products to veterinarians in the United Kingdom. 
• Selling, general and administrative (“SG&A”) expenses as a percentage of total revenues were 7.9% for the quarter, compared to 9.2% for the same period in the prior fiscal year. 
• Operating income increased 38% to $15.1 million, compared to the same period in the prior fiscal year. 
• Net income increased 38% to $9.1 million, compared to the same period in the prior fiscal year. Diluted earnings per share were $0.74 compared to $0.54 in the same period of the prior fiscal year, an increase of 37%. 
• Internet sales to independent veterinary practices and producers in the United States grew by approximately 44% for the quarter compared to the same period in the prior fiscal year. Our product sales from the internet as a percentage of sales in the United States increased to 36% for the quarter as compared to 32% for the same period in the prior fiscal year.
• We generated $5.4 million in cash from operations during the quarter, and as of June 30, 2010 we had borrowings under our credit facilities of $15.9 million. 

“Our results for the quarter continue to demonstrate our strong commitment to providing excellent service and value to our customers and vendor partners,” said Jim Cleary, President and Chief Executive Officer. “Our revenue growth, expense control, earnings growth and value-added services all exceeded our expectations and I would like to thank our employees, customers and vendors for their loyalty to MWI. Also, we continue to be pleased with our integration and collaboration with the Centaur team.”

Quarter ended June 30, 2010 compared to quarter ended June 30, 2009

Total revenues increased 40% to $347.7 million for the quarter ended June 30, 2010, compared to $247.5 million for the quarter ended June 30, 2009. Of the 40% revenue growth, 23% or $57.7 million was related to the acquisition of Centaur. Excluding this acquisition, our revenues attributable to existing customers represented 43% of the growth of total revenues during the quarter ended June 30, 2010. Commissions increased 19% to $4.3 million during the quarter ended June 30, 2010, compared to $3.6 million during the quarter ended June 30, 2009. 

Gross profit increased 27% to $43.9 million for the quarter ended June 30, 2010, compared to $34.5 million for the quarter ended June 30, 2009. Gross profit was benefited by our revenue growth and the addition of Centaur. Gross profit as a percentage of total revenues was 12.6% for the quarter ended June 30, 2010, compared to 13.9% for the quarter ended June 30, 2009. Gross profit as a percentage of total revenues decreased due to the addition of Centaur because Centaur’s gross profit as a percentage of total revenues is generally lower than MWI’s, which serves to reduce the overall gross margin of the consolidated Company when compared to our results for the same period in the prior year. Vendor rebates for the quarter ended June 30, 2010 increased by approximately $540,000 compared to the quarter ended June 30, 2009.

Operating income increased 38% to $15.1 million for the quarter ended June 30, 2010, compared to $10.9 million for the quarter ended June 30, 2009. SG&A expenses increased 21% to $27.4 million for the quarter ended June 30, 2010, compared to $22.7 million for the quarter ended June 30, 2009. SG&A expenses increased primarily due to the acquisition of Centaur and our revenue growth. SG&A expenses as a percentage of total revenues improved to 7.9% for the quarter ended June 30, 2010, compared to 9.2% for the quarter ended June 30, 2009. SG&A expenses as a percentage of total revenues decreased due to the addition of Centaur because Centaur’s SG&A expenses as a percentage of total revenues are generally lower than MWI’s, which serves to reduce the overall SG&A expenses as a percentage of total revenues when compared to our results for the same period in the prior year. Additionally, we had an improvement in our allowance for doubtful accounts as a result of payments made by certain customers. 

Net income increased 38% to $9.1 million for the quarter ended June 30, 2010, compared to $6.6 million for the quarter ended June 30, 2009. Diluted earnings per share were $0.74 and $0.54 for the quarters ended June 30, 2010 and 2009, respectively, an increase of 37%. 

Nine months ended June 30, 2010 compared to nine months ended June 30, 2009

Total revenues increased 25% to $870.4 million for the nine months ended June 30, 2010, compared to $693.8 million for the nine months ended June 30, 2009. Of the 25% revenue growth, 13% or $91.3 million was related to the acquisition of Centaur. Commissions increased 18% to $12.1 million during the nine months ended June 30, 2010, compared to $10.3 million during the nine months ended June 30, 2009.

Gross profit increased by 20% to $119.5 million for the nine months ended June 30, 2010, compared to $99.8 million for the nine months ended June 30, 2009. Gross profit as a percentage of total revenues was 13.7% for the nine months ended June 30, 2010, compared to 14.4% for the nine months ended June 30, 2009. Vendor rebates for the nine months ended June 30, 2010 increased by approximately $165,000 compared to the nine months ended June 30, 2009. 

Operating income increased 36% to $40.5 million for the nine months ended June 30, 2010, compared to $29.8 million for the nine months ended June 30, 2009. SG&A expenses increased 12% to $75.4 million for the nine months ended June 30, 2010, compared to $67.4 million for the nine months ended June 30, 2009. SG&A expenses as a percentage of total revenues were 8.7% for the nine months ended June 30, 2010, compared to 9.7% for the nine months ended June 30, 2009. Included in the increase in SG&A expenses for the nine months ended June 30, 2010 are direct acquisition-related expenses of $1.1 million incurred in connection with the acquisition of Centaur. 

Net income increased 34% to $24.6 million for the nine months ended June 30, 2010, compared to $18.4 million for the nine months ended June 30, 2009. Diluted earnings per share were $1.99 and $1.49 for the nine months ended June 30, 2010 and 2009, respectively, an increase of 34%.

Our cash balance as of June 30, 2010 was $908,000 and we had $15.9 million outstanding on our credit facilities. Compared to September 30, 2009, receivables increased 30%, inventories increased 22% and accounts payable increased 26%. These increases were primarily due to the balances acquired through the acquisition of Centaur as well as our revenue growth.

Business Outlook

The Company updates its previous estimates for the fiscal year ending September 30, 2010. The Company increases its estimate that revenues will be from $1.195 billion to $1.205 billion, which represents growth of 27% to 28% compared to revenues in fiscal year 2009. The Company increases its estimate that diluted earnings per share will be from $2.58 to $2.60 per share, which represents growth of 28% to 29% compared to diluted earnings per share in fiscal year 2009. All of these estimates give effect to the acquisition of Centaur from February 8, 2010 through September 30, 2010. The Company’s previous guidance for the fiscal year ending September 30, 2010 was revenues of approximately $1.16 billion to $1.18 billion and diluted earnings per share of $2.40 to $2.45.

Conference Call

The Company will be hosting a conference call on July 29, 2010 at 11:00 a.m. eastern daylight time to discuss these results and its fiscal year 2010 business outlook in greater detail. Participants can access the conference call by dialing (877) 638-4561 and international callers can access the conference call by dialing (720) 545-0002. The conference call will also be carried live on the Company’s web site at www.mwivet.com. Audio replay will be made available through August 12, 2010 by calling (800) 642-1687 for calls within the United States or (706) 645-9291 for international calls using the passcode 89688546. The conference call will also be available on the Company’s web site, www.mwivet.com.

MWI is a leading distributor of animal health products to veterinarians across the United States of America and United Kingdom. Products MWI sells include pharmaceuticals, vaccines, parasiticides, diagnostics, capital equipment, supplies, veterinary pet food and nutritional products. We market these products to veterinarians in both the companion animal and production animal markets. For more information about MWI, please visit our website at www.mwivet.com. For investor relations information please contact Mary Pat Thompson, Senior Vice President of Finance and Administration, and Chief Financial Officer at (208) 955-8930 or email [email protected].

Certain statements contained herein that are not descriptions of historical facts are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those discussed in filings made by the Company with the Securities and Exchange Commission. Many of the factors that will determine the Company’s future results are beyond the ability of management to control or predict. Readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Important assumptions and other important factors that could cause actual results to differ materially from those set forth in the forward-looking information include the impact of vendor consolidation on our business; changes in or availability of vendor rebate programs; vendor rebates based upon attaining certain growth goals; changes in the way vendors introduce products to market; exclusivity requirements with certain vendors that may prohibit us from distributing competing products manufactured by other vendors; risks associated with our international operations; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; the impact of general economic trends on our business; the recall of a significant product by one of our vendors; extended shortage or backorder of a significant product by one of our vendors; seasonality; the timing and effectiveness of marketing programs offered by our vendors; the timing of the introduction of new products and services by our vendors; the ability to borrow on our credit line, extend the terms of our credit line or obtain alternative financing on favorable terms or at all; risks from potential increases in variable interest rates; unforeseen litigation; a disruption caused by adverse weather or other natural conditions; inability to ship products to the customer as a result of technological or shipping disruptions; and competition. Other factors include changes in the rate of inflation; changes in state or federal legislation or regulation; the continued safety of the products the Company sells; and changes in the general economy. Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any analyst irrespective of the content of the statement or report. Furthermore, we have a policy against issuing or confirming financial forecasts or projections issued by others. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of MWI Veterinary Supply, Inc.

HOUSTON, TX–(Marketwire – July 28, 2010) –  A growing demand for hand, wrist and elbow specialist Dr. David Hildreth, who once practiced exclusively at the Texas Medical Center, has prompted the growth of offices in Sugar Land and Katy. The renowned Houston orthopedic surgeon formerly of Baylor College of Medicine and The Methodist Hospital System is working to meet growing demand since joining The Richmond Bone & Joint Clinic.

Dr. Hildreth is not only available to patients in Richmond, but also now in Sugar Land and Katy. The Sugar Land office is located at 15035 SW Freeway, near Williams Trace Blvd., and the Katy office is located at 21222 Kingsland Blvd.

An original founder of the Tennis Elbow Institute of Houston and among the first Eaton-trained Dupuytren’s physicians in Houston, Dr. Hildreth has served as lead investigator in studies changing the treatment options available for many common hand, wrist and elbow conditions.

A published author who served as an associate professor at The Methodist Hospital System and Weill Medical College of Cornell University, Dr. Hildreth stays ahead of “standard of care” to bring his patients such advanced treatment options as Needle Aponeurotomy (NA) and non surgical XIAFLEX® injection therapy in the treatment of Dupuytren’s Contracture, as well as less invasive treatment for carpal and cubital tunnel syndromes, sports injuries and degenerative joint conditions.

“Practicing at a specialized orthopedic clinic such as RBJC, we have the advantage of offering the latest treatment options far more rapidly. We devote a tremendous amount of time studying the new techniques and technology within the industry to remain ahead of current ‘standards,'” said Hildreth.

“These new offices are a response to patients wanting personalized care and easier access to a higher quality of medical services in their neighborhood. We’re pleased to be able to provide them with this increased accessibility,” added Hildreth.

Featured in “Medical Advances” of Newsweek magazine and named for the fifth consecutive year among the Texas Monthly list of Super Doctors and H Texas magazine’s Top Docs, view a video of Dr. Hildreth and his staff as they provide personalized treatment and rehabilitation programs for hand, wrist and elbow patients.

Click here to see all recent news from this company

IRVINE, CA–(Marketwire – July 28, 2010) – Sun Healthcare Group, Inc. (NASDAQ: SUNH) today
announced its operating results for the second quarter ended June 30, 2010.

Normalized results for the second-quarter period ended June 30, 2010:

--  consolidated revenues rose 1.3 percent to $474.6 million, compared to
    the same period in 2009;
    -- increased patient acuity resulted in an overall improvement in
       reimbursement rates;
    -- hospice and rehabilitation therapy businesses showed solid revenue
       growth;
--  consolidated adjusted EBITDAR was $62.8 million and adjusted EBITDAR
    margin was 13.2 percent;
--  consolidated adjusted EBITDA was $44.0 million and adjusted EBITDA
    margin was 9.3 percent;
--  diluted earnings per share from continuing operations were $0.26;
--  free cash flow was $20.6 million for the quarter;
--  results included $0.9 million of non-recurring project costs associated
    with the continued implementation of a clinical/billing platform; and
--  results have been normalized to exclude a pre-tax charge of $2.2
    million for transaction costs associated with the Separation
    transaction described in further detail later in this press release.

Commenting on the Company’s second-quarter results, Richard K. Matros,
Sun’s chairman and chief executive officer, remarked, “We have navigated
through a particularly tough time in our sector with only a slight
reduction in normalized adjusted EBITDAR and EBITDA. As we get closer to
the Oct. 1 effective date for changes in Medicare reimbursement, which
include the implementation of RUGs IV, restrictions on concurrent therapy
and elimination of the lookback period, we are bullish on the growth
opportunities that these changes provide. We still anticipate top line
softness and no growth in Medicaid rates in 2011, given the continued
budget pressures that exist in many states in which we operate. However, we
expect Medicare growth in both pricing and acuity, a decided improvement
over what we have experienced in 2010 coming off the Medicare rate
reduction in October 2009. The previously announced separation of our
operating assets and our real estate assets and the creation of the REIT
are proceeding as planned.” Matros added, “We are reaffirming our
previously announced 2010 guidance and believe that the high end of the
guidance is achievable.”

Segment Updates

On a year-over-year basis for the quarter, revenue growth in Sun’s
inpatient services business totaled $5.3 million, or 1.3 percent, due
principally to revenue growth in SolAmor, the Company’s hospice business.
SolAmor’s revenues increased from $6.3 million to $11.4 million, due to
census expansion derived from same-store census growth as well as an
October 2009 acquisition. SolAmor contributed $2.2 million of adjusted
EBITDA for the quarter and an adjusted EBITDA margin of 19.6 percent. In
the quarter, revenues from SunBridge’s nursing center operations were flat
on a year-over-year basis due to declines in nursing center customer base
and the lingering effect of the October 2009 Medicare rate reduction,
partially offset by acuity-driven rate growth. This acuity growth was
evidenced by Medicare Rehab RUG utilization of 90.9 percent, which was up
240 basis points year-over-year, and Medicare REX utilization of 45.8
percent, which was up 370 basis points year-over-year. On an overall basis,
the adjusted EBITDAR for inpatient services was $71.6 million for the
quarter, with an adjusted EBITDAR margin of 17.0 percent.

SunDance, Sun’s rehabilitation therapy services business, experienced
revenue growth of $6.5 million, or 14.7 percent, in the quarter as
non-affiliated contracts were increased by nine to a high of 335 contracts
as of June 30, 2010, and revenue per contract also increased by 10 percent.
Given the strong revenue results, adjusted EBITDA margin also expanded in
the quarter by 70 basis points, producing an 8.0 percent adjusted EBITDA
margin.

The slow economy continues to impact the demand for temporary medical
staffing across the industry. Accordingly, revenues from CareerStaff,
Sun’s medical staffing services business, were down compared to revenues in
the second quarter of 2009. Despite the decline in revenues, CareerStaff
achieved adjusted EBITDA margin growth on a sequential quarter basis of 140
basis points to 8.5 percent for the quarter.

Mr. Matros commented, “We have completed the installation of our clinical
billing platform for our nursing centers and are experiencing the benefits
of this integrated system in our daily management of the business. We
opened three new Rehab Recovery Suites® (RRS) during the quarter,
bringing our RRS count to 66 units and our RRS beds to a high of 1,632, a
6.8 percent increase in beds since the beginning of the year, with the
majority of the RRS bed growth coming in the second half of 2010 as
planned. The revenue growth we have achieved in our rehabilitation business
was solid this quarter, driven by the increase in contracts as well as the
increase in revenue per contract. Our hospice business continues to perform
consistently with our expectations, and although our medical staffing
business continues to operate in a tough environment, its adjusted EBITDA
margin remains solid.”

Conference Call

As previously announced, investors and the general public are invited to
listen to a conference call with Sun’s senior management on Thursday, July
29, 2010, at 10 a.m. Pacific / 1 p.m. Eastern, to discuss the Company’s
earnings for the second quarter of 2010.

To listen to the conference call, dial (888) 437-9315 and refer to Sun
Healthcare Group. A recording of the call will be available from 4 p.m.
Eastern on July 29, 2010, until midnight Eastern on Aug. 30, 2010, by
calling (888) 203-1112 and using access code 1833674.

About Sun Healthcare Group, Inc.

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing,
rehabilitative and related specialty healthcare services principally to the
senior population in the United States. Sun’s core business is providing,
through its subsidiaries, inpatient services, primarily through 166 skilled
nursing centers, 16 combined skilled nursing, assisted and independent
living centers, 10 assisted living centers, two independent living centers
and eight mental health centers. On a consolidated basis, Sun has annual
revenues of $1.9 billion and approximately 30,000 employees in 46 states.
At June 30, 2010, SunBridge centers had 23,209 licensed beds located in 25
states, of which 22,427 were available for occupancy. Sun also provides
rehabilitation therapy services to affiliated and non-affiliated centers
through its SunDance subsidiary, medical staffing services through its
CareerStaff Unlimited subsidiary and hospice services through its SolAmor
subsidiary.

In May 2010, Sun announced a plan to restructure its business by separating
its real estate assets and its operating assets into two separate publicly
traded companies (the “Separation”), subject to the approval of
stockholders and other conditions. The Separation will be accomplished by
distributing to stockholders the stock of SHG Services, Inc., a Sun
subsidiary that will own and operate the operating subsidiaries.
Substantially all of Sun’s owned real estate assets will continue to be
owned by Sun, which will, after the Separation, merge into its subsidiary,
Sabra Health Care REIT, Inc. Following this merger, SHG Services, Inc. will
change its name to Sun Healthcare Group, Inc. The common stock of both
companies is expected to trade on the NASDAQ Global Select Market. The
Separation is expected to be completed in the fourth quarter of 2010.

Forward-Looking Statement

Statements made in this release that are not historical facts are
“forward-looking” statements (as defined in the Private Securities
Litigation Reform Act of 1995) that involve risks and uncertainties and are
subject to change at any time. These forward-looking statements may
include, but are not limited to, statements containing words such as
“anticipate,” “believe,” “plan,” “estimate,” “expect,” “hope,” “intend,”
“may” and similar expressions. Forward-looking statements in this release
include all statements regarding our expected future financial position and
results of operations, business strategy, the impact of reductions in
reimbursements and other changes in government reimbursement programs, the
timing and impact of the equity offering and the Separation and
transactions related thereto, growth opportunities and plans and objectives
of management for future operations. Factors that could cause actual
results to differ are identified in the public filings made by the Company
with the Securities and Exchange Commission and include changes in Medicare
and Medicaid reimbursements; the impact that any healthcare reform
legislation will have on our business; our ability to maintain the
occupancy rates and payor mix at our healthcare centers; potential
liability for losses not covered by, or in excess of, our insurance; the
effects of government regulations and investigations; the significant
amount of our indebtedness, covenants in our debt agreements that may
restrict our activities and our ability to make acquisitions, to incur more
indebtedness and to refinance indebtedness on favorable terms; our ability
to accomplish the Separation and the proposed equity and debt financings,
the impact of the current economic downturn on our business; increasing
labor costs and the shortage of qualified healthcare personnel; and our
ability to receive increases in reimbursement rates from government payors
to cover increased costs. More information on factors that could affect our
business and financial results are included in our public filings made with
the Securities and Exchange Commission, including our Annual Report on
Forms 10-K and Quarterly Reports on Form 10-Q, copies of which are
available on Sun’s web site, www.sunh.com. There may be additional risks of
which we are presently unaware or that we currently deem immaterial.

The forward-looking statements involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond our
control. We caution investors that any forward-looking statements made by
Sun are not guarantees of future performance and are only made as of the
date of this release. We disclaim any obligation to update any such factors
or to announce publicly the results of any revisions to any of the
forward-looking statements to reflect future events or developments.

Adjusted EBITDA, adjusted EBITDAR and free cash flow, as used in this press
release and in the accompanying tables, which are non-GAAP financial
measures, are each reconciled to their respective GAAP recognized financial
measures in the accompanying tables. In addition, the normalizing
adjustments to adjusted EBITDA, adjusted EBITDAR and earnings per share as
discussed in this press release and shown, together with normalizing
adjustments to other financial measures, in the accompanying tables, are
non-GAAP adjustments, and are reconciled to GAAP financial measures in the
accompanying tables.

Additional Information

In connection with the Separation, SHG Services, Inc. has filed with the
SEC a Registration Statement on Form S-1 and Sabra Health Care REIT, Inc.
has filed with the SEC a Registration Statement on Form S-4, each
containing an identical proxy statement/prospectus. The definitive proxy
statement/prospectus will be mailed to Sun stockholders. In addition, Sun
has filed a shelf registration statement on Form S-3 (including a
prospectus) relating to shares of common stock of Sun with the SEC, and
such registration statement has been declared effective. This release does
not constitute an offer to sell or a solicitation of an offer to buy shares
of Sun common stock; nor shall there be any offer, solicitation or sale of
these securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful. The offering of shares of Sun
common stock may be made only by means of a prospectus relating to the
proposed offering.

Before making any voting or investment decision, Sun stockholders and
investors are urged to read the proxy statement/prospectus, the prospectus
in the registration statement on FormS-3, and other documents filed with
the SEC carefully and in their entirety when they become available because
they will contain important information about the proposed transactions.
Stockholders will be able to obtain these documents free of charge at the
SEC’s web site at www.sec.gov. In addition, investors and stockholders of
Sun may obtain free copies of the documents filed with the SEC by
contacting Sun’s investor relations department at (505) 468-2341 (TDD
users, please call (505) 468-4458) or by sending a written request to
Investor Relations, Sun Healthcare Group, Inc. 101 Sun Avenue N.E.,
Albuquerque, N.M. 87109.

Sun and its directors and executive officers and other members of its
management and employees may be deemed to be participants in the
solicitation of proxies from the stockholders of Sun in connection with the
transactions described in this release. Information about the directors
and executive officers of Sun and their ownership of shares of Sun common
stock are set forth in the Annual Report on Form 10-K for the year ended
December 31, 2009, filed with the SEC on March 5, 2010, and in the
definitive proxy statement relating to Sun’s 2010 Annual Meeting of
Stockholders filed with the SEC on April 30, 2010. These documents can be
obtained free of charge from the sources indicated above. Additional
information regarding the interests of these participants will also be
included in the definitive proxy statement/prospectus when it becomes
available.

                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                       KEY INCOME STATEMENT FIGURES
                               CONSOLIDATED
                  (in thousands, except per share data)



                                                    For the      For the
                                                 Three Months Three Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------

Revenue                                           $   474,618  $   468,713

Depreciation and amortization                          12,561       11,153

Interest expense, net                                  11,776       12,465

Pre-tax income                                         17,403       18,328

Income tax expense                                      7,135        7,517

Income from continuing operations                      10,268       10,811

Loss from discontinued operations                        (295)        (715)
                                                  -----------  -----------

Net income                                        $     9,973  $    10,096
                                                  ===========  ===========


Diluted earnings per share                        $      0.22  $      0.23
                                                  ===========  ===========


Adjusted EBITDAR                                  $    60,550  $    60,201
Margin - Adjusted EBITDAR                                12.8%        12.8%

Adjusted EBITDAR normalized                       $    62,798  $    64,501
Margin - Adjusted EBITDAR normalized                     13.2%        13.8%


Adjusted EBITDA                                   $    41,740  $    41,986
Margin - Adjusted EBITDA                                  8.8%         9.0%

Adjusted EBITDA normalized                        $    43,988  $    46,286
Margin - Adjusted EBITDA normalized                       9.3%         9.9%


Pre-tax income continuing operations - normalized $    19,651  $    22,628

Income tax expense - normalized                   $     8,057  $     9,280

Income from continuing operations - normalized    $    11,594  $    13,348

Diluted earnings per share - normalized           $      0.26  $      0.30

Net income - normalized                           $    11,299  $    12,981

Diluted earnings per share - normalized           $      0.25  $      0.30

   See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
   "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

   See normalizing adjustments in the table "Normalizing Adjustments -
   Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES                

                       KEY INCOME STATEMENT FIGURES
                               CONSOLIDATED
                  (in thousands, except per share data)


                                                    For the      For the
                                                  Six Months   Six Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------

Revenue                                           $   947,874  $   936,843

Depreciation and amortization                          25,007       21,875

Interest expense, net                                  23,752       25,191

Pre-tax income                                         35,198       37,989

Income tax expense                                     14,431       15,575

Income from continuing operations                      20,767       22,414

Loss from discontinued operations                        (596)      (2,075)
                                                  -----------  -----------

Net income                                        $    20,171  $    20,339
                                                  ===========  ===========


Diluted earnings per share                        $      0.46  $      0.46
                                                  ===========  ===========


Adjusted EBITDAR                                  $   121,319  $   121,673
Margin - Adjusted EBITDAR                                12.8%        13.0%

Adjusted EBITDAR normalized                       $   123,567  $   125,973
Margin - Adjusted EBITDAR normalized                     13.0%        13.4%


Adjusted EBITDA                                   $    83,957  $    85,095
Margin - Adjusted EBITDA                                  8.9%         9.1%

Adjusted EBITDA normalized                        $    86,205  $    89,395
Margin - Adjusted EBITDA normalized                       9.1%         9.5%


Pre-tax income continuing operations - normalized $    37,446  $    42,289

Income tax expense - normalized                   $    15,353  $    17,338

Income from continuing operations - normalized    $    22,093  $    24,951

Diluted earnings per share - normalized           $      0.50  $      0.57

Net income - normalized                           $    21,497  $    23,224

Diluted earnings per share - normalized           $      0.49  $      0.53

   See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
   "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

   See normalizing adjustments in the table "Normalizing Adjustments -
   Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                        CONSOLIDATED BALANCE SHEETS
                    (in thousands, except share data)



                                                    June 30,   December 31,
                                                      2010        2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)
                          ASSETS

Current assets:
  Cash and cash equivalents                       $   106,974  $   104,483
  Restricted cash                                      24,732       24,034
  Accounts receivable, net                            220,373      220,319
  Prepaid expenses and other assets                    18,021       21,757
  Deferred tax assets                                  69,544       68,415
                                                  -----------  -----------
    Total current assets                              439,644      439,008

Property and equipment, net                           620,999      622,682
Intangible assets, net                                 52,640       53,931
Goodwill                                              338,364      338,296
Restricted cash, non-current                              348        3,317
Deferred tax assets                                    96,180      108,999
Other assets                                            5,000        4,961
                                                  -----------  -----------
    Total assets                                  $ 1,553,175  $ 1,571,194
                                                  ===========  ===========


          LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
  Accounts payable                                $    52,922  $    57,109
  Accrued compensation and benefits                    63,015       58,953
  Accrued self-insurance obligations, current          43,794       45,661
  Income taxes payable                                    338            -
  Other accrued liabilities                            55,507       55,265
  Current portion of long-term debt and capital
   lease obligations                                   74,827       46,416
                                                  -----------  -----------
  Total current liabilities                           290,403      263,404

Accrued self-insurance obligations, net of
 current portion                                      128,657      121,948
Long-term debt and capital lease obligations, net
 of current portion                                   588,736      654,132
Unfavorable lease obligations, net                     11,233       12,663
Other long-term liabilities                            60,692       69,983
                                                  -----------  -----------
  Total liabilities                                 1,079,721    1,122,130


Stockholders' equity:
  Preferred stock of $.01 par value, authorized
   10,000,000 shares, no shares were issued and
   outstanding as of June 30, 2010 and
   December 31, 2009                                        -            -
  Common stock of $.01 par value, authorized
   125,000,000 shares, 43,980,405 and 43,764,240
   shares issued and outstanding as of June 30, 2010
   and December 31, 2009, respectively                    440          438
  Additional paid-in capital                          657,875      655,667
  Accumulated deficit                                (183,841)    (204,012)
  Accumulated other comprehensive loss, net            (1,020)      (3,029)
                                                  -----------  -----------
                                                      473,454      449,064
                                                  -----------  -----------
    Total liabilities and stockholders' equity    $ 1,553,175  $ 1,571,194
                                                  ===========  ===========



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                      CONSOLIDATED INCOME STATEMENTS
                  (in thousands, except per share data)


                                                    For the      For the
                                                 Three Months  Three Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)

Total net revenues                                $   474,618  $   468,713
                                                  -----------  -----------
Costs and expenses:
  Operating salaries and benefits                     267,880      261,967
  Self-insurance for workers' compensation and
   general and professional liability insurance        14,558       16,809
  Operating administrative costs                       13,301       13,192
  Other operating costs                                95,884       94,530
  Center rent expense                                  18,810       18,215
  General and administrative expenses                  15,157       15,721
  Depreciation and amortization                        12,561       11,153
  Provision for losses on accounts receivable           5,040        6,293
  Interest, net of interest income of $73 and $96,
   respectively                                        11,776       12,465
  Transaction costs                                     2,248            -
  Loss on sale of assets, net                               -           40
                                                  -----------  -----------
Total costs and expenses                              457,215      450,385
                                                  -----------  -----------

Income before income taxes and discontinued
 operations                                            17,403       18,328
Income tax expense                                      7,135        7,517
                                                  -----------  -----------
Income from continuing operations                      10,268       10,811
                                                  -----------  -----------

Discontinued operations:
  Loss from discontinued operations, net of
   related taxes                                         (295)        (708)
  Loss on disposal of discontinued operations, net
   of related taxes                                         -           (7)
                                                  -----------  -----------
Loss from discontinued operations, net                   (295)        (715)
                                                  -----------  -----------

Net income                                        $     9,973  $    10,096
                                                  ===========  ===========


Basic income per common and common equivalent
 share:
  Income from continuing operations               $      0.23  $      0.25
  Loss from discontinued operations, net                    -        (0.02)
                                                  -----------  -----------
Net income                                        $      0.23  $      0.23
                                                  ===========  ===========

Diluted income per common and common equivalent
 share:
  Income from continuing operations               $      0.23  $      0.25
  Loss from discontinued operations, net                (0.01)       (0.02)
                                                  -----------  -----------
Net income                                        $      0.22  $      0.23
                                                  ===========  ===========

Weighted average number of common and
 common equivalent shares outstanding:
  Basic                                                44,233       43,851
  Diluted                                              44,352       43,960



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                      CONSOLIDATED INCOME STATEMENTS
                  (in thousands, except per share data)


                                                    For the      For the
                                                  Six Months   Six Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)

Total net revenues                                $   947,874  $   936,843
                                                  -----------  -----------
Costs and expenses:
  Operating salaries and benefits                     534,918      524,878
  Self-insurance for workers' compensation and
   general and professional liability insurance        29,096       31,462
  Operating administrative costs                       25,589       25,769
  Other operating costs                               193,363      190,309
  Center rent expense                                  37,362       36,578
  General and administrative expenses                  30,424       32,471
  Depreciation and amortization                        25,007       21,875
  Provision for losses on accounts receivable          10,917       10,281
  Interest, net of interest income of $163 and
   $203, respectively                                  23,752       25,191
  Transaction costs                                     2,248            -
  Loss on sale of assets, net                               -           40
                                                  -----------  -----------
Total costs and expenses                              912,676      898,854
                                                  -----------  -----------

Income before income taxes and discontinued
 operations                                            35,198       37,989
Income tax expense                                     14,431       15,575
                                                  -----------  -----------
Income from continuing operations                      20,767       22,414
                                                  -----------  -----------

Discontinued operations:
  Loss from discontinued operations, net of
   related taxes                                         (596)      (1,760)
  Loss on disposal of discontinued operations, net
   of related taxes                                         -         (315)
                                                  -----------  -----------
Loss from discontinued operations, net                   (596)      (2,075)
                                                  -----------  -----------

Net income                                        $    20,171  $    20,339
                                                  ===========  ===========


Basic income per common and common equivalent
 share:
  Income from continuing operations               $      0.47  $      0.51
  Loss from discontinued operations, net                (0.01)       (0.05)
                                                  -----------  -----------
Net income                                        $      0.46  $      0.46
                                                  ===========  ===========

Diluted income per common and common equivalent
 share:
  Income from continuing operations               $      0.47  $      0.51
  Loss from discontinued operations, net                (0.01)       (0.05)
                                                  -----------  -----------
Net Income                                        $      0.46  $      0.46
                                                  ===========  ===========

Weighted average number of common and
 common equivalent shares outstanding:
  Basic                                                44,119       43,748
  Diluted                                              44,234       43,891



               SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                  CONSOLIDATED STATEMENTS OF CASH FLOWS
                              (in thousands)


                                                    For the      For the
                                                 Three Months  Three Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)

Cash flows from operating activities:
 Net income                                       $     9,973  $    10,096
 Adjustments to reconcile net income to net cash
  provided by operating activities, including
  discontinued operations:
    Depreciation and amortization                      12,561       11,153
    Amortization of favorable and unfavorable
     lease intangibles                                   (474)        (474)
    Provision for losses on accounts receivable         5,125        6,294
    Loss on sale of assets, including
     discontinued operations, net                           -           53
    Stock-based compensation expense                    1,694        1,641
    Deferred taxes                                      6,755        6,345
 Changes in operating assets and liabilities, net
  of acquisitions:
    Accounts receivable                                (4,871)     (11,599)
    Restricted cash                                     3,427        1,415
    Prepaid expenses and other assets                  (1,670)        (392)
    Accounts payable                                    7,140       (1,527)
    Accrued compensation and benefits                  (4,362)      (3,907)
    Accrued self-insurance obligations                  2,805          344
    Income taxes payable                                 (290)           -
    Other accrued liabilities                          (2,457)      (5,571)
    Other long-term liabilities                        (4,144)         885
                                                  -----------  -----------
     Net cash provided by operating activities         31,212       14,756
                                                  -----------  -----------

Cash flows from investing activities:
 Capital expenditures                                 (10,656)     (13,137)
 Purchase of leased real estate                             -       (3,275)
                                                  -----------  -----------
    Net cash used for investing activities            (10,656)     (16,412)
                                                  -----------  -----------

Cash flows from financing activities:
 Principal repayments of long-term debt and
  capital lease obligations                           (16,036)      (2,075)
 Distribution to non-controlling interest                   -         (549)
 Proceeds from issuance of common stock                     -            7
                                                  -----------  -----------
    Net cash used for financing activities            (16,036)      (2,617)
                                                  -----------  -----------

Net (decrease) increase in cash and cash
 equivalents                                            4,520       (4,273)
Cash and cash equivalents at beginning of period      102,454       99,945
                                                  -----------  -----------
Cash and cash equivalents at end of period        $   106,974  $    95,672
                                                  ===========  ===========

Reconciliation of net cash provided by operating
 activities to free cash flow:

   Net cash provided by operating activities      $    31,212  $    14,756
   Capital expenditures                               (10,656)     (13,137)
                                                  -----------  -----------
    Free cash flow                                $    20,556  $     1,619
                                                  ===========  ===========

Free cash flow is defined as net cash flow provided by operating activities
less cash used for capital expenditures.  Free cash flow is used by
management to evaluate discretionary cash flow potentially available for
debt service and other financing activities.



               SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                  CONSOLIDATED STATEMENTS OF CASH FLOWS
                              (in thousands)


                                                    For the      For the
                                                  Six Months   Six Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)

Cash flows from operating activities:
 Net income                                       $    20,171  $    20,339
 Adjustments to reconcile net income to net cash
  provided by operating activities, including
  discontinued operations:
    Depreciation and amortization                      25,007       21,875
    Amortization of favorable and unfavorable
     lease intangibles                                   (948)        (876)
    Provision for losses on accounts receivable        11,139       10,281
    Loss on sale of assets, including
     discontinued operations, net                           -          575
    Stock-based compensation expense                    3,087        2,909
    Deferred taxes                                     11,691       12,520
 Changes in operating assets and liabilities, net
  of acquisitions:
    Accounts receivable                               (11,193)     (21,667)
    Restricted cash                                     2,271        9,521
    Prepaid expenses and other assets                   2,613         (238)
    Accounts payable                                    1,281       (5,063)
    Accrued compensation and benefits                   4,062          366
    Accrued self-insurance obligations                  4,842        1,251
    Income taxes payable                                  338            -
    Other accrued liabilities                              13         (825)
    Other long-term liabilities                        (5,099)       1,181
                                                  -----------  -----------
     Net cash provided by operating activities         69,275       52,149
                                                  -----------  -----------

Cash flows from investing activities:
 Capital expenditures                                 (27,714)     (25,002)
 Purchase of leased real estate                             -       (3,275)
 Proceeds from sale of assets held for sale                 -        2,174
                                                  -----------  -----------
    Net cash used for investing activities            (27,714)     (26,103)
                                                  -----------  -----------

Cash flows from financing activities:
 Principal repayments of long-term debt and
  capital lease obligations                           (36,976)     (21,687)
 Payment to non-controlling interest                   (2,025)           -
 Distribution to non-controlling interest                 (69)        (860)
 Proceeds from issuance of common stock                     -           20
                                                  -----------  -----------
    Net cash used for financing activities            (39,070)     (22,527)
                                                  -----------  -----------

Net increase in cash and cash equivalents               2,491        3,519
Cash and cash equivalents at beginning of period      104,483       92,153
                                                  -----------  -----------
Cash and cash equivalents at end of period        $   106,974  $    95,672
                                                  ===========  ===========

Reconciliation of net cash provided by operating
 activities to free cash flow:
   Net cash provided by operating activities      $    69,275  $    52,149
   Capital expenditures                               (27,714)     (25,002)
                                                  -----------  -----------
    Free cash flow                                $    41,561  $    27,147
                                                  ===========  ===========

Free cash flow is defined as net cash flow provided by operating activities
less cash used for capital expenditures.  Free cash flow is used by
management to evaluate discretionary cash flow potentially available for
debt service and other financing activities.



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

            RECONCILIATION OF NET INCOME TO EBITDA and EBITDAR
                              (in thousands)



                                                    For the      For the
                                                  Three Months Three Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  ------------ ------------
                                                  (unaudited)  (unaudited)

Total net revenues                                $    474,618 $    468,713
                                                  ------------ ------------

Net income                                        $      9,973 $     10,096
                                                  ------------ ------------


  Income from continuing operations                     10,268       10,811

  Income tax expense                                     7,135        7,517

  Interest, net                                         11,776       12,465

  Depreciation and amortization                         12,561       11,153
                                                  ------------ ------------

EBITDA                                            $     41,740 $     41,946

  Loss on sale of assets, net                                -           40

Adjusted EBITDA                                   $     41,740 $     41,986


  Center rent expense                                   18,810       18,215
                                                  ------------ ------------

Adjusted EBITDAR                                  $     60,550 $     60,201
                                                  ============ ============

EBITDA is defined as earnings before loss on discontinued operations,
income taxes, interest, net, depreciation and amortization. Adjusted EBITDA
is defined as EBITDA before loss on sale of assets, net. Adjusted EBITDAR
is defined as Adjusted EBITDA before center rent expense. Adjusted EBITDA
and Adjusted EBITDAR are used by management to evaluate financial
performance and resource allocation for each entity within the operating
units and for the Company as a whole. Adjusted EBITDA and Adjusted EBITDAR
are commonly used as analytical indicators within the healthcare industry
and also serve as measures of leverage capacity and debt service ability.
Adjusted EBITDA and Adjusted EBITDAR should not considered as measures of
financial performance under generally accepted accounting principles. As
the items excluded from Adjusted EBITDA and Adjusted EBITDAR are
significant components in understanding and assessing finance performance,
Adjusted EBITDA and Adjusted EBITDAR should not be considered in isolation
or as alternatives to net income, cash flows generated by or used in
operating, investing or financing activities or other financial statement
data presented in the consolidated financial statements as indicators of
financial performance or liquidity. Because Adjusted EBITDA and Adjusted
EBTIDAR are not measurements determined in accordance with U.S. generally
accepted accounting principles and are thus susceptible to varying
calculations. Adjusted EBITDA and Adjusted EBITDAR as presented may not be
comparable to other similarly titled measures of other companies.



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

   RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA and ADJUSTED EBITDAR
                              (in thousands)


                                                    For the      For the
                                                  Six Months   Six Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  ------------ ------------
                                                  (unaudited)  (unaudited)

 Total net revenues                               $    947,874 $    936,843
                                                  ------------ ------------

 Net income                                       $     20,171 $     20,339
                                                  ------------ ------------


  Income from continuing operations                     20,767       22,414

  Income tax expense                                    14,431       15,575

  Interest, net                                         23,752       25,191

  Depreciation and amortization                         25,007       21,875
                                                  ------------ ------------

 EBITDA                                           $     83,957 $     85,055

  Loss on sale of assets, net                                -           40
                                                  ------------ ------------

 Adjusted EBITDA                                  $     83,957 $     85,095


  Center rent expense                                   37,362       36,578
                                                  ------------ ------------

 Adjusted EBITDAR                                 $    121,319 $    121,673
                                                  ============ ============

EBITDA is defined as earnings before loss on discontinued operations,
income taxes, interest, net, depreciation and amortization.  Adjusted
EBITDA is defined as EBITDA before loss on sale of assets , net.  Adjusted
EBITDAR is defined as Adjusted EBITDA before center rent expense.  Adjusted
EBITDA and Adjusted EBITDAR are used by management to evaluate financial
performance and resource allocation for each entity within the operating
units and for the Company as a whole.  Adjusted EBITDA and Adjusted EBITDAR
are commonly used as analytical indicators within the healthcare industry
and also serve as measures of leverage capacity and debt service ability.
Adjusted EBITDA and Adjusted EBITDAR should not considered as measures of
financial performance under generally accepted accounting principles.  As
the items excluded from Adjusted EBITDA and Adjusted EBITDAR are
significant components in understanding and assessing finance performance,
Adjusted EBITDA and Adjusted EBITDAR should not be considered in isolation
or as alternatives to net income, cash flows generated by or used in
operating, investing or financing activities or other financial statement
data presented in the consolidated financial statements as indicators of
financial performance or liquidity.  Because Adjusted EBITDA and Adjusted
EBTIDAR are not measurements determined in accordance with U.S. generally
accepted accounting principles and are thus susceptible to varying
calculations.  Adjusted EBITDA and Adjusted EBITDAR as presented may not be
comparable to other similarly titled measures of other companies.



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

                 For the Three Months Ended June 30, 2010
                                (unaudited)


                            Rehabi-                     Elimina-
                            litation Medical            tion of
                  Inpatient Therapy  Staffing Other &  Affiliated Consoli-
                  Services  Services Services Corp Seg  Revenue    dated
                  --------  -------  -------  --------  --------  --------
Nonaffiliated
 revenue          $421,720  $30,017  $22,875  $      6  $      -  $474,618
Affiliated revenue       -   21,034      496         -   (21,530)        -
                  --------  -------  -------  --------  --------  --------
  Total revenue   $421,720  $51,051  $23,371  $      6  $(21,530) $474,618
                  --------  -------  -------  --------  --------  --------

Income (loss) from
 continuing
 operations       $ 39,014  $ 3,921  $ 1,802  $(34,469) $      -  $ 10,268
Income tax expense       -        -        -     7,135         -     7,135
Interest, net        2,706        -        -     9,070         -    11,776
Depreciation and
 amortization       11,418      159      182       802         -    12,561
                  --------  -------  -------  --------  --------  --------

  EBITDA          $ 53,138  $ 4,080  $ 1,984  $(17,462) $      -  $ 41,740

Loss on sale of
 assets, net             -        -        -         -         -         -
                  --------  -------  -------  --------  --------  --------

  Adjusted EBITDA $ 53,138  $ 4,080  $ 1,984  $(17,462) $      -  $ 41,740

Center rent
 expense            18,489      118      203         -         -    18,810
                  --------  -------  -------  --------  --------  --------

  Adjusted
   EBITDAR        $ 71,627  $ 4,198  $ 2,187  $(17,462) $      -  $ 60,550
                  ========  =======  =======  ========  ========  ========

  Normalized
   Adjusted
   EBITDA         $ 53,138  $ 4,080  $ 1,984  $(15,214) $      -  $ 43,988
  Normalized
   Adjusted
   EBITDAR        $ 71,627  $ 4,198  $ 2,187  $(15,214) $      -  $ 62,798


   Adjusted EBITDA
            margin    12.6%     8.0%     8.5%                          8.8%
  Adjusted EBITDAR
            margin    17.0%     8.2%     9.4%                         12.8%
        Normalized
   Adjusted EBITDA
            margin    12.6%     8.0%     8.5%                          9.3%
        Normalized
  Adjusted EBITDAR
            margin    17.0%     8.2%     9.4%                         13.2%

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
 "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."


See normalizing adjustments in the table "Normalizing Adjustments -
 Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

                  For the Six Months Ended June 30, 2010
                                (unaudited)


                           Rehabi-                      Elimina-
                           litation Medical             tion of
                 Inpatient Therapy  Staffing  Other &  Affiliated Consoli-
                 Services  Services Services  Corp Seg  Revenue    dated
                 --------  --------  -------  --------  --------  --------
Nonaffiliated
 revenue         $842,248  $ 59,381  $46,231  $     14  $      -  $947,874
Affiliated
 revenue                -    42,187      640         -   (42,827)        -
                 --------  --------  -------  --------  --------  --------
  Total revenue  $842,248  $101,568  $46,871  $     14  $(42,827) $947,874
                 --------  --------  -------  --------  --------  --------

Income (loss)
 from continuing
 operations      $ 76,771  $  7,797  $ 3,283  $(67,084) $      -  $ 20,767
Income tax
 expense                -         -        -    14,431         -    14,431
Interest, net       5,517         -       (1)   18,236         -    23,752
Depreciation and
 amortization      22,698       311      362     1,636         -    25,007
                 --------  --------  -------  --------  --------  --------

  EBITDA         $104,986  $  8,108  $ 3,644  $(32,781) $      -  $ 83,957

Loss on sale of
 assets, net            -         -        -         -         -         -
                 --------  --------  -------  --------  --------  --------

  Adjusted
   EBITDA        $104,986  $  8,108  $ 3,644  $(32,781) $      -  $ 83,957

Center rent
 expense           36,709       240      413         -         -    37,362
                 --------  --------  -------  --------  --------  --------

  Adjusted
   EBITDAR       $141,695  $  8,348  $ 4,057  $(32,781) $      -  $121,319
                 ========  ========  =======  ========  ========  ========

  Normalized
   Adjusted
   EBITDA        $104,986  $  8,108  $ 3,644  $(30,533) $      -  $ 86,205
  Normalized
   Adjusted
   EBITDAR       $141,695  $  8,348  $ 4,057  $(30,533) $      -  $123,567


  Adjusted EBITDA
           margin    12.5%      8.0%     7.8%                          8.9%
 Adjusted EBITDAR
           margin    16.8%      8.2%     8.7%                         12.8%
       Normalized
  Adjusted EBITDA
           margin    12.5%      8.0%     7.8%                          9.1%
       Normalized
         Adjusted
   EBITDAR margin    16.8%      8.2%     8.7%                         13.0%

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
 "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

See normalizing adjustments in the table "Normalizing Adjustments -
 Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

                 For the Three Months Ended June 30, 2009
                                (unaudited)


                            Rehabi-                     Elimina-
                            litation Medical            tion of
                  Inpatient Therapy  Staffing Other &  Affiliated Consoli-
                  Services  Services Services Corp Seg  Revenue    dated
                  --------  -------  -------  --------  --------  --------
Nonaffiliated
 revenue          $416,451  $26,155  $26,097  $     10  $      -  $468,713
Affiliated revenue       -   18,360      563         -   (18,923)        -
                  --------  -------  -------  --------  --------  --------
  Total revenue   $416,451  $44,515  $26,660  $     10  $(18,923) $468,713
                  --------  -------  -------  --------  --------  --------

Income (loss) from
 continuing
 operations       $ 38,804  $ 3,077  $ 2,289  $(33,359) $      -  $ 10,811
Income tax expense       -        -        -     7,517         -     7,517
Interest, net        3,111        -       (1)    9,355         -    12,465
Depreciation and
 amortization       10,118      131      232       672         -    11,153
                  --------  -------  -------  --------  --------  --------

  EBITDA          $ 52,033  $ 3,208  $ 2,520  $(15,815) $      -  $ 41,946
Loss on sale of
 assets, net             6       34        -         -         -        40
                  --------  -------  -------  --------  --------  --------

  Adjusted EBITDA $ 52,039  $ 3,242  $ 2,520  $(15,815) $      -  $ 41,986

Center rent
 expense            17,868      114      233         -         -    18,215
                  --------  -------  -------  --------  --------  --------

  Adjusted
   EBITDAR        $ 69,907  $ 3,356  $ 2,753  $(15,815) $      -  $ 60,201
                  ========  =======  =======  ========  ========  ========

  Normalized
   Adjusted
   EBITDA         $ 56,339  $ 3,242  $ 2,520  $(15,815) $      -  $ 46,286
  Normalized
   Adjusted
   EBITDAR        $ 74,207  $ 3,356  $ 2,753  $(15,815) $      -  $ 64,501


   Adjusted EBITDA
            margin    12.5%     7.3%     9.5%                          9.0%
  Adjusted EBITDAR
            margin    16.8%     7.5%    10.3%                         12.8%
        Normalized
   Adjusted EBITDA
            margin    13.5%     7.3%     9.5%                          9.9%
        Normalized
  Adjusted EBITDAR
            margin    17.8%     7.5%    10.3%                         13.8%

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
 "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

See normalizing adjustments in the table "Normalizing Adjustments -
 Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

                  For the Six Months Ended June 30, 2009
                                (unaudited)


                            Rehabi-                     Elimina-
                            litation Medical            tion of
                  Inpatient Therapy  Staffing Other &  Affiliated Consoli-
                  Services  Services Services Corp Seg  Revenue    dated
                  --------  -------  -------  --------  --------  --------
Nonaffiliated
 revenue          $831,687  $51,671  $53,471  $     14  $      -  $936,843
Affiliated revenue       -   36,576    1,123         -   (37,699)        -
                  --------  -------  -------  --------  --------  --------
  Total revenue   $831,687  $88,247  $54,594  $     14  $(37,699) $936,843
                  --------  -------  -------  --------  --------  --------

Income (loss) from
 continuing
 operations       $ 80,598  $ 5,966  $ 4,310  $(68,460) $      -  $ 22,414
Income tax expense       -        -        -    15,575         -    15,575
Interest, net        6,322       (2)      (1)   18,872         -    25,191
Depreciation and
 amortization       19,845      259      422     1,349         -    21,875
                  --------  -------  -------  --------  --------  --------

  EBITDA          $106,765  $ 6,223  $ 4,731  $(32,664) $      -  $ 85,055
Loss on sale of
 assets, net             6       34        -         -         -        40
                  --------  -------  -------  --------  --------  --------

  Adjusted EBITDA $106,771  $ 6,257  $ 4,731  $(32,664) $      -  $ 85,095

Center rent
 expense            35,872      229      477         -         -    36,578
                  --------  -------  -------  --------  --------  --------

  Adjusted
   EBITDAR        $142,643  $ 6,486  $ 5,208  $(32,664) $      -  $121,673
                  ========  =======  =======  ========  ========  ========

  Normalized
   Adjusted
   EBITDA         $111,071  $ 6,257  $ 4,731  $(32,664) $      -  $ 89,395
  Normalized
   Adjusted
   EBITDAR        $146,943  $ 6,486  $ 5,208  $(32,664) $      -  $125,973


   Adjusted EBITDA
            margin   12.8%     7.1%     8.7%                          9.1%
  Adjusted EBITDAR
            margin   17.2%     7.3%     9.5%                         13.0%
        Normalized
   Adjusted EBITDA
            margin   13.4%     7.1%     8.7%                          9.5%
        Normalized
  Adjusted EBITDAR
            margin   17.7%     7.3%     9.5%                         13.4%

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
 "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

See normalizing adjustments in the table "Normalizing Adjustments -
 Quarter Comparison."



                Sun Healthcare Group, Inc. and Subsidiaries
                      Selected Operating Statistics
                          Continuing Operations


                            For the                     For the
                      Three Months Ended           Six Months Ended
                           June 30,                    June 30,
                    ----------------------      ----------------------
                      2010          2009          2010          2009
                    --------      --------      --------      --------
Consolidated
 Company

Revenues -
 Non-affiliated (in
 thousands)
  Inpatient
   Services         $421,720      $416,451      $842,248      $831,687
  Rehabilitation
   Therapy Services   30,017        26,155        59,381        51,671
  Medical Staffing
   Services           22,875        26,097        46,231        53,471
  Other - non-core
   businesses              6            10            14            14
                    --------      --------      --------      --------
    Total           $474,618      $468,713      $947,874      $936,843
                    ========      ========      ========      ========


Revenue Mix -
 Non-affiliated (in
 thousands)
  Medicare          $141,520  30% $137,863  29% $283,701  30% $279,739  30%
  Medicaid           190,596  40%  188,030  40%  379,920  40%  369,480  39%
  Private and Other  113,475  24%  112,784  24%  225,881  24%  227,282  24%
  Managed Care /
   Insurance          24,045   5%   25,789   6%   48,458   5%   52,198   6%
  Veterans             4,982   1%    4,247   1%    9,914   1%    8,144   1%
                    -------- ---  -------- ---  -------- ---  -------- ---
    Total           $474,618 100% $468,713 100% $947,874 100% $936,843 100%
                    ======== ===  ======== ===  ======== ===  ======== ===



Inpatient Services
 Stats

 Number of centers:      202           202           202           202
 Number of
  available beds:     22,427        22,450        22,427        22,450
 Occupancy %:           86.7%         87.8%         87.1%         88.2%


 Payor Mix % based
  on patient days:
   Medicare - SNF
    Beds                15.3%         15.7%         15.4%         16.1%
   Managed care /
    Ins. - SNF Beds      4.0%          4.1%          4.0%          4.2%
                    --------      --------      --------      --------
       Total SNF
        skilled mix     19.3%         19.8%         19.4%         20.3%
                    --------      --------      --------      --------
  Medicare              14.0%         14.3%         14.1%         14.7%
  Medicaid              62.1%         60.9%         62.1%         60.4%
  Private and Other     19.1%         20.0%         18.9%         20.0%
  Managed Care /
   Insurance             3.6%          3.8%          3.7%          3.9%
  Veterans               1.2%          1.0%          1.2%          1.0%

 Revenue Mix % of
  revenues:
   Medicare - SNF
    Beds                32.1%         32.6%         32.3%         33.2%
   Managed care /
    Ins. - SNF Beds      6.0%          6.5%          6.1%          6.6%
                    --------      --------      --------      --------
       Total SNF
        skilled mix     38.1%         39.1%         38.4%         39.8%
                    --------      --------      --------      --------
  Medicare              32.4%         32.1%         32.6%         32.7%
  Medicaid              45.2%         45.1%         45.1%         44.4%
  Private and Other     15.6%         15.6%         15.4%         15.7%
  Managed Care /
   Insurance             5.6%          6.2%          5.7%          6.2%
  Veterans               1.2%          1.0%          1.2%          1.0%


 Revenues PPD:
  LTC only Medicare
   (Part A)         $ 464.00      $ 454.44      $ 464.99      $ 452.37
  Medicare Blended
   Rate (Part A &
   B)               $ 504.18      $ 494.37      $ 503.24      $ 489.93
  Medicaid          $ 173.30      $ 171.77      $ 173.19      $ 170.25
  Private and Other $ 185.66      $ 175.27      $ 185.99      $ 176.10
  Managed Care /
   Insurance        $ 367.89      $ 376.44      $ 365.84      $ 375.17
  Veterans          $ 240.63      $ 234.73      $ 242.86      $ 227.45


Rehab contracts

 Affiliated              131           121           131           121
 Non-affiliated          335           326           335           326

 Average Qtrly
  Revenue per
  Contract          $    110      $    100      $    109      $     99
  (in thousands)



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

               NORMALIZING ADJUSTMENTS - QUARTER COMPARISON
                  (in thousands, except per share data)


                               AS REPORTED - 2nd QUARTER 2010
                 ---------------------------------------------------------
                                                  Income
                                                   from
                                                  Contin-
                                                   uing
                         Adjusted Adjusted         Opera-             Net
                 Revenue  EBITDAR  EBITDA Pre-tax  tions  Disc Ops  Income
                 -------- ------- ------- ------- ------- -------  -------

As Reported 2nd
 QUARTER 2010    $474,618 $60,550 $41,740 $17,403 $10,268 $  (295) $ 9,973
       Percent of
         Revenue             12.8%    8.8%    3.7%    2.2%   -0.1%     2.1%

Normalizing
 Adjustments:

 Separation
  transaction
  costs                 -   2,248   2,248   2,248   1,326       -    1,326
                 -------- ------- ------- ------- ------- -------  -------

Normalized As
 Reported - 2nd
 QUARTER 2010    $474,618 $62,798 $43,988 $19,651 $11,594 $  (295) $11,299
                 ======== ======= ======= ======= ======= =======  =======
       Percent of
         Revenue             13.2%    9.3%    4.1%    2.4%   -0.1%     2.4%

Diluted EPS:
      As Reported                                 $  0.23 $ (0.01) $  0.22
    As Normalized                                 $  0.26 $ (0.01) $  0.25


                               AS REPORTED - 2nd QUARTER 2009
                 ---------------------------------------------------------
                                                  Income
                                                   from
                                                  Contin-
                                                   uing
                         Adjusted Adjusted         Opera-             Net
                 Revenue  EBITDAR  EBITDA Pre-tax  tions  Disc Ops  Income
                 -------- ------- ------- ------- ------- -------  -------

As Reported - 2nd
 QUARTER 2009    $468,713 $60,201 $41,986 $18,328 $10,811 $  (715) $10,096
       Percent of
         Revenue             12.8%    9.0%    3.9%    2.3%   -0.2%     2.2%

Normalizing
 Adjustments:

 Prior periods'
  self-insurance
  costs                 -   4,300   4,300   4,300   2,537     348    2,885
                 -------- ------- ------- ------- ------- -------  -------

Normalized As
 Reported - 2nd
 QUARTER 2009    $468,713 $64,501 $46,286 $22,628 $13,348 $  (367) $12,981
                 ======== ======= ======= ======= ======= =======  =======
       Percent of
         Revenue             13.8%    9.9%    4.8%    2.8%   -0.1%     2.8%

Diluted EPS:
      As Reported                                 $  0.25 $ (0.02) $  0.23
    As Normalized                                 $  0.30 $     -  $  0.30

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
"Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

Normalizing adjustments are transactions or adjustments not related to
ongoing operations and consist of Separation transaction costs and prior
periods' self-insurance costs.

Since normalizing adjustments are not measurements determined  in
accordance with U.S. generally accepted accounting principles and are thus
susceptible to varying calculations and interpretations, the information
presented herein may not be comparable to other similarly described
information of other companies.



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

            NORMALIZING ADJUSTMENTS - YEAR TO DATE COMPARISON
                  (in thousands, except per share data)


                               AS REPORTED - SIX MONTHS 2010
                 ---------------------------------------------------------
                                                 Income
                                                  from
                                                 Contin-
                                                  uing
                        Adjusted Adjusted         Opera-             Net
               Revenue   EBITDAR  EBITDA Pre-tax  tions   Disc Ops  Income
               -------- -------- ------- ------- -------- -------  -------

As Reported -
 Six Months
 2010          $947,874 $121,319 $83,957 $35,198 $20,767 $   (596) $20,171
     Percent of
       Revenue              12.8%    8.9%    3.7%    2.2%    -0.1%     2.1%

Normalizing
 Adjustments:

 Separation
  transaction
  costs               -    2,248   2,248   2,248   1,326        -    1,326
               -------- -------- ------- ------- ------- --------  -------

Normalized As
 Reported - Six
 Months 2010   $947,874 $123,567 $86,205 $37,446 $22,093 $   (596) $21,497
               ======== ======== ======= ======= ======= ========  =======
     Percent of
       Revenue              13.0%    9.1%    4.0%    2.3%    -0.1%     2.3%

Diluted EPS:
    As Reported                                  $  0.47 $  (0.01) $  0.46
  As Normalized                                  $  0.50 $  (0.01) $  0.49


                               AS REPORTED - SIX MONTHS 2009
                 ---------------------------------------------------------
                                                 Income
                                                  from
                                                 Contin-
                                                  uing
                        Adjusted Adjusted         Opera-             Net
               Revenue   EBITDAR  EBITDA Pre-tax  tions   Disc Ops  Income
               -------- -------- ------- ------- -------- -------  -------

As Reported -
 Six Months
 2009          $936,843 $121,673 $85,095 $37,989 $22,414 $ (2,075) $20,339

     Percent of
       Revenue              13.0%    9.1%    4.1%    2.4%    -0.2%     2.2%

Normalizing
 Adjustments:

 Prior periods'
  self-insurance
  costs               -    4,300   4,300   4,300   2,537      348    2,885
               -------- -------- ------- ------- ------- --------  -------

Normalized As
 Reported - Six
 Months 2009   $936,843 $125,973 $89,395 $42,289 $24,951 $ (1,727) $23,224
               ======== ======== ======= ======= ======= ========  =======
     Percent of
       Revenue              13.4%    9.5%    4.5%    2.7%    -0.2%     2.5%

Diluted EPS:
    As Reported                                  $  0.51 $  (0.05) $  0.46
  As Normalized                                  $  0.57 $  (0.04) $  0.53

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
"Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

Normalizing adjustments are transactions or adjustments not related to
ongoing operations and consist of Separation transaction costs and prior
periods' self-insurance costs.

Since normalizing adjustments are not measurements determined  in
accordance with U.S. generally accepted accounting principles and are thus
susceptible to varying calculations and interpretations, the information
presented herein may not be comparable to other similarly described
information of other companies.

NASHVILLE, TN–(Marketwire – July 28, 2010) – In conjunction with Vanguard Health Systems,
Inc.’s 2010 Fourth Quarter and Year-End Earnings press release, you are
invited to listen to its conference call that will be broadcast live over
the Internet with senior management of Vanguard discussing the operating
results.

WHAT:    Vanguard Health Systems, Inc.'s 2010 Fourth Quarter and Year-End
         Earnings Conference Call on the Web

WHEN:    Thursday, August 26, 2010 at 11:00 a.m. Eastern time

WHERE:   http://www.vanguardhealth.com or
         http://www.visualwebcaster.com/event.asp?id=71303

HOW:     Live over the Internet -- Simply log on to the web at one of the
         addresses above.  If you connect through www.vanguardhealth.com,
         select the "Latest News" link on the Investor Relations page.

Vanguard Health Systems, Inc. will release its 2010 fourth quarter and
year-end operating results on Wednesday, August 25, 2010, after 4:00 p.m.
Eastern time. The Company’s earnings press release will be posted under
the “Latest News” link on the Investor Relations page of the Company’s web
site www.vanguardhealth.com.

Vanguard Health Systems, Inc. owns and operates 15 acute care hospitals and
complementary facilities and services in Chicago, Illinois; Phoenix,
Arizona; San Antonio, Texas and Massachusetts.

If you are unable to participate during the live Webcast, the call will be
archived on our web site www.vanguardhealth.com. To access the replay,
click on the “Latest News” link on the Investor Relations page of our web
site.

LOS GATOS, CA–(Marketwire – July 28, 2010) –  SCI Solutions^®, the premier Access Management solution provider for healthcare, today announced the release of a new version (v33) of its powerful, rules-based, enterprise scheduling solution, Schedule Maximizer®.

Schedule Maximizer (v33) features numerous updates, including enhanced scheduling functionality that incorporates insurance verification/eligibility rules affecting consumer driven health plans. The revamped Encounter Module, Multi-entity Rules and Worklist features further simplify and streamline a hospital’s pre-registration/registration processes.

Additionally, Schedule Maximizer’s reporting capabilities have been expanded to include a new report that provides the total number of patients that are scheduled for a particular date or date range. This report is a quick and efficient method to assist in Registration clerk staffing needs for a facility and/or a particular location/clinic in that facility.

According to Kristy Roesner, SCI’s SVP of Product Development, “The enhancements in Schedule Maximizer (v33) reflect SCI’s position as innovators in the Healthcare Information Technology arena.” She continued, “We are proud of this version’s updates as they represent significant enhancements that expand its overall capabilities as an insurance verification and pre-registration process improvement tool.”

SCI Solutions, through its Software as a Service (SaaS) model, provides a full complement of front-end patient access and revenue cycle tools that include comprehensive enterprise scheduling and registration, sophisticated workflow to manage a hospital’s orders, scheduling and pre-encounter revenue cycle requirements. Additionally, SCI provides customer self-service solutions that help physicians and patients interact seamlessly with your organization for all their access-related needs. SCI’s Access Management offerings fall into the following categories:

• Order Facilitator^®
• Schedule Maximizer^®
• Revenue Accelerator^®
• Consumer Portal
• Provider Portal

About SCI Solutions

SCI Solutions is transforming healthcare Access Management with web-based products and services that facilitate the efficient and secure exchange of clinical and financial information between patients, physicians and healthcare facilities. SCI provides a variety of products and self-service portals that help physicians and patients interact easily and at their convenience for many of their access-related needs. From a hospital’s clinical departments, to its financial executives, to its physicians SCI improves their effectiveness while making the patient’s service experience first class.

Founded in 1999, SCI Solutions is headquartered in Los Gatos, Calif. with additional offices in Tucson, Ariz., Pensacola, Fla. and employees throughout the United States. For more information about SCI Solutions, visit www.scisolutions.com.

Click here to see all recent news from this company

NATICK, MA–(Marketwire – July 28, 2010) –  To ensure downtime access to current patient data after moving to electronic medical records (EMRs) and electronic medication administration records (eMARs), Hancock Regional Hospital in Greenfield, IN implemented NetSafe, Interbit Data‘s downtime protection and business continuance solution. NetSafe downloads up-to-the-minute patient data and records from the hospital’s MEDITECH Healthcare Information System (HCIS) and provides access to it from local machines, allowing clinicians to obtain the information they need where they need it whenever the system or network goes down. With NetSafe, critical patient data is always available and the hospital assures patient safety and the delivery of uninterrupted care.

“NetSafe is a terrific safety net if the HCIS, a server or the network goes down,” states Doug Hogue, information analyst at Hancock Regional Hospital. “It’s one of those tools we hope to never have to use, but if and when we do need to rely on it, we have complete trust it will perform superbly. With NetSafe, we have peace of mind knowing that the latest eMARs and other important patient information are in a location that we can access when that information is needed.”

A one-minute video on the downtime protection and business continuance benefits of NetSafe is available at: http://interbitdata.com/business-continuance/netsafe/

Using NetSafe, Hancock Regional Hospital downloads updates of the eMARs every hour to ensure that clinicians can obtain the most up-to-date medication information on their patients whenever the system is unavailable. Electronic physician orders are updated twice per day and in PDF format, allowing staffers at registration desks to bring up and view the orders easily. Patient profiles, surgery schedules and out-patient schedules are also downloaded and updated. Physicians’ practices use NetSafe as well to back up their schedules. 

Since Hancock Regional Hospital started using NetSafe in 2007, it has had four planned downtimes due to MEDITECH updates. It has had no unplanned downtimes as yet. 

“If an unplanned downtime were to happen, we’re confident that we’re ready,” confirms Hogue. “NetSafe has performed flawlessly during the downtimes Hancock Regional Hospital has experienced so far, providing clinicians with whatever information they needed during those times.”

Over the three-plus years of using NetSafe, Hancock Regional Hospital’s experience with it has been nothing but positive.

“I love it, it’s a great product,” affirms Hogue. “NetSafe is easy to use, and other than normal server maintenance, I don’t need to do anything to it.”

More information on NetSafe can be obtained at http://interbitdata.com/business-continuance/netsafe/.

About Hancock Regional Hospital
Hancock Regional Hospital in Greenfield, IN is a full-service primary care facility serving the residents in east-central Indiana. The hospital offers a state-of-the-art surgery department, 24-hour emergency services, progressive and critical care, occupational health, a transitional care unit, a total oncology program, and comprehensive inpatient and outpatient services, including the more specialized Diabetes Center and Center for Wound Healing.

About Interbit Data
Founded in 1997 and named to the 2009 Inc. 5000 list of America’s fastest growing companies, Interbit Data helps healthcare organizations deliver better, more consistent patient care with secure, reliable and cost-effective software solutions that improve operational efficiency. The company’s information distribution products deliver information securely over the Internet in multiple formats, such as fax, print, email, encrypted file or HL7 message format, and integrate it easily into physicians’ practice EMRs. Interbit Data’s business continuance products give healthcare providers continuous access to patient data in the event of a network or system outage. Interbit Data products are used by more than 650 MEDITECH^® customers worldwide. For more information about Interbit Data and its NetSolutions products, visit the company Website at www.interbitdata.com.

Click here to see all recent news from this company

WINNIPEG, MANITOBA–(Marketwire – July 28, 2010) – DiaMedica Inc., (TSX VENTURE:DMA) today announces the initiation of the Company’s autoimmune program with the success of DM-99 for the treatment of rheumatoid arthritis and other autoimmune diseases.

DM-99 was found to reduce joint swelling by up to 90% (p<0.001) in a collagen induced animal model of rheumatoid arthritis (RA) during the peak of the disease. A single dose of the protein DM-99 administered at the first signs of RA symptoms delayed the onset and severity of the disease. Furthermore, treatment given every forth day appears to have halted the autoimmune attack altogether. 

“We believe that DM-99 is able to activate or increase the number of regulatory T cells (Tregs), which plays a vital role in suppressing the autoimmune attack in a wide range of autoimmune diseases,” commented Dr. Mark Williams, DiaMedica’s Vice President Research.

In a delayed hypersensitivity model, skin inflammation was reduced by 67% (p<0.05) and could be prevented for up to 14 days following a single administration of DM-99. DM-99 also delayed skin graft rejection by several days (p<0.05).

“Based on the ability of DM-99 to modulate the autoimmune attack in several autoimmune diseases, we will be starting a study shortly to determine if our more active form of DM-99, DM-199, can halt or slow the autoimmune attack in type I diabetes. DM-199, may be the only compound that both proliferates beta cells and protects them against the autoimmune attack in type I diabetes,” stated Rick Pauls, President and CEO of DiaMedica.

About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments for diabetes and neurological disorders. The Company’s type 2 diabetes program is based on a critical liver nerve signaling mechanism involved in enhancing insulin sensitivity after meal consumption. Two of DiaMedica’s products, DM-71 and DM-99, have previously demonstrated human efficacy in lowering blood sugar levels in people diagnosed with type 2 diabetes based on this novel nerve signaling mechanism.

DiaMedica has expanded its DM-199 recombinant protein program into neurological and autoimmune disorders. The Company has demonstrated that DM-99, the naturally occurring form of DM-199, confers neural protection (protects brain cells) and triggers neural stem cell proliferation (creates brain cells) for the treatment of numerous neurological disorders including Alzheimer’s disease. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions, which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. Additional risk factors, factors which could cause actual results to differ materially from expectations, and assumptions relating specifically to our acquisition of Sanomune may be found in our press releases dated February 18, 2010 and April 20, 2010.

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – July 28, 2010) –

TO: Investors, Analysts and Journalists

WHAT: NicOx S.A. will release its 2010 half year financial results on July
30 before the opening of the market trading in France and will host a
conference call at 3:00 pm CET.

WHO: Michele Garufi, Chairman and CEO

Eric Castaldi, Chief Financial Officer

Gavin Spencer, VP Business Development

WHEN: Friday July 30 – 3:00 pm CET (2:00 pm UK – 9:00 am EST)

Phone number: +44 (0)20 7138 0845 or +1 212 444 0895 (for conference call
and Q&A session).

A presentation will be available on NicOx’s website: www.nicox.com.

A replay of the conference call will be available from July 30 at 6:00 pm
CET until August 6 midnight. To listen to the replay, dial +44 (0) 20 7111
1244 or +1 347 366 9565 – Access code: 3771435?

Thanks to confirm your participation to Irène Lalande, Investor and
Media Relations Coordinator. Tel: +33 (0)4 97 24 53 11 / [email protected]

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the U.S. Food and Drug
Administration (FDA) provided a Complete Response Letter to the New Drug
Application (NDA) for naproxcinod stating that it does not approve the
naproxcinod application. The naproxcinod Marketing Authorization
Application (MAA) submitted by NicOx in December 2009 is currently under
review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This information is provided by HUGIN

BETHESDA, MD–(Marketwire – July 28, 2010) –  GetWellNetwork, Inc., the leader in interactive patient care, today welcomed new customer Adventist Medical Center-Hanford located in Hanford, California. The hospital will implement the GetWellNetwork solution hospital-wide and go live this fall. 

Adventist Health/Central Valley Network is the first organization in the region to offer the GetWellNetwork interactive patient care system to its patients. The GetWellNetwork solution enables clinicians and hospital staff to more actively engage patients and their families in the care process by using the bedside TV to provide them with information specific to their condition, medication, treatment and discharge procedures.

“GetWellNetwork goes beyond patient entertainment to create an environment that empowers patients and their families to be truly involved in their care,” said Kristen Johnson, MHA, BSN, RN, vice president of Patient Care Services, Adventist Medical Center-Hanford. “Hospitals that have implemented the GetWellNetwork solution have raised patient satisfaction, improved patient safety and quality, and reduced hospital costs. We are excited to offer the GetWellNetwork system in our hospital.”

In the first phase, the hospital will offer patients satellite TV channels, HBO movies, 74 games, high quality Internet browsing capabilities, as well as a variety of hospital information and resources such as visiting hours, cafeteria menu, maps, chaplain services, hospital services and staff information.

In the second phase of the implementation, beginning in 2011, the hospital will look to offer additional features such as:

• Personalized information on the home screen such as the patient’s primary physician, the nurse on duty and other clinical providers, in English and Spanish;

• Patient Pathways to actively send messages to patients to complete medication teaching, answer patient satisfaction surveys, learn about discharge instructions, and more; 

• Patients may also be asked to “nominate” their favorite nurse or doctor through an electronic comment card prior to discharge; and

• The hospital expects to implement the pain management capability that prompts patients to rate their level of pain at set intervals, and program the system to turn on healing video content such as soothing nature scenes.

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

Click here to see all recent news from this company

SALT LAKE CITY, UT–(Marketwire – July 28, 2010) –  AdvancedMD^® Software, Inc., the leader in all-in-one, web-based practice management, electronic health record (EHR), and billing applications for medical practices and medical billing services, today announced that PhySource Solutions, Inc., an AdvancedMD AdvancedBiller^® partner, has achieved two significant milestones in client service and company growth. On average, over the past 12 months the company’s new clients have reduced outstanding accounts receivable balances considered uncollectible from 30% to 2%. This caliber of results has fueled more than 100% growth in the company’s client list over the past year.

With the prolonged economic downturn, PhySource Solutions has seen many medical group clients struggle to keep accounts receivable within acceptable limits. Typical new clients have more than 30% of their receivables in the 90-day or greater category, which is considered mostly uncollectible. After only six months with PhySource Solutions, new medical practice clients see accounts receivable numbers come into line with MGMA industry benchmarks. PhySource clients realize on average 80% of claims in the current category (within 30 days) and only 10% at 90 days or more.

“Bringing accounts receivable in line is an exciting thing for clients, particularly when they see the impact it can have on revenues and profitability,” said Zina Kacha, director of business relations for PhySource Solutions. “In a scenario like this, clients regularly see at least a 15 percent improvement in revenues and profits.” PhySource founders Patricia Rosbrook and Kacha each have more than 25 years of experience in medical billing, financial analysis, consulting and executive management in a variety of healthcare related companies.

Largely as a result of the magnitude of payment improvement PhySource regularly achieves for clients, the company recently signed a new contract to provide billing services to San Diego Heart and Vascular, a seven provider Cardiology group serving the San Diego region. “The number one reason we switched [to PhySource Solutions] was that Dr. Salami’s trial EOB reports came in showing line after line of ‘paid’ instead of the multiple zeros we saw under the previous system,” said Mary Augenbaugh, practice administrator for San Diego Heart and Vascular.

As a participant in the AdvancedBiller partner network, PhySource Solutions runs its revenue management service on the AdvancedMD Software-as-a-Service platform, featuring a continuously updated payer rules engine, connectivity to more than 1,400 payers and instant software updates. In a large measure due to these AdvancedMD automation tools for claims management and the system’s robust reporting capabilities, PhySource was able to double its business last year and expects to double again next year. By avoiding stacks of paper, unwieldy filing systems, and tedious work in tracking down details, the firm has built a highly effective claims management system that can be quickly scaled up to handle the significant growth PhySource is experiencing.

“AdvancedMD is quality backed by functionality that equals manageability,” said Kacha. “It allows us to compile, maintain and track the mountains of data endemic to our industry in a way that I’ve never seen before. It’s the WOW of medical billing software.”

“AdvancedMD has made a corporate commitment that we will not compete with our billing service provider customers,” said Bill Stone, vice president and general manager of AdvancedMD Billing Services Partner Division. “Our relationship with PhySource Solutions is a prime example of this philosophy in action. We couldn’t be more pleased with their growth and success, and we remain committed to helping them grow their client base.” The AdvancedBiller program not only provides medical billing services with a leading technology platform, it provides lead generation opportunities to partners and sales support to help the billing service accelerate sales.

AdvancedMD Resources

• Learn more about PhySource Solutions: http://advancedmd.com/resources/medical-billing-software-case-study/
• Learn about the AdvancedBiller program: www.advancedbiller.com
• Learn about SaaS-based medical office software

About PhySource Solutions, Inc.

PhySource Solutions is a dynamic company located in San Diego, California. PhySource Solutions uses extensive surgical coding and medical billing knowledge to deliver comprehensive Revenue Cycle Management Services to its providers. The company has deep specialty specific experience and proficiencies for cardiology surgeon groups, helping their providers optimize their bottom line by providing a fully integrated Revenue Cycle Management service that includes surgical coding, medical billing, front-end training and financial analysis and reports. For more information, please visit www.physourcesolutions.com.

About AdvancedMD Software

AdvancedMD provides a market leading Software-as-a-Service (SaaS) electronic health record (EHR) and practice management (PM) software platform delivered to more than 10,000 providers and 300 medical billing service providers nationwide. As a complete Medical Practice Optimization solution, the product combines the clinical with the financial to improve workflow and revenue capture. The AdvancedMD solution includes a certified EHR, patient portal, scheduling, electronic eligibility verification, electronic prescribing, and mobile access capabilities for the practice. It provides sophisticated, efficient claims processing, denial tracking and revenue management for the billing professional. Processing more than 1M claims per month through its clearinghouse, the company is able to identify payer rule changes quickly and continuously adjust the software to reflect those changes, yielding first-pass claim acceptance rates of 95 percent or better, compared to the national average of 70 percent. For more information, please visit www.advancedmd.com.

*AdvancedBiller is a registered trademark of AdvancedMD

DUBAI, UNITED ARAB EMIRATES–(Marketwire – July 28, 2010) – A survey published today by a prominent Medical Tourism consultant has revealed that 94% of medical tourism industry insiders believe their sector of the industry has yet to reach its full potential. The report, which can be viewed on-line at www.DrPrem.com, shows that confusion, a lack of information and fear about complications following surgery are the main reasons for patient reluctance to cross international borders for health services.

“The medical tourism industry is going through an exciting phase where international and intra-regional activities are taking places within this sector of the health market,” said Dr. Prem Jagyasi, architect of the survey and an experienced consultant in the healthcare travel sector. “The responses received clearly revealed that there is an overwhelming perception among industry leaders that there is so much more that can be achieved,” he added.

The findings are particularly interesting as more than 35 countries were identified as important medical tourism destinations. Of the 35 countries, India was ranked as the number one popular destination, with Thailand and Singapore positioned at second and third places respectively. The United States had a surprise ranking at number four.

“The Asian and Far Eastern countries are well-established medical tourism destinations, so the top three placing were expected,” said Dr. Jagyasi. “The United States came in at number four, which clearly indicate Medical Tourism is not all about low price affairs. The quality of healthcare services at a destination is deemed to be of utmost importance. Latin American and European countries were in the top ten, indicating that medical tourism is not dominated by one continent or geography – it’s a truly global industry” added Dr Prem Jagyasi who is also Honorary Chief Strategy Officer of Medical Tourism Association, world’s biggest non-profit organization of this particular industry, based in Florida US with representative office across the world.

The purpose of the health tourism survey, according to Dr. Jagyasi, was to gain valuable insights into aspects of medical tourism from professionals who are closely involved with the industry. Ninety-five per cent of the survey’s participants identified themselves as being either directly or indirectly involved with healthcare travel in the scope of their work and the resulting information supplied by these insiders revealed many important facts concerning this specialised sector; including its terms, trends, status, opportunities and challenges. The knowledge gleaned from the survey will be used to promote this sector of the healthcare industry and will provide important content for a soon-to-be published guidebook for consumers who are considering undertaking treatment abroad.

“One of the survey questions enquired why the respondents thought that there may be a reluctance in some consumers to participate in healthcare tourism and the main responses we received were that they may have concerns about complications, experience confusion over aspects of available services, be uninformed and find the option complicated,” said Dr. Jagyasi. “This is important information, as it clearly shows that education is a vital component in allowing us to facilitate medical tourism to reach its greatest potential. If we can allay people’s fears about foreign treatments and guide potential health tourists with information on what to expect and important advice on visa and travel issues, then we will be providing a vital service and as well as giving a welcome boost to the region’s health sector,” he added. 

Hence, Dr Prem Jagyasi has taken initiative to publish a guidebook. He has high hopes that it will become a handy reference tool for those wanting to know more about the intricacies of travelling across borders for healthcare services. The book is the latest achievement in his specialist interest in medical tourism and he has visited more than 20 countries and spoken at 30 international congresses relating to this sector of the healthcare industry. “Medical tourism can offer huge benefits in terms of quality of service and its affordability, in fact, the survey revealed that industry leaders view these as being its key drivers,” he said. “The industry is set to grow enormously over the next two decades as more and more destinations open up to patients from overseas,” he added.

The medical tourism survey was conducted on-line and contained questions that had been developed over a six month period and based on intensive research. The qualitative assessment was sent to medical tourism professionals in North America, South America, Africa, Europe, the Middle East and Gulf regions, Asia and the Far East. It found that medical tourism facilitators are in a prime position to capitalise on the promising opportunities offered by this sector of the health market; with 88% of respondents agreeing that role of facilitator – those agencies providing health-related travel services – are either important or very important in this segment.

Selected Observations from Survey Results (Download complete report from www.DrPrem.com )

• The preferred term from respondents for this particular sector of the healthcare industry is ‘Medical Tourism’, with 35% selecting this option. ‘Global Healthcare’ was the next most popular term at 22%, with ‘Health Tourism’ running a close third at 21%. “Medical Travel’ was identified by 10% of respondents as their preferred description, with ‘Healthcare Travel’ and ‘Value Medical Travel’ both at 6%.

• 35 countries in total were identified as being medical tourism destinations; which were (in alphabetical order: Argentina, Australia, Belgium, Brazil, Caribbean, China, Costa Rica, Cuba, France, Germany, Hungary, India, Israel, Japan, Jordan, Malaysia, Mexico, Morocco, New Zealand, Panama, Philippines, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Tunisia, Turkey, UAE, UK and USA.

• India, Thailand and Singapore were ranked first, second and third as the most popular medical tourism destinations respectively. The United States was placed at number four.

• 94% of respondents agreed with a statement that medical tourism was yet to reach its full potential.

• The four most popular reasons given for why patients travel abroad to receive medical treatment were ‘Affordability (costly in home country)’ at 88%, ‘Accessibility (waiting period is high)’ at 66% ‘Better quality (care and support services are better quality than the home country) at 38% and ‘Availability (not available in home country) at 46%.

• The four most popular reasons given for patients being unwilling to avail themselves of treatment abroad were ‘Concern about complications’ at 50%, ‘Confusion’ at 46%, patients being ‘Uninformed’ at 44% and finding the option ‘Complicated’ at 39%

• The top four challenges to the medical tourism industry were identified as being ‘Accessing reliable information’ at 59%, ‘Too many newcomers jumping on the medical tourism bandwagon, not experienced or understanding of the industry’ at 54%, ‘Lack of pre and post operative care arrangements at 52% and ‘Complicated intra-country laws and legal procedures’ at 49%.

• The top three reasons identified that are essential components of a good medical tourism destination were ‘Quality standards of healthcare and wellness services’ which was marked by 51% of respondents, followed by ‘Accessibility of the destination’ at 30% and ‘Technology, facilities & specialisations available’ at 27%.

• The survey takers were asked why they thought Medical tourism was a new ‘buzzword’ (or more accurately a ‘buzz phrase’). Fifty-six per cent (56%) agreed that it was ‘Because increasing numbers are travelling for healthcare’, with almost the same percentage (55%) also agreeing that it was ‘Because medical tourism benefits a cross section, including governments insurance companies, travel/tourism, healthcare and facilitators’. Fifty-seven per cent (57%) agreed that it was ‘Because it offers value for money’ and 46% said that it was ‘Because big hospitals are promoting it’. 

• The role of facilitators in the industry was deemed by the respondents to be significant (an explanation of facilitators being that they arrange medical tourism either in part or in whole for health tourists). Sixty-one per cent (61%) said that facilitators were ‘Very important’, 27% said that they were ‘Important’, 10% regarded them as ‘Optional’ and 2% said that they were ‘Not important’.

About ExHealth:

Motivated by a creative vision and committed to an innovative mission, ExHealth offers a comprehensive array of tailor-made, media-related healthcare services, encompassing Marketing, Public Relations, Conference and Event Management, Design & Publication, Healthcare Tourism Consulting and Medical Management Consulting, all of which are located under one roof at Dubai HealthCare City. ExHealth’s key concern is to perform and execute incomparable solutions for healthcare organisations across all sectors of the industry. Aiming to achieve and surpass its customers’ stated goals, ExHealth is focused on ensuring that its clients’ business has the edge in today’s competitive market place.

About Dr Prem Jagyasi

Dr Prem Jagyasi is a successful entrepreneur and experienced strategic professional. He is a renowned chartered management, healthcare marketing and medical tourism consultant responsible for providing high-profile consultancy services to both government authorities and private healthcare organisations. Dr. Prem Jagyasi’s commitment to developing medical tourism has seen him become a leading figure in the international healthcare tourism world.

Currently, Dr Prem Jagyasi is MD & CEO of ExHealth; a Dubai Health Care City-based firm engaged in offering multi-dimensional healthcare solutions across the international domain. He also serves the Medical Tourism Association — a non-profit organization based in USA – as Honorary Chief Strategy Officer. He is also the Chief Editor of UAE’s leading health magazine, HealthFirst, which is published in association with one of the region’s leading English language daily newspapers.

Direct Download Link

http://www.drprem.com/Medical_Tourism_Research_and_Survey_Report_by_Dr_Prem_Jagyasi.pdf

BOCA RATON, FL–(Marketwire – July 28, 2010) –  David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor Chief Medical Officer Dr. Daniel Weiss will present an abstract of the results of a pilot study to test the ability of Vicor’s PD2i^® nonlinear algorithm to detect acute hypovolemia at the AABB 2010 Annual Meeting. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

Dr. Weiss will present Mild Hemorrhage Results in Observable Changes in Heart Rate Variability (S106-040B) on October 12, 2010 at 3:15pm in room 339/340, during the session entitled Donor Recruitment, Retention and Adverse Events: Hemoglobin and Iron. The AABB Annual Meeting & CTTXPO 2010 will be held at the Baltimore Convention Center on October 9-12, 2010. 

“We’re honored to have Dr. Weiss’s abstract of our hypovolemia study selected for presentation before this prestigious group. We believe the results achieved by the PD2i^® in this small pilot study suggest the prospect of incorporating the PD2i^® nonlinear algorithm into a noninvasive diagnostic for use in identifying patients who are bleeding internally. We hope that having the opportunity to share these results with those active in the field of transfusion medicine and cellular technologies worldwide will further opportunities to advance study of the PD2i^® as a noninvasive diagnostic to detect acute hypovolemia, and further our commercialization efforts for the PD2i^®,” stated Mr. Fater.

The study on which the abstract is based was conducted in cooperation with the University of Mississippi Medical Center and Mississippi Blood Services on December 12, 2009 in Smithdale, MS. The goal of the study was to test the ability of Vicor’s PD2i^® nonlinear algorithm to identify acute hypovolemia in blood donors as a preliminary step toward ascertaining whether it could be a useful noninvasive diagnostic for detecting blood loss from internal bleeding. All 18 participants in the pilot study were tested prior to donation to determine a baseline PD2i^® value, and re-tested during and after collection. The average PD2i^® value of participants prior to donation was 2.60; the average PD2i^® value following donation was 1.80. With a P value of 0.001, the study results are highly statistically significant; this indicates a better than 99% probability that the results were not achieved randomly.

The AABB is an international, not-for-profit association representing individuals and institutions involved in the field of transfusion medicine and cellular therapies. The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety. AABB membership consists of nearly 2,000 institutions and 8,000 individuals, including physicians, nurses, scientists, researchers, administrators, medical technologists and other health care providers. Members are located in more than 80 countries.

About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.

Vicor anticipates developing additional applications utilizing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense, the U.S. Government, or the AABB of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-12

Click here to see all recent news from this company

IRVINE, CA–(Marketwire – July 28, 2010) –  Lantronix, Inc. (NASDAQ: LTRX), a leading provider of secure, remote management, device networking and data center management technologies, today announced the worldwide availability of the EDS1100 and EDS2100 Linux software development kit (SDK), furthering its commitment to Linux and strategy for open source computing. The new SDK allows Linux developers to quickly and easily create value-added applications on the EDS1100/2100. Built on the proven, stable 2.6 Linux kernel, the SDK includes a robust set of components for building secure network-enabled products and applications using Linux, one of the world’s most popular open operating systems. Also included in the announcement are firmware updates for the XPort® Pro Linux SDK and MatchPort® AR Linux SDK, available for download at www.Lantronix.com/downloads. 

The EDS1100 and EDS2100 Linux SDK key improvements include:

• uClinux baseline upgrade (Linux kernel 2.6.29);
• IPv6-ready Certification;
• SDK VMWare VM Image to enable developers to build, deploy, customize and maintain Linux applications in a Windows environment;
• Serial-to-Ethernet with SSL and SSH support sample application.

“While we will continue to offer our customers the tools to develop products using our tried and true operating systems, expanding our Linux offerings extends the capabilities of our products for current customer needs and opens up our products to an exponentially wider audience,” said Daryl Miller vice president of engineering for Lantronix. “Every new product we launch will now support Linux.”

The EDS1100/2100 is also available with Lantronix’ powerful operating system, Evolution OS®, which provides end-users a rich, turnkey option with robust functionality right out of the box.

About EDS1100/2100
The EDS1100 and EDS2100 are unique, hybrid Ethernet terminal/multiport device servers which allow remote access to and management of virtually any IT/networking equipment or edge device such as medical equipment, POS terminals or security equipment. Available with Linux and IPv6 or Lantronix’ powerful Evolution OS, the EDS1100/2100 is the best choice when critical data needs to be remotely and securely accessed anywhere, at any time, via the Internet.

For more details on EDS1100/2100, please visit http://www.lantronix.com/device-networking/external-device-servers/eds1100_eds2100.html or contact [email protected].

The Lantronix blog, http://www.lantronix.com/blog, features industry discussion and updates. To follow Lantronix on Twitter, visit http://www.twitter.com/Lantronix

To receive an RSS feed of all Lantronix’ news, please visit http://www.lewiswire.com/us/lewiswire/Lantronix/c/458 and click on subscribe.

About Lantronix
Lantronix, Inc. (NASDAQ: LTRX) is a global leader of secure communication technologies that simplify remote access, management and control of any electronic device. Its solutions empower businesses to make better decisions based on real-time information, and gain a competitive advantage by generating new revenue streams, improving productivity and increasing efficiency and profitability. Easy to integrate and deploy, Lantronix products remotely connect and control electronic equipment via the Internet; provide secure remote access to firewall-protected equipment; and enable remote management of IT equipment over the Internet. Founded in 1989, Lantronix serves some of the largest security, industrial and building automation, medical, transportation, retail/POS, financial, government, consumer electronics/appliances, IT/data center and pro-AV/signage entities in the world. The company’s headquarters are located in Irvine, Calif. For more information, visit www.lantronix.com.

VANCOUVER, BRITISH COLUMBIA–(Marketwire – July 27, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF)(PINK SHEETS:APCSF) (the “Company”) announces that, as a result of prevailing market conditions, the private placement financing originally announced on April 15, 2010 (and subsequently revised as disclosed in the Company’s news releases of April 28^th and May 28^th), will not be proceeding on the terms disclosed. The Company is proceeding with a smaller private placement of $325,000 to be used for general corporate purposes by the sale of 3,250,000 share purchase units on a private placement basis, pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange, at $0.10 per unit. Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.20 per common share for a period of two (2) years from the date of the issuance of the purchase warrant with an accelerated exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.40 then the exercise period of the warrants will be reduced to a period of 10 days following such trading days. All securities issued will be subject to a four month restricted period and will bear a restrictive legend accordingly.

Insiders of ALDA will be subscribing for 25% of the offering, constituting a related party transaction pursuant to Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9 which is exempt from the requirement to obtain an independent valuation pursuant to Section 5.5(b) of MI 61-101 and the requirement to obtain minority shareholder approval pursuant to Section 5.7(1)(b) of MI 61-101. Their participation will be on the same terms as arm’s length investors, and such insiders’ shareholdings in the Company will increase as a result of any such participation. The revised private placement is intended to close within the next week as soon as the requisite approvals of the TSX Venture Exchange are obtained.

The Company also wishes to clarify that a report on the TSX Venture Exchange website on Tuesday, July 20, 2010 that an insider sold 108,500 shares at $0.12 was not correct. The Company has confirmed that the transaction did not involve a current insider of the Company and was incorrectly designated as such on the TSX Venture Exchange website.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The Company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO, ALDA Pharmaceuticals Corp.

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

DURHAM, NC–(Marketwire – July 27, 2010) –  On the heels of significant Midwest success, Third Degree Advertising is now offering its healthcare-oriented internal communications expertise on a national scale — starting with the East Coast.

“Strong brands start on the inside, and all positive outward change must first be embraced internally,” said Third Degree CEO Roy Page. Third Degree has helped healthcare organizations improve their brands by taking a unique, tailored approach to defining culture and creating opportunities for fruitful conversation between staff and doctors.

One of the key tools for introducing a brand internally is a Culture Book, outlining either a new or updated visual identity as well as the philosophical standards of the strategic branding initiative. “Culture Books can be short and sweet, or comprehensive and corporate,” said Page. 

Jackson County Memorial Hospital
Third Degree worked closely with Jackson County Memorial Hospital to develop their new strategic branding platform, which depended entirely on the buy-in of hospital employees. “This is My Hospital” was launched with an open house event to which staff, patients and community members were invited. Elements of this custom program included an employee Culture Book, a community newsletter, a redeveloped social website, and a Facebook page which helped promote JCMH’s culture both internally and to the community that JCMH serves.

Unity Health Center
Unity Health Center has a strong, community-focused brand. Third Degree developed their positioning: “It starts at the center,” to communicate how patients and employees are at the core of Unity’s commitment to greater health care in the local community. Their internal integrated marketing launch took place in a Unity town-hall style meeting where a brand video, specialty brochure and T-shirts with brand artwork were shared with all levels of staff. The Unity Culture Book, “It Starts with You” informed staff about the new brand and special programs like their teamwork-building paper puzzle pieces and “brag boxes” to recognize co-worker excellence. 

About Third Degree
Third Degree (www.thirddegreeadv.com) fosters more effective doctor-staff communication, and greater patient satisfaction. Third Degree provides strategic marketing research and planning, public relations, media planning and buying, and creative integrated marketing services for print, broadcast, and web-based applications. Based in Oklahoma City, OK and now Durham, NC, the agency works with clients in numerous industries across the U.S.

For more information contact Roy Page at [email protected] or call 1-888-871-3729.

SAN DIEGO, CA–(Marketwire – July 27, 2010) –  SpectraScience, Inc. (OTCBB: SCIE), a San Diego based medical device company, today announced that it was named in the top 50 publicly Traded biotech firms by the American Registry. The award was recognized in the San Diego Daily Transcript. The company’s WavSTAT cancer Screening Technology was also recently featured in a cover story in the June 2010 issue of MTI, as a company to watch that is developing and advancing GI diagnostics and screening technologies. Other companies mentioned in the story include Fuji Photo Optical, Olympus Optical and Smiths Group.

According to the article about 20 million endoscopic procedures are performed annually in the U.S. and key factors driving growth in procedures includes the aging population and increasing prevalence of gastrointestinal disorders.

“One of the most exciting areas of technology development for gastroenterology is enhanced imaging modalities,” says author Staylo. “Researchers are continually looking for new ways to improve the accuracy and diagnostic utility of endoscopic screening methods.”

Jim Hitchin, CEO of SpectraScience, said, “We are pleased to have been named in the top 50 publicly traded biotech firms by the American Registry and to also have received significant attention at this year’s Digestive Disease Week (DDW), which led to this article highlighting our technology for the medical community. This shows that SpectraScience is making a name for itself with its state of the art technology.”

Benefits of WavSTAT Technology

• Doesn’t require physical interpretation of screening results, but gives results in objective, standardized format
• Both a therapeutic and diagnostic device so it can remove abnormal tissue at the exact location where it is detected
• Enables physicians to identify where to biopsy rather than perform physical biopsies on a random basis
• Capable of detecting dysplasia at deeper level than other image enhancement technologies

About WavSTAT
The WavSTAT Optical Biopsy System employs a spectrophotometry technique called Laser Induced Fluorescence (LIF) to optically illuminate and analyze tissue using a standard biopsy forceps. The System uses an optical fiber to send cool, safe UV laser light into suspected tissue, where the light reflects back to a computer at different frequencies, depending on the type of tissue. For example, in abnormal tissue, cells fluoresce differently than in healthy tissue and have a different “signature” that our system can interpret as either normal or abnormal. This can greatly assist the physician by providing an additional indication, displaying a green light for normal tissue and a red light for abnormal tissue. If the tissue appears abnormal, physicians can also use the WavSTAT System to biopsy the tissue.

The WavSTAT has FDA clearance to market for detecting pre-cancerous and cancerous tissue in the colon. The Company made several upgrades to its original technology before introducing it at this year’s DDW and launching it in the European market. SpectraScience is planning a full-scale market launch in the US in late 2010 or early 2011. Currently the Company holds approximately 60 patents for its optical probes and underlying technology.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company’s LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

SAN JOSE, CA–(Marketwire – July 27, 2010) –  NightHawk Radiology Services, which provides high-quality, cost-effective services to approximately 1,600 healthcare sites — including 26 percent of all U.S. hospitals — has selected the Cisco (NASDAQ: CSCO) Unified Computing System® as a highly available and scalable platform for the company’s new main data center, which consolidates many smaller server sites around the country into a single primary site. NightHawk Radiology processes 3 million radiology studies per year with an average turnaround time of under 20 minutes per study, uses the flexible architecture of the Cisco Unified Computing System and its virtualized environment to support its goal of providing best in class radiology services and ensuring patients receive timely service 24 hours a day, seven days a week. The Cisco Unified Computing System unites computational, network, storage access, and virtualization resources in a single energy efficient system that reduces IT infrastructure costs and complexity, helps extend capital assets and improves business agility.

In addition to its impact on customer-facing services, deploying the Cisco Unified Computing System and Nexus 5000 data center switches has resulted in lower costs, easier management, and improved business agility for NightHawk Radiology. With the new system, the IT team reduced servers by 50 percent, reduced the time needed to deploy and manage servers by 80 percent, reduced cabling infrastructure by a factor of five, and can provision servers in just 20 minutes..

KEY FACTS / HIGHLIGHTS

• NightHawk provides a complete suite of high-quality, cost-effective solutions, including professional services, and an advanced, proprietary clinical workflow technology, to increase efficiencies and improve the quality of patient care. NightHawk’s team of U.S. board-certified, state-licensed and hospital-privileged physicians provide radiology healthcare services around the clock, and require a mission-critical data center to support timely information delivery.
• NightHawk has configured eight Cisco Unified Computing System blades as VMware ESX servers, each hosting approximately 10 virtual machines, with plans to double the number of virtual machines in the future. NightHawk also uses the Cisco Nexus 1000V Switch, a software switch that operates inside the VMware ESX hypervisor to give the network team complete visibility into the virtual machine environment for easier management.
• NightHawk Radiology has deployed a full suite of Cisco data center solutions. In addition to the Cisco UCS and Nexus 5000 Series data center switches, the company also deployed Cisco Nexus 2000 Series Fabric Extenders, Cisco MDS storage switches, and the Cisco Catalyst® 4900 Series switch as part of the overall infrastructure. These solutions will enable NightHawk to deploy unified fabric in the data center that is more cost-effective, lower in power and cooling demands, and easier to manage.
• Cisco Services and World Wide Technology supported the project with design, planning and deployment to help NightHawk achieve its goal to design a next-generation system that scales easily and provides investment protection. In addition to the Cisco data center technologies, the solution includes a VMware virtual environment and NetApp storage infrastructure. 
• The Cisco Unified Computing System enables NightHawk to achieve:
  • Competitive Differentiation through High Availability: The Cisco Unified Computing System delivers the high availability that is crucial in an industry where server outages not only cause revenue loss, but also delay delivery of critical patient care. The ease of moving virtual machines between servers helps ensure adequate compute capacity between midnight and 5:00 a.m., when the company receives three-quarters of its images. Server operating system upgrades can be quickly achieved by moving virtual machines to a different blade, and moving them back after. With UCS, Nighthawk no longer has to postpone software updates out of concern for reduced production capacity.
  • Simplified Management: Using the Cisco Unified Computing System Manager service profiles, an administrator can change an operating system configuration and then apply it to multiple server blades at the same time, saving time and reducing configuration errors. Firmware upgrades are easier as well, because the IT team simply attaches the upgrade to the template, and then Cisco UCS Manager automatically updates all server blades associated with that template. This means the IT team can update all servers in just 30 minutes compared to the 20 hours required previously.
  • Lower Costs: NightHawk has made significant cost savings through the need to maintain fewer physical servers as well as halving the number of cables and network interfaces needed to support virtualization. This means more of NightHawk’s power and cooling budgets can be used on servers. 
  • Increased Business Agility: The Cisco Unified Computing System Manager has decreased the time needed to deploy and manage servers by 80 percent, while also increasing stability and availability.

SUPPORTING QUOTES

“Systems availability is a paramount concern in our industry as server outages, even brief ones, can prohibit the delivery of patient care. Because medical practitioners and patients depend on our systems to be 100 percent reliable, we looked for technology with the highest level of redundancy and resiliency. With the Cisco Unified Computing System and Nexus solutions, we’ve experienced extremely high availability, coupled with lower costs and simplified management. Cisco UCS delivers the high availability we need to attract and retain customers.”

-Ken Brande, Vice President, IT, NightHawk Radiology Services

SUPPORTING RESOURCES

• View Cisco Unified Computing website
• Read Cisco Data Center Networks blog
• View Cisco Services
• Read NightHawk Radiology Case Study

Technorati Tags: Cisco, Data Center, Data Center Switches, Unified Computing System, Storage

About Cisco Systems
Cisco (NASDAQ: CSCO), the worldwide leader in networking that transforms how people connect, communicate and collaborate, this year celebrates 25 years of technology innovation, operational excellence and corporate social responsibility. Information about Cisco can be found at http://www.cisco.com. For ongoing news, please go to http://newsroom.cisco.com.

Cisco, the Cisco logo, Cisco Systems, Cisco Unified Computing System and Catalyst are registered trademarks or trademarks of Cisco Systems, Inc. and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. This document is Cisco Public Information.

For direct RSS Feeds of all Cisco news, please visit “News@Cisco” at the following link:

http://newsroom.cisco.com/dlls/rss.html

Click here to see all recent news from this company

TAMARAC, FL–(Marketwire – July 27, 2010) –  AcuMedSpa Holdings, Inc. (PINKSHEETS: AMSZ), a provider of Medical Aesthetic, Spa and Acupuncture services, announced it is initiating a share buyback program in order to lower the outstanding share count and increase shareholder value.

The company’s board of directors is reviewing and wants to purchase shares of AcuMedSpa on the open market and would like to retire those shares back into the treasury. The goal of the program is to purchase up to 10 million shares which will be retired immediately in order to reduce the outstanding shares by the total amount of shares purchased. The current outstanding share total is 146,610,679.

In recent months the company has taken important steps to improve shareholder value by reforming the share structure. Both the outstanding and the authorized shares have been reduced, and decision making power has been given to shareholders over all major decisions including all future share structure changes.

AcuMedSpa Holdings President Gregory Antoine, stated, “This share buyback program is the latest in a series of actions we have taken in our ongoing effort to improve shareholder value. Many small company investors have grown accustomed to share dilution, but we are in effect doing the opposite of dilution by eventually reducing the outstanding shares.” Mr. Antoine continued, “Reduced outstanding shares will benefit the shareholders in several ways and improves the company’s financials. Calculating our earnings with a lower outstanding share total will increase our earnings per share and reflect better on the balance sheet.”

Please follow our progress on twitter: http://twitter.com/acumedinc

For additional info please visit our website: http://www.acumedspa.com/

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements as a result of various factors, and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and AcuMedSpa Holdings, Inc. takes no obligation to update such statements.

KANKAKEE, IL–(Marketwire – July 27, 2010) –  Riverside Medical Center, a south Chicago, Illinois hospital network, is expanding its role as a teaching hospital with the creation of a residency program in Internal Medicine. Riverside also offers fellowships in Gastroenterology and Cardiology. In its inaugural year of the three-year program, the team of residents and various faculty members will work side by side treating patients at various Riverside, Illinois hospital facilities.

“Becoming a teaching hospital really elevates the level of care for the patient and the community,” said Dr. Naresh Chandan, DO, FACOI, FACP, Riverside Medical Center Director of Medical Education and Internal Medicine Program Director. “Not only does it give patients another set of eyes looking out for them, it continues to instill confidence in their care at Riverside. To teach is to learn twice.”

“A residency program at any hospital or clinic is a stage of graduate medical training where physicians, who have received their medical degree, practice under the close supervision of fully licensed physicians. Successful completion of residency training is a requirement to practice medicine independently,” Chandan continues.

Riverside’s Internal Medicine Program provides a holistic learning environment. “The program prepares residents to practice independently in general osteopathic Internal Medicine or to enter into a sub-specialty fellowship program,” said Dr. John Jurica, Riverside Medical Center vice-president of medical affairs.

In addition to an Internal Medicine residency program, Riverside also offers a sub-specialty fellowship in Cardiology and Gastroenterology. The three-year Cardiology fellowship program offers one position per year. The Cardiology Fellowship program will provide exposure to a comprehensive treatment plan, including triple bypass and other related heart center services, and will allow the graduate to practice Cardiology anywhere. The overall goal of the Gastroenterology fellowship program at Riverside is to provide the fellow with a well-balanced experience that is essential for a successful community practice.

“Riverside’s residency program is an investment in our community,” Jurica said. “When the time comes for us to be the patients, we can rest assured knowing that we are receiving the best possible care because of Riverside’s unending commitment to teaching and molding residents into world-class doctors.”

To view more on Riverside Medical Center’s world-class residency program, please visit www.RiversideMC.net/residency.

Click here to see all recent news from this company

BRENTWOOD, MO–(Marketwire – July 26, 2010) –  Scrubs & Beyond, a leading retailer of print and solid scrub tops, jackets, pants, lab coats, shoes and accessories, revealed its fall catalog this week. The highly anticipated fall catalog is set to reach customers across the United States during the week of July 25, 2010 and will offer customers old favorites in addition to new items in a variety of colors, styles and price points. 

Scrubs & Beyond is very excited to be introducing their exclusive S&B solids, starting at just $9.99 each, and S&B print scrubs, starting at $14.99 each. There has never been a better time to stock up for fall. These scrubs are made from soft cotton poplin in both unisex and women’s sizing. Extra details in construction for just the right fit every time, it’s easy for busy medical professionals to mix and match favorite fall colors.

This fall animal print scrubs are one of many must-have items. Customers will find a veritable color safari with fun animal prints from Baby Phat, Cherokee, Los Angeles Rose, Cherokee Flexibles, and Koi. Animal-print seeking fashionistas can also take a walk on the wild side in some great styles in animal-print footwear from Alegria, Nurse Mates and Dansko. Customers will see new offerings from favorite brands such as Koi, Landau, Cherokee, Peaches, Barco, Skechers, Urbane, Scrub Zone, Do No Harm and more. 

Customers have been heard and the call to “Just Give it to Me in Black & White” is here for fall in full force. Scrubs & Beyond’s exclusive black and white scrubs will be a favorite for even the most discriminating Scrubinistas. Koi continues to provide outstanding assortments of styles and prints to mix and match with their essential solid basics and has some great offerings in black and white too! 

As the cooler weather leads into fall, Scrubs & Beyond is ready with value-priced holiday prints to get you in the mood for the season. With so many fashion forward scrubs available for fall, now is the perfect time for medical professionals to shop with Scrubs & Beyond and get exclusive looks that can’t be found anywhere else.

To request the Fall 2010 catalog, or to find a list of all Scrubs & Beyond store locations visit www.ScrubsAndBeyond.com, or call direct at 1-888-255-2668. 

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 26, 2010) –  Every two years, healthcare market research firm Kalorama Information releases the highly anticipated update to its industry leading report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition.” In seven best-selling editions, Kalorama Information’s lead diagnostic analyst Shara Rosen has provided a total view of every aspect of the market for in vitro diagnostic (IVD) testing, in one complete volume.

“We’re very pleased to release this completely updated edition of our best-selling title,” said Bruce Carlson, publisher of Kalorama Information. “The idea behind our unique report is that the entire market can be captured in one volume and business planners can use it as a key reference.”

This go-to reference for the IVD industry reveals the trends that are impacting the field now, and provides a realistic forecast five years into the future for companies already participating in or considering entry into this growing industry. All of the major segments of clinical lab testing are covered.

Kalorama has reorganized the presentation of the IVD market in this latest edition in a manner that better reflects how the industry has evolved. For instance, there is an increased focus on lab automation. Due to a lack of trained lab technologists to run the more complex new set of molecular and histological tests and immunoassays, a proliferation of test and lab automation tools has been launched that remove precious human resources from mundane pre-analytical and sample tracking tasks to make time for more sophisticated ones.

“Worldwide Market for In Vitro Diagnostic Tests, 7th Edition” stands as a testament to the Kalorama methodology — real industry knowledge combined with numerous interviews of leading experts in the field and company executives, as well as an exhaustive review of the medical, business, and company literature. More than 900 pages and over 230 key company profiles reveal one vital piece of exclusive industry information after another. The report is available at: http://www.kaloramainformation.com/redirect.asp?progid=79375&productid=2613362.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

MILWAUKEE, WISCONSIN–(Marketwire – July 26, 2010) – Extendicare Health Services, Inc. announced today that 27 of its health centers are the proud recipients of the American Health Care Association and the National Center for Assisted Living’s (AHCA/NCAL) Bronze – Commitment to Quality, National Quality Award in recognition of their strong commitment to continuous quality improvement.

The health centers receiving the award are:

“The AHCA/NCAL Quality Awards – comprised of three levels, Bronze – Commitment to Quality award; a more rigorous Silver – Achievement in Quality award; and a comprehensive Gold – Excellence in Quality award – are the most prestigious recognition of quality within the long term care profession,” stated AHCA/NCAL President and CEO, Bruce Yarwood. This Bronze – Commitment to Quality award recognizes dedicated frontline caregivers, administrators, nurses and physicians, who demonstrate their commitment to quality of care in order to meet the needs for our nation’s most vulnerable population.

As a Bronze award recipient, these health centers demonstrated their organization-wide commitment to a customer-focused facility mission, defined its principal customers and their expectations, and indicated ways that they are striving to meet their needs.

“The Quality Award program is an independently judged, criteria-based, award program. This year, only 456 long term care centers nationwide received this noteworthy award and we are pleased to be counted among them. We are proud of this accomplishment and thank our team members for their strong commitment to excellence,” said Tim Lukenda, Chairman and CEO of Extendicare Health Services, Inc.

AHCA/NCAL’s Quality Award is modeled after the criteria of the Malcolm Baldrige National Quality Award, the nation’s premier award recognizing distinguished achievements. AHCA/NCAL’s award is designed to support both continuous quality improvement efforts in long term care by promoting quality awareness and education and to recognize quality achievements.

About Extendicare

Extendicare Health Services, Inc. located in Milwaukee, Wisconsin is a wholly owned subsidiary of Extendicare Real Estate Investment Trust, or Extendicare REIT (TSX symbol “EXE.UN”). Extendicare REIT is a leading North American provider of long-term and short-term senior care services through its network of owned and operated health care centers. We employ 37,700 qualified and experienced individuals dedicated to helping people live better through a commitment to quality service that includes post-acute care, rehabilitative therapies and home health care services. Our 258 senior care centers in North America have capacity for approximately 28,900 residents. 

OAKLAND, CA–(Marketwire – July 26, 2010) –  The Center for Technology and Aging (CTA), is collaborating with the Administration on Aging (AoA) and the Centers for Medicare & Medicaid Services (CMS) on funding innovative care transition projects for older adults and persons with disabilities through the national system of Aging and Disability Resource Centers (ADRC).

CTA’s “Technologies for Improving Post-Acute Care Transitions,” (Tech4Impact) grants are designed to encourage ADRC programs (www.aoa.gov/AoARoot/Grants/Funding/index.aspx) to expand use of technologies that promote better patient transitions from hospitals, rehabilitation centers or nursing facilities back to homes or other community settings.

According to The New England Journal of Medicine, avoidable hospital readmissions within 30 days of discharge cost Medicare $17.4 billion annually.

“We are privileged to be a partner in this national effort to improve care transitions,” said David Lindeman, director of the Center for Technology and Aging. “Improving care transitions and lowering hospital readmissions is a national priority. Use of selected technologies, such as remote patient monitoring and medication management technologies, is associated with reduced hospitalizations, so it makes sense to focus on expanding their use.”

Tech4Impact grants will complement grantee funding made available through the $60 million AoA and CMS initiative, “Implementing the Affordable Care Act: Making it Easier for Individuals to Navigate their Health and Long-Term Care through Person-Centered Systems of Information, Counseling and Access.” Complete details are available at: www.aoa.gov/AoARoot/Grants/Funding/index.aspx.

CTA will make Tech4Impact funds available to states that are awarded grants by AoA/CMS for program Option D: ADRCs Evidence-Based Care Transition Programs. (AoA/CMS grant applications are submitted electronically at www.grants.gov.) The CTA application for states will be released by September 30, 2010, and full proposals will be due October 15, 2010. Grants are expected to commence by January 2011. Additional guidelines pertaining to the Tech4Impact grants are available at www.techandaging.org 

ADRCs (www.adrc-tae.org) are community-based programs designed to streamline access to long-term care services under the auspice of the Administration on Aging, an arm of the U.S. Department of Health and Human Services.

In addition to the Tech4Impact grants, CTA administers grant-funding programs for projects that seek to expand the use of medication optimization and remote patient monitoring technologies for the care of older Americans.

The Center for Technology and Aging (www.techandaging.org) supports the rapid adoption and diffusion of technologies that enhance independence and improve home and community-based care for older adults. Through grants, research, public policy involvement and development of practical tools and best practice guidelines, the Center serves as an independent, non-profit resource for improving the quality and cost-effectiveness of long-term care services. The Center was established with funding from The SCAN Foundation (www.thescanfoundation.org) and is affiliated with the Public Health Institute (www.phi.org) in Oakland, CA.

Click here to see all recent news from this company

ROCKVILLE, MD–(Marketwire – July 26, 2010) –  MarketResearch.com has announced the addition of Business Insights’ new report “Drug Discovery Collaborations between Academia and the Pharmaceutical Industry: Cultural factors, intellectual property considerations, case studies, and future trends,” to their collection of Pharmaceuticals market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2738133.

The pharmaceutical and biopharmaceutical industries are engaged in a business environment which is witnessing a dramatic escalation of R&D costs, key patent expiries, and sustained high attrition rates for new molecules in development.

In response, pharmaceutical companies have recognized the need to expand the range of creative stimuli for their research processes in order to reinvigorate their drug discovery pipelines. Consequently the industry has sought to develop external collaborations not only with other companies but also more frequently with academia, to obtain access to new technologies to enhance their drug discovery capabilities and to in-license candidates for further development. Indeed, collaboration is becoming an essential component of today’s drug discovery efforts and it is commonly undertaken with multiple partners through an often iterative, continuous, and long lasting process, which adds to the complexity of efficiently managing both the collaboration itself and the data generated.

This report explores the opportunities and challenges that are presented by collaboration with university researchers as well as identifying the key inputs from both the industrial and academic partners. The different organizational cultures and structures are examined along with consideration of the goals for each institution and the issues these create. The report discusses the various types of agreement which can be used, highlights legislation of importance to the appropriate protection of intellectual property, and presents case studies of notable collaborations In addition the report offers thoughts on the future for collaborative agreements and the benefits they will bring to both parties.

Questions Answered within the report include…

• What are the key drivers influencing change to a more collaborative approach to R&D in the pharmaceutical industry?
• What are the latest developments in the collaborative approach to R&D and which models represent the best opportunities for the pharmaceutical industry?
• What are the issues and concerns over the evolving collaborative R&D paradigms?
• What are the intellectual property management issues that should be considered by each party?
• Which changes in patent legislation are of greatest relevance to the formation of collaborations in different countries?
• What are the different types of academia-industry collaborations?
• What are the pros and cons for each party in academia-industry collaborations?
• What are the critical success factors for academia-industry collaborations?
• What are the main factors to take into account when negotiating academia-industry collaborations?
• What are the cultural, change management and goal alignment challenges?
• What are the future directions for academia-industry collaborations?

For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2738133.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – July 26, 2010) –  Typenex Medical, LLC, a leader in transfusion recipient verification solutions, has launched their latest barcoded blood band innovation, the FlexiBlood Recipient Verification System.

The FlexiBlood Recipient Verification System was developed using feedback from blood bankers and nurses to ensure that the product improved on the legacy “band and form” recipient verification systems available today. FlexiBlood uses GS1-128 linear barcodes and can accommodate pre-printed patient information labels to reduce transcription errors at the bedside and in the blood bank. It also boasts a barcoded specimen tube sticker that stays attached to the band during application to help promote the accurate labeling of the pre-transfusion specimen at the patient bedside.

“Blood bankers asked for a solution that leverages barcodes to reduce transcription errors and provides a way to help clinical staff label specimens accurately to avoid wrong blood in tube errors,” said Scott Leece, General Manager of Typenex Medical. “Nurses wanted a solution that is easy to use, comfortable for patients, and that supports them throughout the specimen collection and blood administration processes. FlexiBlood was designed to meet all of these requirements.” 

FlexiBlood has additional features that differentiate it from other offerings, such as the ability to be easily reapplied if removed during the patient stay using the Typenex R3 Attachment System and directions for use on every FlexiBlood form. “Based on clinical feedback and the many features of FlexiBlood, we are confident that it is a better solution than Ident-A™ Blood or Securlink®,” stated Leece.

The FlexiBlood Recipient Verification System has two standard forms and six standard insert band colors. For more information on FlexiBlood, please call (866) TYPENEX or visit http://www.typenex.com/. 

About Typenex Medical
Typenex Medical enables hospitals to achieve safer transfusion practices via our suite of recipient verification solutions. These solutions — our Original Alphanumeric Bands, our Next Generation Barcode Bands, and our FlexiBlood Recipient Verification System–provide independent, unique identifiers in various embodiments to help hospitals provide control over their transfusion processes and reduce the costly and dangerous errors associated with blood transfusions. Typenex also improves safety in the laboratory via our TypeSafe™ Segment Sampling Device, which is used to safely pierce blood segments for cross-matching.

Ident-A™ and Securlink® are trademarks of Precision Dynamics Corporation.

MONMOUTH JUNCTION, NJ–(Marketwire – July 26, 2010) –  CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced that it is exhibiting at two leading military healthcare conferences in August. The first is the 13^th Annual Force Health Protection Conference (FHP) at the Phoenix Convention Center in Phoenix, Arizona, where CytoSorbents will exhibit in Booth #507 from August 10-11, 2010 (http://phc.amedd.army.mil/fhpc/). The FHP conference is expected to gather more than 2,000 healthcare medical providers, policymakers and vendors from around the world, focused on the latest research, services and products for disease prevention and treatment, safety and homeland security for both military and public health purposes.

The second is the Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference to be held at the Tradewinds Beach Resort, in St. Pete Beach, Florida. CytoSorbents will be exhibiting from August 16-19, 2010 in Booth #19. ATACCC is the Department of Defenses’ premier scientific meeting that addresses critical advances in trauma medicine and the unique medical needs of the warfighter (https://www.ataccc.org/). At both venues, the Company will be showcasing its blood purification technology with a hands-on demonstration of how the device works, how it is easily administered, and how it could be applied in a number of clinical situations facing critically wounded military personnel.

Dr. Phillip Chan, Chief Executive Officer and President, commented, “Members of our military forces put their lives on the line every day, not only in Iraq and Afghanistan, but all over the world. The injuries they sustain in protecting our freedom include penetrating wound injuries, infection and sepsis, and blast, trauma, crush and burn injuries that are extremely complex and severe. Standard of care therapy remains predominantly supportive, and does not address the cytokine storm and subsequent severe inflammation that can lead to multi-organ failure and death in these patients.” 

Dr. Chan continued, “We believe that our flagship product CytoSorb™, a powerful cytokine removal technology currently in human clinical trials, is the key to changing the current treatment paradigm of ‘supportive care and watchful waiting’ to one of ‘active treatment,’ potentially saving more lives. In addition, blood purification using CytoSorb or other resins under development, may solve many other vexing problems facing the military and the DOD, such as how to treat soldiers or civilians exposed to chemical or biologic warfare. Exhibiting at these major conferences continues our efforts to build funding support for our technologies within the military and the DOD and to expand the number of clinical applications for our products.”

About CytoSorbents and CytoSorb™

CytoSorbents Corporation is a critical care focused therapeutic device company in clinical trials to treat severe sepsis, the end result of “overwhelming infection,” with a novel blood purification device called CytoSorb™. Severe sepsis afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. However, it is the body’s abnormal immune response to the trigger that leads to severe inflammation and the unregulated, massive production of cytokines, often called “cytokine storm,” that then causes multi-organ failure and often death. CytoSorb™ is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped repeatedly through the CytoSorb™ cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial – a multi-center, randomized, controlled clinical trial using CytoSorb™ to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb™ in the European Union and then commence clinical trials in the U.S. for approval. Importantly, cytokine reduction via CytoSorb™ has broad applicability to a number of other critical care diseases where cytokine storm plays a detrimental role, including burn and smoke inhalation injury, trauma, acute respiratory distress syndrome, advanced influenza, acute pancreatitis and others. CytoSorb™ is one of a number of different resins designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the Company’s website: www.cytosorbents.com

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management’s current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company’s medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company’s products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company’s Form 10-K filed with the SEC on April 9, 2010, which is available at http://www.sec.gov.

ROCKVILLE, MD and SEOUL, SOUTH KOREA–(Marketwire – July 26, 2010) –  Seegene today announced SeePrep™ and SeeCycler™, new clinical instrumentation optimized for Seegene’s multiplex real-time detection tests. SeePrep performs automated magnetic bead nucleic acid extraction, and SeeCycler is an automated detection system for processing samples in real-time. With the addition of these equipment Seegene is now able to provide a complete molecular diagnostic workflow optimized for its multiplex tests, including nucleic acid extraction, amplification, real-time PCR testing and data analysis. The complete system will be on display at the 2010 Annual Meeting and Clinical Lab Expo of the American Association for Clinical Chemistry (AACC), booth #1800.

“Seegene multiplex real-time PCR products are defining a new era of powerful assays that can rapidly and accurately diagnose a pathogenic infection and genetic mutation. These tests arm medical professionals with the information they need for better and more cost-effective patient care,” said Jong-Yoon Chun, Chief Executive Officer of Seegene. “SeePrep and SeeCycler are the cutting edge in test sample prep and processing, and are a perfect complement to our multiplex testing format. Used together as a complete system, clinicians will benefit from a comprehensive system which simplifies and speeds up the entire test process.”

Seegene is pioneering a new category of multiplex PCR technology that enables the simultaneous detection of viruses and bacteria in a single reaction. Seegene currently has a wide range of assay panels for multiple pathogen screening. The assays primarily target viral and bacterial infections and include panels for viral respiratory infections, sexually transmitted diseases, herpes, diarrhea, HPV, viral meningitis and sepsis.

SeePrep is an automated nucleic acid extraction machine utilizing magnetic bead technology. The hallmark of the instrument is the ability to utilize specimens that are very difficult to extract by any other instrument.

SeeCycler uses patented block dissipation technology for accurate and fast heating and cooling rates, required for better efficiency in DNA amplification, resulting in fast reaction time. It has a capacity of 96 wells and covers and with 6 channels, 5 different analyses can be detected in one sample.

About Seegene

Seegene, Inc. is the leading biotechnology company developing, manufacturing and marketing innovative molecular diagnostic products and services. It holds proprietary technologies of both PCR and Real-time PCR named ACP™, DPO™, and READ™, which sets a standard in high-throughput and simultaneous multi-pathogen detection called “multiplex PCR.” The novel multiplex Real-time PCR technology, READ™, overcomes the limitations of conventional Real-time PCR, providing dramatic improvement in sensitivity and specificity. Seegene holds three novel Molecular diagnostic platforms: Seeplex® system adapting DPO™ Technology, Anyplex® and Magicplex® system which are Real-time PCR detection platform adapting DPO™ and READ™ Technology. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.

For more information please visit www.seegene.com or call +301-762-9066.

ATLANTA, GA–(Marketwire – July 26, 2010) –  ALR Technologies Inc. (OTCBB: ALRT) announces that on July 23, 2010 the Company submitted a 510(k) application to the FDA for its proprietary Health-e-Connect (HeC) System. The HeC system is an internet-based product intended for diabetic patients and their health care providers to improve communication and monitoring of patients’ health management programs. One aspect of the system is that HeC will incorporate data uploaded from patients’ glucometers into the ALRT database to quickly assess user compliance and performance compared to provider set targets. The HeC system currently supports data transfer from glucometers manufactured by Abbott, Bayer, Lifescan (a Johnson & Johnson company) and Roche.

In a recently presented clinical evaluation, diabetic patients using the HeC system showed statistically significant improvement in A1c when compared to a control group using standard methods for monitoring and feedback.

About ALR Technologies Inc.
ALRT Health-e-Connect (HeC) System is the principal product of the Company. HeC is a web based application for medical professionals to improve compliance and adherence of care plans of patients in their homes. HeC is programmed to assist healthcare providers caring for diabetes patients. The platform will be expanded to cover patients with other chronic diseases. More information on ALR Technologies and its products can be found at http://www.alrt.com. 

This release contains certain “forward-looking statements” relating to ALR Technologies’ business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words “estimate,” “expect,” “anticipate,” “believe” and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company’s quarterly filings with the Securities Exchange Commission.

MENOMONEE FALLS, WI–(Marketwire – July 23, 2010) –  Assisted Living Concepts, Inc. (NYSE: ALC) announced that it plans to release its 2010 second quarter financial results after the New York Stock Exchange closes on Monday August 9, 2010. The release will be posted on ALC’s website at www.alcco.com. ALC has scheduled a conference call on Tuesday August 10, 2010 at 10:00 a.m. (ET) to discuss its financial results for the second quarter. The toll-free number for the live call is (800) 230-1096 or international (612) 332-0107. A taped rebroadcast of the conference call will be available approximately three hours following the live call until midnight on September 10, 2010, by dialing toll free (800) 475-6701 or international (320) 365-3844 and using access code 165684.

About Us

Assisted Living Concepts, Inc. and its subsidiaries operate 211 senior living residences with capacity for approximately 9,400 residents in 20 states in the United States. ALC’s residences typically consist of 35 to 60 units and offer residents a supportive, home-like setting and assistance with activities of daily living. ALC employs approximately 4,100 people.

LANHAM, MD–(Marketwire – July 23, 2010) –  The Residence at Greenbelt, offering the new standard in modern assisted living, announced today that it will celebrate its grand opening on Tuesday, July 27^th and Wednesday, July 28^th, 2010 from 4pm-7pm. During this monumental two-day event, guests can experience a VIP tour of The Residence on Greenbelt, its new modern models and see first-hand the dignity and vitality of assisted living in a unique community geared towards residents, their families and friends. 

A special tree-planting dedication ceremony will take place on the second day, Wednesday, July 28^th. Samuel H. Dean, Councilman for Ward 6 in Prince George’s County, will lead the dedication of a Southern Magnolia tree that was graciously donated by Behnke Nurseries. Additionally, summer fare and jazz entertainment will be provided both days.

At The Residence on Greenbelt, the warmth and comfort of home and modern convenience come together to define modern assisted living. This unique community offers charm, extensive care and superior care, while allowing residents to experience its modern set of amenities including a Skype lounge and stately movie theatre equipped for the hearing impaired. Conveniently located on Greenbelt Road, The Residence on Greenbelt has recently undergone a complete renovation that has created a vibrant and interesting senior living residence, where residents can experience unrivaled service in modern and fun surroundings.

Three different service programs exist at The Residence on Greenbelt, providing the right match for the needs of seniors. In addition to Assisted Living, the community offers a Special Needs living area that provides for residents with higher acuity and mobility needs in an environment with features focused on maximizing independence while offering comfort and service. The Residence on Greenbelt also provides the Pathways Memory Care Program, an exceptional option for seniors with memory impairments as it offers a stimulating and engaging environment for residents and peace of mind for their families and friends.

For more information about The Residence on Greenbelt, or to attend the Grand Opening event, please call (866) 712-1172 or visit TheResidenceonGreenbelt.com.

About IntegraCare
IntegraCare’s mission is to “improve the quality of life for its employees, residents, and their families.” The company’s goal is to create an environment where its primary customer, the employee, experiences respect, dignity, and personal development. By providing this environment for its employees, the second half of our mission, “improve the quality life for our residents and their families,” will be achieved.

INDIANAPOLIS, IN–(Marketwire – July 23, 2010) –  Health Systems International (HSI), a global provider of outsourced medical cost management solutions, has just received the spotlight in the Indianapolis Business Journal’s Fastest Growing Indianapolis-Area Private Companies — coming in at number 3. View the article at http://www.us-hsi.com/files/Fastest%20Growing%20HSI_July%202010.pdf. This is the second year in a row HSI has received this honor. In 2009, the company appeared on the list at number 9. 

Russell W. Sherlock, Chief Executive Officer of HSI, said, “Our strong sales team and our service results help us to continue to grow even in tough economic times. Healthcare continues to get more complex, and HSI works consultatively with clients to find out how each one can carve dollars out of the healthcare bill. Everyone’s program is unique, and we offer niche services and solutions to fit many markets.”

HSI solutions include cost containment technology and business services customized to meet specific industry needs in the PPO, Maritime, Workers’ Compensation, Property and Casualty, HMO, Health Insurance Carrier, TPA, Self-funded, Reinsurer, and International Health Payor Markets.

About HSI
Headquartered in Indianapolis, Indiana, HSI is a leading provider of outsourced medical cost management solutions. HSI is backed by Great Point Partners, LLC, a private investment firm with over $900 million of equity capital under management. Since 1987, HSI has utilized proprietary technology, experienced staff medical discount services to relieve clients’ administrative burdens and achieve the lowest possible cost of medical care. Visit www.us-hsi.com for more information.

NEW YORK, NY–(Marketwire – July 23, 2010) –  (PINKSHEETS: SREH) — SREH Scientific News International (www.scientificnewsroom.com) releases its subscription-based gross revenue projections today as it prepares for an upcoming wave of fall medical conferences for its industry reporting brainchild, www.scientificnewsroom.com.

The projections have been laid out conservatively and factors in a variable attrition rate. “Further,” states CEO Anthony Dibiase, “these figures were calculated with an assumption that only the lower subscription tier was selected by all members. We did this to remain conservative in our projections and even a fraction of doctors choosing to subscribe as premium members would have a significant impact on these numbers. As well, these figures are only based on subscription fees and do not include iPhone app sales, doctor2doctor social networking platform upgrades or doctor2doctor prospective ad revenue.”

SNI Execs are confident it can reach at least 10% of its target market by July 31, 2011 resulting in more than $1 million in gross revenues there. SNI target market includes professionals from all of the major fields the site currently covers: Cardiology, Gastroenterology, Hematology, Nephrology, Oncology, Primary Care, Rheumatology, Urology and Radiology. By year 3, the site expects to reach approximately $5 million in subscription fees alone. “With supplementary medical fields, increased conference attendance, additional iPhone apps and doctor2doctor revenues, we release these projections with the understanding that they are only a fraction of revenues overall for the company. Expanded projections will be released in the near future to reflect additional revenue streams,” comments Dibiase.

CUTTING EDGE MEDICAL MEETING NEWS EXCLUSIVELY AT Scientific News International! (www.scientificnewsroom.com) is SREH’s premiere all-in-one platform for medical conference and news information focusing on Cardiology, Gastroenterology, Hematology, Nephrology, Oncology, Primary Care, Rheumatology and Urology. The site is the web’s only online resource for medical professionals with access to the latest, cutting edge data presented at major medical meetings worldwide. Staffed by global medical writers, SNI reports the most current research and therapy findings directly. The site’s profitability is IP and subscription based without bias from any medical or pharmaceutical provider. 

In the beginning, there was… Fishing, Manga, global tide reports and more! Get your iPhoneMobile2Earth (www.mobile2earth.com) app now. Choose from the iPhone King James Bible, fishing reports worldwide, Japanese e-books and comics and so much more! Get ready, as Mobile2Earth unleashes phase 1 of its iPhone app releases for mass consumption.

Safe Harbor: This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

ALEXANDRIA, VA–(Marketwire – July 23, 2010) –  The American Diabetes Association applauds the new White House rule which will help people with diabetes and other chronic diseases appeal the denials of health insurance claims. This rule comes under the new Patient Protection and Affordable Care Act. The rules will help simplify the denial process and create consistency in all 50 states.

“In order to stay healthy, people with diabetes have to manage their disease with supplies like test strips, meters and insulin,” said Nash Childs, PE, Chair of the Board, American Diabetes Association. “Diabetes is a costly disease and without good coverage, the costs can make it difficult to manage properly. It is important that people with diabetes are treated fairly and given the opportunity to appeal any claims that are denied. The American Diabetes Association is grateful to the Obama administration for recognizing the need to make this available to everyone.”

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

WEST PALM BEACH, FL–(Marketwire – July 22, 2010) – HearUSA, Inc. (NYSE Amex: EAR), a leader among the nation’s hearing care providers, will hold a conference call on Tuesday, August 10, 2010 to discuss results for the second quarter ended June 26, 2010. Financial results will be issued in a press release after the close of the market on the same day.

HearUSA’s Chairman and CEO Stephen J. Hansbrough, President and COO Gino Chouinard, and CFO Frank Puñal will host the call starting at 4:30 p.m. Eastern time. A question and answer session will follow management’s presentation.

To participate in the call, dial the appropriate number 5-10 minutes prior to the start time, request the HearUSA conference call and provide the conference ID: 7HEARUSA.

A Web audio simulcast and replay will be available via the investor relations section of the company’s website at www.hearusa.com.

If you have any difficulty connecting with the conference call or webcast, please contact Liolios Group at 1-949-574-3860.

A telephone replay of the call will be available later that evening and will be accessible until August 17, 2010:

About HearUSA
HearUSA is the recognized leader in hearing care for the nation’s top managed care organizations through its 177 company-owned centers and network of more than 2,000 hearing care providers. HearUSA is the nation’s only hearing care provider accredited by URAC, an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation. HearUSA is also the administrator of the AARP Hearing Care program, designed to help millions of Americans aged 50+ who have untreated hearing loss. For more information about HearUSA visit www.hearusa.com, or go to www.hearingshop.com for a wide selection of hearing related products available for purchase online.

BELGRADE, SERBIA–(Marketwire – July 22, 2010) – Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS) http://www.htdsmedical.com) is pleased to announce that researchers from its Slavica BioChem (www.slavicabiochem.com) division established the cooperation with world-leading market analysis company from UK.

Dr. Sanja Pekovic, Chief Project Scientist of HTDS, said, “The Datamonitor Group (http://www.datamonitor.com/) is world leader in the business intelligence sector. We expect that the multiple sclerosis and traumatic brain injury pipeline and unmet analysis needs of these two markets, prepared by Datamonitor’s healthcare and pharmaceutical analysis team, will provide us with insight into most recent findings in order to be a step ahead to our competitors. After getting permission, complete material comprising of clinical opinion, leader intelligence, best-in-class case studies, R&D pipeline, unmet need analysis, scenario-based revenue, epidemiology forecasting, a slide pack and a data pack covering seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) will be available at the HTDS (http://www.htdsmedical.com) and Slavica BioChem (www.slavicabiochem.com) web sites.

About Mina Mar Group:

Mina Mar Group (MMG) is a corporate consultancy firm that specializes in small cap or OTC market business services, including public markets in Frankfurt, Germany, and the UK. We provide our clients with comprehensive advisory and consulting services regarding mergers and acquisitions, including reverse mergers of private companies into publicly traded entities, and special purpose companies (SPC) offshore. MMG also offers a full suite of related ancillary services subsequent to the successful completion of a reverse merger, including private placements, Pink Sheets Adequate Disclosure documentation, various SEC regulatory filings and a broad range of other corporate governance matters. Mina Mar Marketing Group, MMMG (www.minamargroup.net), offers publicly traded companies full array of services such as Investor Relations and maintenance investor awareness. Mina Mar Group pioneered the “Go Public Free” program, the first firm to challenge the short sellers, stock bashers and repeal of the “Communication Decency Act”. Visit www.minamargroup.com/ice to learn more.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company’s email database for press releases, “Friday Tips” industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe for opt in mailer at http://www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision’s under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project,” and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.’s control. In addition to those discussed in Hard to Treat Diseases, Inc.’s press releases, public filings, and statements by Hard to Treat Diseases, Inc.’s management, including, but not limited to, Hard to Treat Diseases, Inc.’s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.’s ability to raise additional capital to fund future operations, HTDS Corporation’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.